Failure to respond to two or more trials of antidepressant monotherapy or failure to respond to four or more trials of different antidepressant therapies. (Campbell's Psychiatric Dictionary, 9th ed.)
Marked depression appearing in the involution period and characterized by hallucinations, delusions, paranoia, and agitation.
Disorders related to substance abuse.
Electrically induced CONVULSIONS primarily used in the treatment of severe AFFECTIVE DISORDERS and SCHIZOPHRENIA.
Health facilities providing therapy and/or rehabilitation for substance-dependent individuals. Methadone distribution centers are included.
A specialized residential treatment program for behavior disorders including substance abuse. It may include therapeutically planned group living and learning situations including teaching of adaptive skills to help patient functioning in the community. (From Kahn, A. P. and Fawcett, J. Encyclopedia of Mental Health, 1993, p320.)
A group of disorders characterized by physiological and psychological disturbances in appetite or food intake.
Mood-stimulating drugs used primarily in the treatment of affective disorders and related conditions. Several MONOAMINE OXIDASE INHIBITORS are useful as antidepressants apparently as a long-term consequence of their modulation of catecholamine levels. The tricyclic compounds useful as antidepressive agents (ANTIDEPRESSIVE AGENTS, TRICYCLIC) also appear to act through brain catecholamine systems. A third group (ANTIDEPRESSIVE AGENTS, SECOND-GENERATION) is a diverse group of drugs including some that act specifically on serotonergic systems.
Diminished or failed response of an organism, disease or tissue to the intended effectiveness of a chemical or drug. It should be differentiated from DRUG TOLERANCE which is the progressive diminution of the susceptibility of a human or animal to the effects of a drug, as a result of continued administration.
An affective disorder manifested by either a dysphoric mood or loss of interest or pleasure in usual activities. The mood disturbance is prominent and relatively persistent.
Agents that control agitated psychotic behavior, alleviate acute psychotic states, reduce psychotic symptoms, and exert a quieting effect. They are used in SCHIZOPHRENIA; senile dementia; transient psychosis following surgery; or MYOCARDIAL INFARCTION; etc. These drugs are often referred to as neuroleptics alluding to the tendency to produce neurological side effects, but not all antipsychotics are likely to produce such effects. Many of these drugs may also be effective against nausea, emesis, and pruritus.
Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.
A direct form of psychotherapy based on the interpretation of situations (cognitive structure of experiences) that determine how an individual feels and behaves. It is based on the premise that cognition, the process of acquiring knowledge and forming beliefs, is a primary determinant of mood and behavior. The therapy uses behavioral and verbal techniques to identify and correct negative thinking that is at the root of the aberrant behavior.
Persistent and disabling ANXIETY.
A major affective disorder marked by severe mood swings (manic or major depressive episodes) and a tendency to remission and recurrence.
Standardized procedures utilizing rating scales or interview schedules carried out by health personnel for evaluating the degree of mental illness.
Categorical classification of MENTAL DISORDERS based on criteria sets with defining features. It is produced by the American Psychiatric Association. (DSM-IV, page xxii)
Those disorders that have a disturbance in mood as their predominant feature.
Chronically depressed mood that occurs for most of the day more days than not for at least 2 years. The required minimum duration in children to make this diagnosis is 1 year. During periods of depressed mood, at least 2 of the following additional symptoms are present: poor appetite or overeating, insomnia or hypersomnia, low energy or fatigue, low self esteem, poor concentration or difficulty making decisions, and feelings of hopelessness. (DSM-IV)
Psychiatric illness or diseases manifested by breakdowns in the adaptational process expressed primarily as abnormalities of thought, feeling, and behavior producing either distress or impairment of function.
A structurally and mechanistically diverse group of drugs that are not tricyclics or monoamine oxidase inhibitors. The most clinically important appear to act selectively on serotonergic systems, especially by inhibiting serotonin reuptake.
Compounds that specifically inhibit the reuptake of serotonin in the brain.
Depressive states usually of moderate intensity in contrast with major depression present in neurotic and psychotic disorders.
A furancarbonitrile that is one of the SEROTONIN UPTAKE INHIBITORS used as an antidepressant. The drug is also effective in reducing ethanol uptake in alcoholics and is used in depressed patients who also suffer from tardive dyskinesia in preference to tricyclic antidepressants, which aggravate this condition.
Monohydroxy derivatives of cyclohexanes that contain the general formula R-C6H11O. They have a camphorlike odor and are used in making soaps, insecticides, germicides, dry cleaning, and plasticizers.
The presence of co-existing or additional diseases with reference to an initial diagnosis or with reference to the index condition that is the subject of study. Comorbidity may affect the ability of affected individuals to function and also their survival; it may be used as a prognostic indicator for length of hospital stay, cost factors, and outcome or survival.
A directed conversation aimed at eliciting information for psychiatric diagnosis, evaluation, treatment planning, etc. The interview may be conducted by a social worker or psychologist.
The first highly specific serotonin uptake inhibitor. It is used as an antidepressant and often has a more acceptable side-effects profile than traditional antidepressants.
A class of traumatic stress disorders with symptoms that last more than one month. There are various forms of post-traumatic stress disorder, depending on the time of onset and the duration of these stress symptoms. In the acute form, the duration of the symptoms is between 1 to 3 months. In the chronic form, symptoms last more than 3 months. With delayed onset, symptoms develop more than 6 months after the traumatic event.
Check list, usually to be filled out by a person about himself, consisting of many statements about personal characteristics which the subject checks.
The unsuccessful attempt to kill oneself.
Levels within a diagnostic group which are established by various measurement criteria applied to the seriousness of a patient's disorder.
A generic term for the treatment of mental illness or emotional disturbances primarily by verbal or nonverbal communication.
An anxiety disorder characterized by recurrent, persistent obsessions or compulsions. Obsessions are the intrusive ideas, thoughts, or images that are experienced as senseless or repugnant. Compulsions are repetitive and seemingly purposeful behavior which the individual generally recognizes as senseless and from which the individual does not derive pleasure although it may provide a release from tension.
Anxiety disorders in which the essential feature is persistent and irrational fear of a specific object, activity, or situation that the individual feels compelled to avoid. The individual recognizes the fear as excessive or unreasonable.
A behavior disorder originating in childhood in which the essential features are signs of developmentally inappropriate inattention, impulsivity, and hyperactivity. Although most individuals have symptoms of both inattention and hyperactivity-impulsivity, one or the other pattern may be predominant. The disorder is more frequent in males than females. Onset is in childhood. Symptoms often attenuate during late adolescence although a minority experience the full complement of symptoms into mid-adulthood. (From DSM-V)
The total number of cases of a given disease in a specified population at a designated time. It is differentiated from INCIDENCE, which refers to the number of new cases in the population at a given time.
A selective serotonin uptake inhibitor that is used in the treatment of depression.
The determination and evaluation of personality attributes by interviews, observations, tests, or scales. Articles concerning personality measurement are considered to be within scope of this term.
Disorders having the presence of physical symptoms that suggest a general medical condition but that are not fully explained by a another medical condition, by the direct effects of a substance, or by another mental disorder. The symptoms must cause clinically significant distress or impairment in social, occupational, or other areas of functioning. In contrast to FACTITIOUS DISORDERS and MALINGERING, the physical symptoms are not under voluntary control. (APA, DSM-V)
Feeling or emotion of dread, apprehension, and impending disaster but not disabling as with ANXIETY DISORDERS.
An aspect of personal behavior or lifestyle, environmental exposure, or inborn or inherited characteristic, which, on the basis of epidemiologic evidence, is known to be associated with a health-related condition considered important to prevent.
Assessment of psychological variables by the application of mathematical procedures.
A personality disorder marked by a pattern of instability of interpersonal relationships, self-image, and affects, and marked impulsivity beginning by early adulthood and present in a variety of contexts. (DSM-IV)
Child with one or more parents afflicted by a physical or mental disorder.
The part of CENTRAL NERVOUS SYSTEM that is contained within the skull (CRANIUM). Arising from the NEURAL TUBE, the embryonic brain is comprised of three major parts including PROSENCEPHALON (the forebrain); MESENCEPHALON (the midbrain); and RHOMBENCEPHALON (the hindbrain). The developed brain consists of CEREBRUM; CEREBELLUM; and other structures in the BRAIN STEM.
Studies which start with the identification of persons with a disease of interest and a control (comparison, referent) group without the disease. The relationship of an attribute to the disease is examined by comparing diseased and non-diseased persons with regard to the frequency or levels of the attribute in each group.
Disorders in which there is a loss of ego boundaries or a gross impairment in reality testing with delusions or prominent hallucinations. (From DSM-IV, 1994)
The act of killing oneself.
Disorders in which the essential feature is a severe disturbance in mood (depression, anxiety, elation, and excitement) accompanied by psychotic symptoms such as delusions, hallucinations, gross impairment in reality testing, etc.
The feeling-tone accompaniment of an idea or mental representation. It is the most direct psychic derivative of instinct and the psychic representative of the various bodily changes by means of which instincts manifest themselves.
Predetermined sets of questions used to collect data - clinical data, social status, occupational group, etc. The term is often applied to a self-completed survey instrument.
A type of anxiety disorder characterized by unexpected panic attacks that last minutes or, rarely, hours. Panic attacks begin with intense apprehension, fear or terror and, often, a feeling of impending doom. Symptoms experienced during a panic attack include dyspnea or sensations of being smothered; dizziness, loss of balance or faintness; choking sensations; palpitations or accelerated heart rate; shakiness; sweating; nausea or other form of abdominal distress; depersonalization or derealization; paresthesias; hot flashes or chills; chest discomfort or pain; fear of dying and fear of not being in control of oneself or going crazy. Agoraphobia may also develop. Similar to other anxiety disorders, it may be inherited as an autosomal dominant trait.
One of the convolutions on the medial surface of the CEREBRAL HEMISPHERES. It surrounds the rostral part of the brain and CORPUS CALLOSUM and forms part of the LIMBIC SYSTEM.
Inability to experience pleasure due to impairment or dysfunction of normal psychological and neurobiological mechanisms. It is a symptom of many PSYCHOTIC DISORDERS (e.g., DEPRESSIVE DISORDER, MAJOR; and SCHIZOPHRENIA).
Those affective states which can be experienced and have arousing and motivational properties.
Disorders in which the symptoms are distressing to the individual and recognized by him or her as being unacceptable. Social relationships may be greatly affected but usually remain within acceptable limits. The disturbance is relatively enduring or recurrent without treatment.
Non-invasive method of demonstrating internal anatomy based on the principle that atomic nuclei in a strong magnetic field absorb pulses of radiofrequency energy and emit them as radiowaves which can be reconstructed into computerized images. The concept includes proton spin tomographic techniques.
Stress wherein emotional factors predominate.
Sodium chloride-dependent neurotransmitter symporters located primarily on the PLASMA MEMBRANE of serotonergic neurons. They are different than SEROTONIN RECEPTORS, which signal cellular responses to SEROTONIN. They remove SEROTONIN from the EXTRACELLULAR SPACE by high affinity reuptake into PRESYNAPTIC TERMINALS. Regulates signal amplitude and duration at serotonergic synapses and is the site of action of the SEROTONIN UPTAKE INHIBITORS.
The return of a sign, symptom, or disease after a remission.
Substances that contain a fused three-ring moiety and are used in the treatment of depression. These drugs block the uptake of norepinephrine and serotonin into axon terminals and may block some subtypes of serotonin, adrenergic, and histamine receptors. However the mechanism of their antidepressant effects is not clear because the therapeutic effects usually take weeks to develop and may reflect compensatory changes in the central nervous system.
A repetitive and persistent pattern of behavior in which the basic rights of others or major age-appropriate societal norms or rules are violated. These behaviors include aggressive conduct that causes or threatens physical harm to other people or animals, nonaggressive conduct that causes property loss or damage, deceitfulness or theft, and serious violations of rules. The onset is before age 18. (From DSM-IV, 1994)
Those occurrences, including social, psychological, and environmental, which require an adjustment or effect a change in an individual's pattern of living.
Abnormal or excessive excitability with easily triggered anger, annoyance, or impatience.
Maleness or femaleness as a constituent element or influence contributing to the production of a result. It may be applicable to the cause or effect of a circumstance. It is used with human or animal concepts but should be differentiated from SEX CHARACTERISTICS, anatomical or physiological manifestations of sex, and from SEX DISTRIBUTION, the number of males and females in given circumstances.
The age, developmental stage, or period of life at which a disease or the initial symptoms or manifestations of a disease appear in an individual.
Studies in which variables relating to an individual or group of individuals are assessed over a period of time.
A risk factor for suicide attempts and completions, it is the most common of all suicidal behavior, but only a minority of ideators engage in overt self-harm.
Disturbances in mental processes related to learning, thinking, reasoning, and judgment.
Conditions characterized by disturbances of usual sleep patterns or behaviors. Sleep disorders may be divided into three major categories: DYSSOMNIAS (i.e. disorders characterized by insomnia or hypersomnia), PARASOMNIAS (abnormal sleep behaviors), and sleep disorders secondary to medical or psychiatric disorders. (From Thorpy, Sleep Disorders Medicine, 1994, p187)
The rostral part of the frontal lobe, bounded by the inferior precentral fissure in humans, which receives projection fibers from the MEDIODORSAL NUCLEUS OF THE THALAMUS. The prefrontal cortex receives afferent fibers from numerous structures of the DIENCEPHALON; MESENCEPHALON; and LIMBIC SYSTEM as well as cortical afferents of visual, auditory, and somatic origin.
Primarily a technique of group psychotherapy which involves a structured, directed, and dramatized acting out of the patient's personal and emotional problems.
Studies in which the presence or absence of disease or other health-related variables are determined in each member of the study population or in a representative sample at one particular time. This contrasts with LONGITUDINAL STUDIES which are followed over a period of time.
A disorder beginning in childhood. It is marked by the presence of markedly abnormal or impaired development in social interaction and communication and a markedly restricted repertoire of activity and interest. Manifestations of the disorder vary greatly depending on the developmental level and chronological age of the individual. (DSM-V)
Elements of limited time intervals, contributing to particular results or situations.
A statistical technique that isolates and assesses the contributions of categorical independent variables to variation in the mean of a continuous dependent variable.
Depression in POSTPARTUM WOMEN, usually within four weeks after giving birth (PARTURITION). The degree of depression ranges from mild transient depression to neurotic or psychotic depressive disorders. (From DSM-IV, p386)
A systematic collection of factual data pertaining to health and disease in a human population within a given geographic area.
Tests designed to assess neurological function associated with certain behaviors. They are used in diagnosing brain dysfunction or damage and central nervous system disorders or injury.
A primary, chronic disease with genetic, psychosocial, and environmental factors influencing its development and manifestations. The disease is often progressive and fatal. It is characterized by impaired control over drinking, preoccupation with the drug alcohol, use of alcohol despite adverse consequences, and distortions in thinking, most notably denial. Each of these symptoms may be continuous or periodic. (Morse & Flavin for the Joint Commission of the National Council on Alcoholism and Drug Dependence and the American Society of Addiction Medicine to Study the Definition and Criteria for the Diagnosis of Alcoholism: in JAMA 1992;268:1012-4)
A loosely defined grouping of drugs that have effects on psychological function. Here the psychotropic agents include the antidepressive agents, hallucinogens, and tranquilizing agents (including the antipsychotics and anti-anxiety agents).
A severe emotional disorder of psychotic depth characteristically marked by a retreat from reality with delusion formation, HALLUCINATIONS, emotional disharmony, and regressive behavior.
Thiophenes are aromatic heterocyclic organic compounds containing a five-membered ring with four carbon atoms and one sulfur atom, which are found in various natural substances and synthesized for use in pharmaceuticals and agrochemicals.
A major deviation from normal patterns of behavior.
A latent susceptibility to disease at the genetic level, which may be activated under certain conditions.
Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease.
Severe distortions in the development of many basic psychological functions that are not normal for any stage in development. These distortions are manifested in sustained social impairment, speech abnormalities, and peculiar motor movements.
Maladaptive reactions to identifiable psychosocial stressors occurring within a short time after onset of the stressor. They are manifested by either impairment in social or occupational functioning or by symptoms (depression, anxiety, etc.) that are in excess of a normal and expected reaction to the stressor.
The co-existence of a substance abuse disorder with a psychiatric disorder. The diagnostic principle is based on the fact that it has been found often that chemically dependent patients also have psychiatric problems of various degrees of severity.
Persons who receive ambulatory care at an outpatient department or clinic without room and board being provided.
The genetic constitution of the individual, comprising the ALLELES present at each GENETIC LOCUS.
Statistical models which describe the relationship between a qualitative dependent variable (that is, one which can take only certain discrete values, such as the presence or absence of a disease) and an independent variable. A common application is in epidemiology for estimating an individual's risk (probability of a disease) as a function of a given risk factor.
Neurotic reactions to unusual, severe, or overwhelming military stress.
Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group.
Age as a constituent element or influence contributing to the production of a result. It may be applicable to the cause or the effect of a circumstance. It is used with human or animal concepts but should be differentiated from AGING, a physiological process, and TIME FACTORS which refers only to the passage of time.
The term "United States" in a medical context often refers to the country where a patient or study participant resides, and is not a medical term per se, but relevant for epidemiological studies, healthcare policies, and understanding differences in disease prevalence, treatment patterns, and health outcomes across various geographic locations.
Branch of psychiatry concerned with the provision and delivery of a coordinated program of mental health care to a specified population. The foci included in this concept are: all social, psychological and physical factors related to etiology, prevention, and maintaining positive mental health in the community.
Country located in EUROPE. It is bordered by the NORTH SEA, BELGIUM, and GERMANY. Constituent areas are Aruba, Curacao, Sint Maarten, formerly included in the NETHERLANDS ANTILLES.
The study of significant causes and processes in the development of mental illness.
A serotonin receptor subtype found distributed through the CENTRAL NERVOUS SYSTEM where they are involved in neuroendocrine regulation of ACTH secretion. The fact that this serotonin receptor subtype is particularly sensitive to SEROTONIN RECEPTOR AGONISTS such as BUSPIRONE suggests its role in the modulation of ANXIETY and DEPRESSION.
The ability of microorganisms, especially bacteria, to resist or to become tolerant to chemotherapeutic agents, antimicrobial agents, or antibiotics. This resistance may be acquired through gene mutation or foreign DNA in transmissible plasmids (R FACTORS).
The outward appearance of the individual. It is the product of interactions between genes, and between the GENOTYPE and the environment.
Genus of perennial plants in the family CLUSIACEAE (sometimes classified as Hypericaceae). Herbal and homeopathic preparations are used for depression, neuralgias, and a variety of other conditions. Hypericum contains flavonoids; GLYCOSIDES; mucilage, TANNINS; volatile oils (OILS, ESSENTIAL), hypericin and hyperforin.
Care which provides integrated, accessible health care services by clinicians who are accountable for addressing a large majority of personal health care needs, developing a sustained partnership with patients, and practicing in the context of family and community. (JAMA 1995;273(3):192)
Studies in which subsets of a defined population are identified. These groups may or may not be exposed to factors hypothesized to influence the probability of the occurrence of a particular disease or other outcome. Cohorts are defined populations which, as a whole, are followed in an attempt to determine distinguishing subgroup characteristics.
Imaging techniques used to colocalize sites of brain functions or physiological activity with brain structures.
Almond-shaped group of basal nuclei anterior to the INFERIOR HORN OF THE LATERAL VENTRICLE of the TEMPORAL LOBE. The amygdala is part of the limbic system.
Disorders related to or resulting from abuse or mis-use of alcohol.
Obsessive, persistent, intense fear of open places.
Includes two similar disorders: oppositional defiant disorder and CONDUCT DISORDERS. Symptoms occurring in children with these disorders include: defiance of authority figures, angry outbursts, and other antisocial behaviors.
Any tests that demonstrate the relative efficacy of different chemotherapeutic agents against specific microorganisms (i.e., bacteria, fungi, viruses).
A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment.
Substances that reduce the growth or reproduction of BACTERIA.
Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations.
Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care. (Dictionary of Health Services Management, 2d ed)
Organized services to provide mental health care.
Physiological changes that occur in bodies after death.
A collection of NEURONS, tracts of NERVE FIBERS, endocrine tissue, and blood vessels in the HYPOTHALAMUS and the PITUITARY GLAND. This hypothalamo-hypophyseal portal circulation provides the mechanism for hypothalamic neuroendocrine (HYPOTHALAMIC HORMONES) regulation of pituitary function and the release of various PITUITARY HORMONES into the systemic circulation to maintain HOMEOSTASIS.
The part of the cerebral hemisphere anterior to the central sulcus, and anterior and superior to the lateral sulcus.
A member of the nerve growth factor family of trophic factors. In the brain BDNF has a trophic action on retinal, cholinergic, and dopaminergic neurons, and in the peripheral nervous system it acts on both motor and sensory neurons. (From Kendrew, The Encyclopedia of Molecular Biology, 1994)
Adaptation of the person to the social environment. Adjustment may take place by adapting the self to the environment or by changing the environment. (From Campbell, Psychiatric Dictionary, 1996)
Disorders characterized by recurrent TICS that may interfere with speech and other activities. Tics are sudden, rapid, nonrhythmic, stereotyped motor movements or vocalizations which may be exacerbated by stress and are generally attenuated during absorbing activities. Tic disorders are distinguished from conditions which feature other types of abnormal movements that may accompany another another condition. (From DSM-IV, 1994)
Mood or emotional responses dissonant with or inappropriate to the behavior and/or stimulus.
The medical science that deals with the origin, diagnosis, prevention, and treatment of mental disorders.
The interactions between the anterior pituitary and adrenal glands, in which corticotropin (ACTH) stimulates the adrenal cortex and adrenal cortical hormones suppress the production of corticotropin by the anterior pituitary.
Pricing statements presented by more than one party for the purpose of securing a contract.
A set of forebrain structures common to all mammals that is defined functionally and anatomically. It is implicated in the higher integration of visceral, olfactory, and somatic information as well as homeostatic responses including fundamental survival behaviors (feeding, mating, emotion). For most authors, it includes the AMYGDALA; EPITHALAMUS; GYRUS CINGULI; hippocampal formation (see HIPPOCAMPUS); HYPOTHALAMUS; PARAHIPPOCAMPAL GYRUS; SEPTAL NUCLEI; anterior nuclear group of thalamus, and portions of the basal ganglia. (Parent, Carpenter's Human Neuroanatomy, 9th ed, p744; NeuroNames, http://rprcsgi.rprc.washington.edu/neuronames/index.html (September 2, 1998)).
The statistical reproducibility of measurements (often in a clinical context), including the testing of instrumentation or techniques to obtain reproducible results. The concept includes reproducibility of physiological measurements, which may be used to develop rules to assess probability or prognosis, or response to a stimulus; reproducibility of occurrence of a condition; and reproducibility of experimental results.
A state of harmony between internal needs and external demands and the processes used in achieving this condition. (From APA Thesaurus of Psychological Index Terms, 8th ed)
A personality disorder characterized by a pervasive and excessive need to be taken care of that leads to submissive and clinging behavior and fears of separation, beginning by early adulthood and present in a variety of contexts. (From DSM-IV, 1994)
I'm sorry for any confusion, but the term "Oregon" is a geographical location and not a medical concept or condition. It is a state in the Pacific Northwest region of the United States. If you have any questions related to medical topics, I would be happy to help answer those!
Facilities which administer the delivery of mental health counseling services to children.
Methods for visualizing REGIONAL BLOOD FLOW, metabolic, electrical, or other physiological activities in the CENTRAL NERVOUS SYSTEM using various imaging modalities.
The main glucocorticoid secreted by the ADRENAL CORTEX. Its synthetic counterpart is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions.
A serotonin uptake inhibitor that is effective in the treatment of depression.
Observable changes of expression in the face in response to emotional stimuli.
A reversible inhibitor of monoamine oxidase type A; (RIMA); (see MONOAMINE OXIDASE INHIBITORS) that has antidepressive properties.
A generic concept reflecting concern with the modification and enhancement of life attributes, e.g., physical, political, moral and social environment; the overall condition of a human life.
The sum of all nonspecific systemic reactions of the body to long-continued exposure to systemic stress.
Abuse of children in a family, institutional, or other setting. (APA, Thesaurus of Psychological Index Terms, 1994)
Social and economic factors that characterize the individual or group within the social structure.
A personality disorder whose essential feature is a pervasive pattern of disregard for, and violation of, the rights of others that begins in childhood or early adolescence and continues into adulthood. The individual must be at least age 18 and must have a history of some symptoms of CONDUCT DISORDER before age 15. (From DSM-IV, 1994)
Agents that are used to treat bipolar disorders or mania associated with other affective disorders.
A single nucleotide variation in a genetic sequence that occurs at appreciable frequency in the population.
Measurable biological (physiological, biochemical, and anatomical features), behavioral (psychometric pattern) or cognitive markers that are found more often in individuals with a disease than in the general population. Because many endophenotypes are present before the disease onset and in individuals with heritable risk for disease such as unaffected family members, they can be used to help diagnose and search for causative genes.
Disorders affecting TWINS, one or both, at any age.

Using electronic medical records to enable large-scale studies in psychiatry: treatment resistant depression as a model. (1/41)

 (+info)

Rumination-focused cognitive-behavioural therapy for residual depression: phase II randomised controlled trial. (2/41)

 (+info)

Baseline brain metabolism in resistant depression and response to transcranial magnetic stimulation. (3/41)

 (+info)

Association between antidepressant resistance in unipolar depression and subsequent bipolar disorder: cohort study. (4/41)

 (+info)

Treatment-resistant depressed youth show a higher response rate if treatment ends during summer school break. (5/41)

 (+info)

Brain blood-flow change with acute vagus nerve stimulation in treatment-refractory major depressive disorder. (6/41)

 (+info)

Ketamine as a novel antidepressant: from synapse to behavior. (7/41)

 (+info)

Bipolar depression and treatment with antidepressants. (8/41)

 (+info)

Treatment-resistant depressive disorder is a severe form of depression that does not respond to standard treatments. It is also known as refractory depression or treatment-refractory depression.

The Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) defines treatment-resistant depressive disorder as a major depressive disorder that has not responded to at least two trials of adequate doses of appropriately chosen antidepressant medications, either singly or in combination, for a sufficient duration of time.

The definition may also include cases where the patient has not responded to psychotherapy, electroconvulsive therapy (ECT), transcranial magnetic stimulation (TMS), or other forms of treatment.

It is important to note that determining whether a depression is truly treatment-resistant can be challenging and requires careful evaluation by a mental health professional. Factors such as medication adherence, dosage, duration of treatment, and the presence of co-occurring medical or psychiatric conditions must be taken into account before making this diagnosis.

Major Depressive Disorder (MDD), also simply referred to as depression, is a serious mental health condition characterized by the presence of one or more major depressive episodes. A major depressive episode is a period of at least two weeks during which an individual experiences a severely depressed mood and/or loss of interest or pleasure in nearly all activities, accompanied by at least four additional symptoms such as significant changes in appetite or weight, sleep disturbances, psychomotor agitation or retardation, fatigue or loss of energy, feelings of worthlessness or excessive guilt, difficulty thinking, concentrating, or making decisions, and recurrent thoughts of death or suicide.

MDD can significantly impair an individual's ability to function in daily life, and it is associated with increased risks of suicide, substance abuse, and other mental health disorders. The exact cause of MDD is not fully understood, but it is believed to result from a complex interplay of genetic, biological, environmental, and psychological factors. Treatment typically involves a combination of psychotherapy (such as cognitive-behavioral therapy) and medication (such as selective serotonin reuptake inhibitors or tricyclic antidepressants).

Substance-related disorders, as defined in the Diagnostic and Statistical Manual of Mental Disorders (DSM-5), refer to a group of conditions caused by the use of substances such as alcohol, drugs, or medicines. These disorders are characterized by a problematic pattern of using a substance that leads to clinically significant impairment or distress. They can be divided into two main categories: substance use disorders and substance-induced disorders. Substance use disorders involve a pattern of compulsive use despite negative consequences, while substance-induced disorders include conditions such as intoxication, withdrawal, and substance/medication-induced mental disorders. The specific diagnosis depends on the type of substance involved, the patterns of use, and the presence or absence of physiological dependence.

Electroconvulsive therapy (ECT) is a medical treatment most commonly used in cases of severe or treatment-resistant major depression, bipolar disorder, and catatonia. In ECT, a brief electrical current is passed through the brain, intentionally triggering a seizure. The purpose and specific effects of this procedure are not fully understood, but it's believed to cause changes in brain chemistry that can help relieve symptoms of certain mental health conditions.

The treatment is typically administered under general anesthesia and is usually given two to three times a week for a total of six to twelve treatments. While ECT has been associated with certain risks, such as memory loss and confusion, it is generally considered safe when performed by trained medical professionals. It's important to note that ECT should only be used in cases where other treatment options have been exhausted or have proven ineffective.

Substance abuse treatment centers are healthcare facilities that provide a range of services for individuals struggling with substance use disorders (SUDs), including addiction to alcohol, illicit drugs, prescription medications, and other substances. These centers offer comprehensive, evidence-based assessments, interventions, and treatments aimed at helping patients achieve and maintain sobriety, improve their overall health and well-being, and reintegrate into society as productive members.

The medical definition of 'Substance Abuse Treatment Centers' encompasses various levels and types of care, such as:

1. **Medical Detoxification:** This is the first step in treating substance abuse, where patients are closely monitored and managed for withdrawal symptoms as their bodies clear the harmful substances. Medical detox often involves the use of medications to alleviate discomfort and ensure safety during the process.
2. **Inpatient/Residential Treatment:** This level of care provides 24-hour structured, intensive treatment in a controlled environment. Patients live at the facility and receive various therapeutic interventions, such as individual therapy, group counseling, family therapy, and psychoeducation, to address the underlying causes of their addiction and develop coping strategies for long-term recovery.
3. **Partial Hospitalization Programs (PHP):** Also known as day treatment, PHPs offer structured, intensive care for several hours a day while allowing patients to return home or to a sober living environment during non-treatment hours. This level of care typically includes individual and group therapy, skill-building activities, and case management services.
4. **Intensive Outpatient Programs (IOP):** IOPs provide flexible, less intensive treatment than PHPs, with patients attending sessions for a few hours per day, several days a week. These programs focus on relapse prevention, recovery skills, and addressing any co-occurring mental health conditions.
5. **Outpatient Treatment:** This is the least restrictive level of care, where patients attend individual or group therapy sessions on a regular basis while living at home or in a sober living environment. Outpatient treatment often serves as step-down care after completing higher levels of treatment or as an initial intervention for those with milder SUDs.
6. **Aftercare/Continuing Care:** Aftercare or continuing care services help patients maintain their recovery and prevent relapse by providing ongoing support, such as 12-step meetings, alumni groups, individual therapy, and case management.

Each treatment modality has its unique benefits and is tailored to meet the specific needs of individuals at various stages of addiction and recovery. It's essential to consult with a healthcare professional or an addiction specialist to determine the most appropriate level of care for each person's situation.

Residential treatment, also known as inpatient treatment, refers to a type of healthcare service in which patients receive 24-hour medical and psychological care in a residential setting. This type of treatment is typically provided for individuals who require a higher level of care than what can be provided on an outpatient basis. Residential treatment programs may include a variety of services such as medical and psychiatric evaluations, medication management, individual and group therapy, psychoeducation, and recreational activities. These programs are often used to treat various mental health conditions including substance use disorders, depression, anxiety, bipolar disorder, and other serious mental illnesses. The goal of residential treatment is to provide a safe and structured environment where patients can focus on their recovery and develop the skills they need to manage their condition and improve their overall quality of life.

Eating disorders are mental health conditions characterized by significant disturbances in eating behaviors and associated distressing thoughts and emotions. They include several types of disorders, such as anorexia nervosa, bulimia nervosa, binge eating disorder, and other specified feeding or eating disorders (OSFED). These disorders can have serious medical and psychological consequences if left untreated.

Anorexia nervosa is characterized by restrictive eating, low body weight, and an intense fear of gaining weight or becoming fat. Individuals with anorexia may also have a distorted body image and deny the severity of their low body weight.

Bulimia nervosa involves recurrent episodes of binge eating followed by compensatory behaviors such as purging (e.g., self-induced vomiting, misuse of laxatives or diuretics), fasting, or excessive exercise to prevent weight gain.

Binge eating disorder is characterized by recurrent episodes of eating large amounts of food in a short period of time, often to the point of discomfort, accompanied by feelings of loss of control and distress. Unlike bulimia nervosa, individuals with binge eating disorder do not engage in compensatory behaviors to prevent weight gain.

Other specified feeding or eating disorders (OSFED) include atypical anorexia nervosa, subthreshold bulimia nervosa, and subthreshold binge eating disorder, which may have similar symptoms to the above disorders but do not meet all the diagnostic criteria.

Eating disorders can affect people of any age, gender, race, or ethnicity, and they are often associated with other mental health conditions such as depression, anxiety, and obsessive-compulsive disorder. Treatment typically involves a combination of psychological therapy, nutrition counseling, and medical management to address both the physical and psychological aspects of the disorder.

Antidepressive agents are a class of medications used to treat various forms of depression and anxiety disorders. They act on neurotransmitters, the chemical messengers in the brain, to restore the balance that has been disrupted by mental illness. The most commonly prescribed types of antidepressants include selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), and monoamine oxidase inhibitors (MAOIs). These medications can help alleviate symptoms such as low mood, loss of interest in activities, changes in appetite and sleep patterns, fatigue, difficulty concentrating, and thoughts of death or suicide. It is important to note that antidepressants may take several weeks to reach their full effectiveness and may cause side effects, so it is essential to work closely with a healthcare provider to find the right medication and dosage.

Drug resistance, also known as antimicrobial resistance, is the ability of a microorganism (such as bacteria, viruses, fungi, or parasites) to withstand the effects of a drug that was originally designed to inhibit or kill it. This occurs when the microorganism undergoes genetic changes that allow it to survive in the presence of the drug. As a result, the drug becomes less effective or even completely ineffective at treating infections caused by these resistant organisms.

Drug resistance can develop through various mechanisms, including mutations in the genes responsible for producing the target protein of the drug, alteration of the drug's target site, modification or destruction of the drug by enzymes produced by the microorganism, and active efflux of the drug from the cell.

The emergence and spread of drug-resistant microorganisms pose significant challenges in medical treatment, as they can lead to increased morbidity, mortality, and healthcare costs. The overuse and misuse of antimicrobial agents, as well as poor infection control practices, contribute to the development and dissemination of drug-resistant strains. To address this issue, it is crucial to promote prudent use of antimicrobials, enhance surveillance and monitoring of resistance patterns, invest in research and development of new antimicrobial agents, and strengthen infection prevention and control measures.

A depressive disorder is a mental health condition characterized by persistent feelings of sadness, hopelessness, and loss of interest or pleasure in activities. It can also include changes in sleep, appetite, energy levels, concentration, and self-esteem, as well as thoughts of death or suicide. Depressive disorders can vary in severity and duration, with some people experiencing mild and occasional symptoms, while others may have severe and chronic symptoms that interfere with their ability to function in daily life.

There are several types of depressive disorders, including major depressive disorder (MDD), persistent depressive disorder (PDD), and postpartum depression. MDD is characterized by symptoms that interfere significantly with a person's ability to function and last for at least two weeks, while PDD involves chronic low-grade depression that lasts for two years or more. Postpartum depression occurs in women after childbirth and can range from mild to severe.

Depressive disorders are thought to be caused by a combination of genetic, biological, environmental, and psychological factors. Treatment typically involves a combination of medication, psychotherapy (talk therapy), and lifestyle changes.

Antipsychotic agents are a class of medications used to manage and treat psychosis, which includes symptoms such as delusions, hallucinations, paranoia, disordered thought processes, and agitated behavior. These drugs work by blocking the action of dopamine, a neurotransmitter in the brain that is believed to play a role in the development of psychotic symptoms. Antipsychotics can be broadly divided into two categories: first-generation antipsychotics (also known as typical antipsychotics) and second-generation antipsychotics (also known as atypical antipsychotics).

First-generation antipsychotics, such as chlorpromazine, haloperidol, and fluphenazine, were developed in the 1950s and have been widely used for several decades. They are generally effective in reducing positive symptoms of psychosis (such as hallucinations and delusions) but can cause significant side effects, including extrapyramidal symptoms (EPS), such as rigidity, tremors, and involuntary movements, as well as weight gain, sedation, and orthostatic hypotension.

Second-generation antipsychotics, such as clozapine, risperidone, olanzapine, quetiapine, and aripiprazole, were developed more recently and are considered to have a more favorable side effect profile than first-generation antipsychotics. They are generally effective in reducing both positive and negative symptoms of psychosis (such as apathy, anhedonia, and social withdrawal) and cause fewer EPS. However, they can still cause significant weight gain, metabolic disturbances, and sedation.

Antipsychotic agents are used to treat various psychiatric disorders, including schizophrenia, bipolar disorder, major depressive disorder with psychotic features, delusional disorder, and other conditions that involve psychosis or agitation. They can be administered orally, intramuscularly, or via long-acting injectable formulations. The choice of antipsychotic agent depends on the individual patient's needs, preferences, and response to treatment, as well as the potential for side effects. Regular monitoring of patients taking antipsychotics is essential to ensure their safety and effectiveness.

Treatment outcome is a term used to describe the result or effect of medical treatment on a patient's health status. It can be measured in various ways, such as through symptoms improvement, disease remission, reduced disability, improved quality of life, or survival rates. The treatment outcome helps healthcare providers evaluate the effectiveness of a particular treatment plan and make informed decisions about future care. It is also used in clinical research to compare the efficacy of different treatments and improve patient care.

Cognitive Therapy (CT) is a type of psychotherapeutic treatment that helps patients understand the thoughts and feelings that influence behaviors. It is a form of talk therapy where the therapist and the patient work together to identify and change negative or distorted thinking patterns and beliefs, with the goal of improving emotional response and behavior.

Cognitive Therapy is based on the idea that our thoughts, feelings, and behaviors are all interconnected, and that negative or inaccurate thoughts can contribute to problems like anxiety and depression. By identifying and challenging these thoughts, patients can learn to think more realistically and positively, which can lead to improvements in their mood and behavior.

In cognitive therapy sessions, the therapist will help the patient identify negative thought patterns and replace them with healthier, more accurate ways of thinking. The therapist may also assign homework or exercises for the patient to practice between sessions, such as keeping a thought record or challenging negative thoughts.

Cognitive Therapy has been shown to be effective in treating a wide range of mental health conditions, including depression, anxiety disorders, eating disorders, and post-traumatic stress disorder (PTSD). It is often used in combination with other forms of treatment, such as medication, and can be delivered individually or in group settings.

Anxiety disorders are a category of mental health disorders characterized by feelings of excessive and persistent worry, fear, or anxiety that interfere with daily activities. They include several different types of disorders, such as:

1. Generalized Anxiety Disorder (GAD): This is characterized by chronic and exaggerated worry and tension, even when there is little or nothing to provoke it.
2. Panic Disorder: This is characterized by recurring unexpected panic attacks and fear of experiencing more panic attacks.
3. Social Anxiety Disorder (SAD): Also known as social phobia, this is characterized by excessive fear, anxiety, or avoidance of social situations due to feelings of embarrassment, self-consciousness, and concern about being judged or viewed negatively by others.
4. Phobias: These are intense, irrational fears of certain objects, places, or situations. When a person with a phobia encounters the object or situation they fear, they may experience panic attacks or other severe anxiety responses.
5. Agoraphobia: This is a fear of being in places where it may be difficult to escape or get help if one has a panic attack or other embarrassing or incapacitating symptoms.
6. Separation Anxiety Disorder (SAD): This is characterized by excessive anxiety about separation from home or from people to whom the individual has a strong emotional attachment (such as a parent, sibling, or partner).
7. Selective Mutism: This is a disorder where a child becomes mute in certain situations, such as at school, but can speak normally at home or with close family members.

These disorders are treatable with a combination of medication and psychotherapy (cognitive-behavioral therapy, exposure therapy). It's important to seek professional help if you suspect that you or someone you know may have an anxiety disorder.

Bipolar disorder, also known as manic-depressive illness, is a mental health condition that causes extreme mood swings that include emotional highs (mania or hypomania) and lows (depression). When you become depressed, you may feel sad or hopeless and lose interest or pleasure in most activities. When your mood shifts to mania or hypomania (a less severe form of mania), you may feel euphoric, full of energy, or unusually irritable. These mood swings can significantly affect your job, school, relationships, and overall quality of life.

Bipolar disorder is typically characterized by the presence of one or more manic or hypomanic episodes, often accompanied by depressive episodes. The episodes may be separated by periods of normal mood, but in some cases, a person may experience rapid cycling between mania and depression.

There are several types of bipolar disorder, including:

* Bipolar I Disorder: This type is characterized by the occurrence of at least one manic episode, which may be preceded or followed by hypomanic or major depressive episodes.
* Bipolar II Disorder: This type involves the presence of at least one major depressive episode and at least one hypomanic episode, but no manic episodes.
* Cyclothymic Disorder: This type is characterized by numerous periods of hypomania and depression that are not severe enough to meet the criteria for a full manic or depressive episode.
* Other Specified and Unspecified Bipolar and Related Disorders: These categories include bipolar disorders that do not fit the criteria for any of the other types.

The exact cause of bipolar disorder is unknown, but it appears to be related to a combination of genetic, environmental, and neurochemical factors. Treatment typically involves a combination of medication, psychotherapy, and lifestyle changes to help manage symptoms and prevent relapses.

Psychiatric Status Rating Scales are standardized assessment tools used by mental health professionals to evaluate and rate the severity of a person's psychiatric symptoms and functioning. These scales provide a systematic and structured approach to measuring various aspects of an individual's mental health, such as mood, anxiety, psychosis, behavior, and cognitive abilities.

The purpose of using Psychiatric Status Rating Scales is to:

1. Assess the severity and improvement of psychiatric symptoms over time.
2. Aid in diagnostic decision-making and treatment planning.
3. Monitor treatment response and adjust interventions accordingly.
4. Facilitate communication among mental health professionals about a patient's status.
5. Provide an objective basis for research and epidemiological studies.

Examples of Psychiatric Status Rating Scales include:

1. Clinical Global Impression (CGI): A brief, subjective rating scale that measures overall illness severity, treatment response, and improvement.
2. Positive and Negative Syndrome Scale (PANSS): A comprehensive scale used to assess the symptoms of psychosis, including positive, negative, and general psychopathology domains.
3. Hamilton Rating Scale for Depression (HRSD) or Montgomery-Ã…sberg Depression Rating Scale (MADRS): Scales used to evaluate the severity of depressive symptoms.
4. Young Mania Rating Scale (YMRS): A scale used to assess the severity of manic or hypomanic symptoms.
5. Brief Psychiatric Rating Scale (BPRS) or Symptom Checklist-90 Revised (SCL-90-R): Scales that measure a broad range of psychiatric symptoms and psychopathology.
6. Global Assessment of Functioning (GAF): A scale used to rate an individual's overall psychological, social, and occupational functioning on a hypothetical continuum of mental health-illness.

It is important to note that Psychiatric Status Rating Scales should be administered by trained mental health professionals to ensure accurate and reliable results.

The Diagnostic and Statistical Manual of Mental Disorders (DSM) is a publication of the American Psychiatric Association (APA) that provides diagnostic criteria for mental disorders. It is widely used by mental health professionals in the United States and around the world to diagnose and classify mental health conditions.

The DSM includes detailed descriptions of symptoms, clinical examples, and specific criteria for each disorder, which are intended to facilitate accurate diagnosis and improve communication among mental health professionals. The manual is regularly updated to reflect current research and clinical practice, with the most recent edition being the DSM-5, published in 2013.

It's important to note that while the DSM is a valuable tool for mental health professionals, it is not without controversy. Some critics argue that the manual medicalizes normal human experiences and that its categories may be too broad or overlapping. Nonetheless, it remains an essential resource for clinicians, researchers, and policymakers in the field of mental health.

Mood disorders are a category of mental health disorders characterized by significant and persistent changes in mood, affect, and emotional state. These disorders can cause disturbances in normal functioning and significantly impair an individual's ability to carry out their daily activities. The two primary types of mood disorders are depressive disorders (such as major depressive disorder or persistent depressive disorder) and bipolar disorders (which include bipolar I disorder, bipolar II disorder, and cyclothymic disorder).

Depressive disorders involve prolonged periods of low mood, sadness, hopelessness, and a lack of interest in activities. Individuals with these disorders may also experience changes in sleep patterns, appetite, energy levels, concentration, and self-esteem. In severe cases, they might have thoughts of death or suicide.

Bipolar disorders involve alternating episodes of mania (or hypomania) and depression. During a manic episode, individuals may feel extremely elated, energetic, or irritable, with racing thoughts, rapid speech, and impulsive behavior. They might engage in risky activities, have decreased sleep needs, and display poor judgment. In contrast, depressive episodes involve the same symptoms as depressive disorders.

Mood disorders can be caused by a combination of genetic, biological, environmental, and psychological factors. Proper diagnosis and treatment, which may include psychotherapy, medication, or a combination of both, are essential for managing these conditions and improving quality of life.

Dysthymic disorder, also known as persistent depressive disorder, is a chronic type of depression where a person's moods are regularly low. It is characterized by depressed mood that occurs for most of the day, for at least two years, and is accompanied by at least two other symptoms such as appetite or sleep changes, low energy, low self-esteem, difficulty making decisions, or feelings of hopelessness.

To meet the diagnostic criteria, the symptoms cannot be explained by substance abuse or a medical condition, and they must cause significant distress or impairment in social, occupational, or other important areas of functioning. Dysthymic disorder typically has a chronic course, but it may respond to treatment, including psychotherapy and medication.

A mental disorder is a syndrome characterized by clinically significant disturbance in an individual's cognition, emotion regulation, or behavior. It's associated with distress and/or impaired functioning in social, occupational, or other important areas of life, often leading to a decrease in quality of life. These disorders are typically persistent and can be severe and disabling. They may be related to factors such as genetics, early childhood experiences, or trauma. Examples include depression, anxiety disorders, bipolar disorder, schizophrenia, and personality disorders. It's important to note that a diagnosis should be made by a qualified mental health professional.

Second-generation antidepressants (SGAs) are a class of medications used primarily for the treatment of depression, although they are also used for other psychiatric and medical conditions. They are called "second-generation" because they were developed after the first generation of antidepressants, which include tricyclic antidepressants (TCAs) and monoamine oxidase inhibitors (MAOIs).

SGAs are also known as atypical antidepressants or novel antidepressants. They work by affecting the levels of neurotransmitters in the brain, such as serotonin, norepinephrine, and dopamine. However, they have a different chemical structure and mechanism of action than first-generation antidepressants.

Some examples of second-generation antidepressants include:

* Selective serotonin reuptake inhibitors (SSRIs) such as fluoxetine (Prozac), sertraline (Zoloft), and citalopram (Celexa)
* Serotonin-norepinephrine reuptake inhibitors (SNRIs) such as venlafaxine (Effexor) and duloxetine (Cymbalta)
* Norepinephrine and dopamine reuptake inhibitors (NDRIs) such as bupropion (Wellbutrin)
* Atypical antidepressants such as mirtazapine (Remeron), trazodone, and vortioxetine (Brintellix)

SGAs are generally considered to have a more favorable side effect profile than first-generation antidepressants. They are less likely to cause anticholinergic effects such as dry mouth, constipation, and blurred vision, and they are less likely to cause cardiac conduction abnormalities or orthostatic hypotension. However, SGAs may still cause side effects such as nausea, insomnia, sexual dysfunction, and weight gain.

It's important to note that the choice of antidepressant medication should be individualized based on the patient's specific symptoms, medical history, and other factors. It may take some trial and error to find the most effective and well-tolerated medication for a given patient.

Serotonin uptake inhibitors (also known as Selective Serotonin Reuptake Inhibitors or SSRIs) are a class of medications primarily used to treat depression and anxiety disorders. They work by increasing the levels of serotonin, a neurotransmitter in the brain that helps regulate mood, appetite, and sleep, among other functions.

SSRIs block the reuptake of serotonin into the presynaptic neuron, allowing more serotonin to be available in the synapse (the space between two neurons) for binding to postsynaptic receptors. This results in increased serotonergic neurotransmission and improved mood regulation.

Examples of SSRIs include fluoxetine (Prozac), sertraline (Zoloft), paroxetine (Paxil), citalopram (Celexa), and escitalopram (Lexapro). These medications are generally well-tolerated, with side effects that may include nausea, headache, insomnia, sexual dysfunction, and increased anxiety or agitation. However, they can have serious interactions with other medications, so it is important to inform your healthcare provider of all medications you are taking before starting an SSRI.

Depression is a mood disorder that is characterized by persistent feelings of sadness, hopelessness, and loss of interest in activities. It can also cause significant changes in sleep, appetite, energy level, concentration, and behavior. Depression can interfere with daily life and normal functioning, and it can increase the risk of suicide and other mental health disorders. The exact cause of depression is not known, but it is believed to be related to a combination of genetic, biological, environmental, and psychological factors. There are several types of depression, including major depressive disorder, persistent depressive disorder, postpartum depression, and seasonal affective disorder. Treatment for depression typically involves a combination of medication and psychotherapy.

Citalopram is a type of antidepressant known as a selective serotonin reuptake inhibitor (SSRI). It works by increasing the levels of serotonin, a neurotransmitter in the brain that helps maintain mental balance. Citalopram is primarily used to treat major depressive disorder and is also sometimes used to treat anxiety disorders, such as panic disorder or social anxiety disorder.

The medical definition of Citalopram can be described as follows:

Citalopram (brand name Celexa) is a selective serotonin reuptake inhibitor (SSRI) antidepressant that is primarily used to treat major depressive disorder. It works by increasing the levels of serotonin, a neurotransmitter in the brain that helps maintain mental balance. Citalopram may also be used off-label for the treatment of anxiety disorders, such as panic disorder or social anxiety disorder.

Common side effects of citalopram include nausea, dry mouth, increased sweating, sleepiness, fatigue, and insomnia. More serious side effects can include an increased risk of suicidal thoughts or behavior in children, adolescents, and young adults, as well as an increased risk of bleeding, particularly if taken with other medications that increase the risk of bleeding. Citalopram should be used with caution in patients with a history of heart disease, liver disease, or seizure disorders. It is important to follow the dosage instructions provided by your healthcare provider and to inform them of any other medications you are taking, as well as any medical conditions you have, before starting citalopram.

Cyclohexanols are a class of organic compounds that contain a cyclohexane ring (a six-carbon saturated ring) with a hydroxyl group (-OH) attached to it. The hydroxyl group makes these compounds alcohols, and the cyclohexane ring provides a unique structure that can adopt different conformations.

The presence of the hydroxyl group in cyclohexanols allows them to act as solvents, intermediates in chemical synthesis, and starting materials for the production of other chemicals. They are used in various industries, including pharmaceuticals, agrochemicals, and polymers.

Cyclohexanols can exist in different forms, such as cis- and trans-isomers, depending on the orientation of the hydroxyl group relative to the cyclohexane ring. The physical and chemical properties of these isomers can differ significantly due to their distinct structures and conformations.

Examples of cyclohexanols include cyclohexanol itself (C6H11OH), as well as its derivatives, such as methylcyclohexanol (C7H13OH) and phenylcyclohexanol (C12H15OH).

Comorbidity is the presence of one or more additional health conditions or diseases alongside a primary illness or condition. These co-occurring health issues can have an impact on the treatment plan, prognosis, and overall healthcare management of an individual. Comorbidities often interact with each other and the primary condition, leading to more complex clinical situations and increased healthcare needs. It is essential for healthcare professionals to consider and address comorbidities to provide comprehensive care and improve patient outcomes.

A psychological interview is a clinical assessment tool used by mental health professionals to gather information about a person's cognitive, emotional, and behavioral status. It is a structured or unstructured conversation between the clinician and the client aimed at understanding the client's symptoms, concerns, personal history, current life situation, and any other relevant factors that contribute to their psychological state.

The interview may cover various topics such as the individual's mental health history, family background, social relationships, education, occupation, coping mechanisms, and substance use. The clinician will also assess the person's cognitive abilities, emotional expression, thought processes, and behavior during the interview to help form a diagnosis or treatment plan.

The psychological interview is an essential component of a comprehensive mental health evaluation, as it provides valuable insights into the individual's subjective experiences and helps establish a therapeutic relationship between the clinician and the client. It can be conducted in various settings, including hospitals, clinics, private practices, or community centers.

Fluoxetine is a selective serotonin reuptake inhibitor (SSRI) medication that is primarily used to treat major depressive disorder, obsessive-compulsive disorder, bulimia nervosa, panic disorder, and premenstrual dysphoric disorder. It works by increasing the levels of serotonin, a neurotransmitter in the brain that helps maintain mental balance.

Fluoxetine is available under the brand name Prozac and is also available as a generic medication. It comes in various forms, including capsules, tablets, delayed-release capsules, and liquid solution. The typical starting dose for adults with depression is 20 mg per day, but the dosage may be adjusted based on individual patient needs and response to treatment.

Fluoxetine has a relatively long half-life, which means it stays in the body for an extended period of time. This can be beneficial for patients who may have difficulty remembering to take their medication daily, as they may only need to take it once or twice a week. However, it also means that it may take several weeks for the full effects of the medication to become apparent.

As with any medication, fluoxetine can cause side effects, including nausea, dry mouth, sleepiness, insomnia, dizziness, and headache. In some cases, it may also increase the risk of suicidal thoughts or behavior in children, adolescents, and young adults, particularly during the initial stages of treatment. It is important for patients to discuss any concerns about side effects with their healthcare provider.

Post-traumatic stress disorder (PTSD) is a psychiatric condition that can occur in people who have experienced or witnessed a traumatic event such as a natural disaster, serious accident, war combat, rape, or violent personal assault. According to the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5), PTSD is characterized by the following symptoms, which must last for more than one month:

1. Intrusion symptoms: These include distressing memories, nightmares, flashbacks, or intense psychological distress or reactivity to internal or external cues that symbolize or resemble an aspect of the traumatic event.
2. Avoidance symptoms: Persistent avoidance of stimuli associated with the traumatic event, including thoughts, feelings, conversations, activities, places, or people.
3. Negative alterations in cognitions and mood: This includes negative beliefs about oneself, others, or the world; distorted blame of self or others for causing the trauma; persistent negative emotional state; decreased interest in significant activities; and feelings of detachment or estrangement from others.
4. Alterations in arousal and reactivity: This includes irritable behavior and angry outbursts, reckless or self-destructive behavior, hypervigilance, exaggerated startle response, problems with concentration, and sleep disturbance.
5. Duration of symptoms: The symptoms must last for more than one month.
6. Functional significance: The symptoms cause clinically significant distress or impairment in social, occupational, or other important areas of functioning.

It is essential to note that PTSD can occur at any age and can be accompanied by various physical and mental health problems, such as depression, substance abuse, memory problems, and other difficulties in cognition. Appropriate treatment, which may include psychotherapy, medication, or a combination of both, can significantly improve the symptoms and overall quality of life for individuals with PTSD.

A Personality Inventory is a standardized test used in psychology to assess an individual's personality traits and characteristics. It typically consists of a series of multiple-choice questions or statements that the respondent must rate according to their level of agreement or disagreement. The inventory measures various aspects of an individual's behavior, attitudes, and temperament, providing a quantifiable score that can be compared to normative data to help diagnose personality disorders, assess personal strengths and weaknesses, or provide insights into an individual's likely responses to different situations. Examples of well-known personality inventories include the Minnesota Multiphasic Personality Inventory (MMPI) and the California Psychological Inventory (CPI).

According to the World Health Organization (WHO), "An attempted suicide is a non-fatal self-directed, potentially injurious behavior with intent to die as a result of the behavior. It's a clear expression of intention to die."

It's important to note that anyone who has attempted suicide requires immediate professional medical attention and support. They should be assessed for their level of suicidal ideation and any underlying mental health conditions, and provided with appropriate care and treatment. If you or someone you know is struggling with thoughts of suicide, please reach out to a healthcare provider or a trusted mental health professional immediately.

A Severity of Illness Index is a measurement tool used in healthcare to assess the severity of a patient's condition and the risk of mortality or other adverse outcomes. These indices typically take into account various physiological and clinical variables, such as vital signs, laboratory values, and co-morbidities, to generate a score that reflects the patient's overall illness severity.

Examples of Severity of Illness Indices include the Acute Physiology and Chronic Health Evaluation (APACHE) system, the Simplified Acute Physiology Score (SAPS), and the Mortality Probability Model (MPM). These indices are often used in critical care settings to guide clinical decision-making, inform prognosis, and compare outcomes across different patient populations.

It is important to note that while these indices can provide valuable information about a patient's condition, they should not be used as the sole basis for clinical decision-making. Rather, they should be considered in conjunction with other factors, such as the patient's overall clinical presentation, treatment preferences, and goals of care.

Psychotherapy is a type of treatment used primarily to treat mental health disorders and other emotional or behavioral issues. It involves a therapeutic relationship between a trained psychotherapist and a patient, where they work together to understand the patient's thoughts, feelings, and behaviors, identify patterns that may be causing distress, and develop strategies to manage symptoms and improve overall well-being.

There are many different approaches to psychotherapy, including cognitive-behavioral therapy (CBT), psychodynamic therapy, interpersonal therapy, and others. The specific approach used will depend on the individual patient's needs and preferences, as well as the training and expertise of the therapist.

Psychotherapy can be conducted in individual, group, or family sessions, and may be provided in a variety of settings, such as hospitals, clinics, private practices, or online platforms. The goal of psychotherapy is to help patients understand themselves better, develop coping skills, improve their relationships, and enhance their overall quality of life.

Obsessive-Compulsive Disorder (OCD) is a mental health disorder characterized by the presence of obsessions and compulsions. Obsessions are recurrent and persistent thoughts, urges, or images that are intrusive, unwanted, and often distressing. Compulsions are repetitive behaviors or mental acts that an individual feels driven to perform in response to an obsession or according to rigid rules, and which are aimed at preventing or reducing anxiety or distress, or preventing some dreaded event or situation. These obsessions and/or compulsions cause significant distress, take up a lot of time (an hour or more a day), and interfere with the individual's daily life, including social activities, relationships, and work or school performance. OCD is considered a type of anxiety disorder and can also co-occur with other mental health conditions.

A phobic disorder is a type of anxiety disorder characterized by an excessive and irrational fear or avoidance of specific objects, situations, or activities. This fear can cause significant distress and interfere with a person's daily life. Phobic disorders are typically classified into three main categories: specific phobias (such as fear of heights, spiders, or needles), social phobia (or social anxiety disorder), and agoraphobia (fear of open spaces or situations where escape might be difficult).

People with phobic disorders often recognize that their fear is excessive or unreasonable, but they are unable to control it. When exposed to the feared object or situation, they may experience symptoms such as rapid heartbeat, sweating, trembling, and difficulty breathing. These symptoms can be so distressing that individuals with phobic disorders go to great lengths to avoid the feared situation, which can have a significant impact on their quality of life.

Treatment for phobic disorders typically involves cognitive-behavioral therapy (CBT), which helps individuals identify and challenge their irrational thoughts and fears, as well as exposure therapy, which gradually exposes them to the feared object or situation in a safe and controlled environment. In some cases, medication may also be recommended to help manage symptoms of anxiety.

Attention Deficit Hyperactivity Disorder (ADHD) with hyperactivity is a neurodevelopmental disorder that affects both children and adults. The condition is characterized by symptoms including:

1. Difficulty paying attention or staying focused on a single task
2. Impulsivity, or acting without thinking
3. Hyperactivity, or excessive fidgeting, restlessness, or talking

In order to be diagnosed with ADHD with hyperactivity, an individual must exhibit these symptoms to a degree that is developmentally inappropriate and interferes with their daily functioning. Additionally, the symptoms must have been present for at least six months and be present in multiple settings (e.g., at home, school, work).

It's important to note that ADHD can manifest differently in different people, and some individuals may experience predominantly inattentive or impulsive symptoms rather than hyperactive ones. However, when the hyperactive component is prominent, it is referred to as ADHD with hyperactivity.

Effective treatments for ADHD with hyperactivity include a combination of medication (such as stimulants) and behavioral therapy. With appropriate treatment, individuals with ADHD can learn to manage their symptoms and lead successful, fulfilling lives.

Prevalence, in medical terms, refers to the total number of people in a given population who have a particular disease or condition at a specific point in time, or over a specified period. It is typically expressed as a percentage or a ratio of the number of cases to the size of the population. Prevalence differs from incidence, which measures the number of new cases that develop during a certain period.

Sertraline is a medication that belongs to a class of drugs called selective serotonin reuptake inhibitors (SSRIs). It is primarily used to treat depression, obsessive-compulsive disorder, panic disorder, post-traumatic stress disorder, social anxiety disorder, and in some cases, premenstrual dysphoric disorder.

Sertraline works by increasing the levels of serotonin, a neurotransmitter in the brain that helps maintain mental balance, in the synaptic cleft (the space between two nerve cells where neurotransmitters are released and received). By inhibiting the reuptake of serotonin, sertraline enhances the signal strength and duration of action of this neurotransmitter, which can help alleviate symptoms associated with various mental health conditions.

It is important to note that sertraline should only be taken under the supervision of a healthcare professional, as it may have side effects and potential interactions with other medications. Always consult a medical provider for personalized advice regarding medication use.

A personality assessment is a systematic process used by healthcare professionals to evaluate and understand an individual's characteristic patterns of thought, emotion, and behavior. It typically involves the use of standardized measures, such as self-report questionnaires, interviews, and observational techniques, to gather information about an individual's personality traits, attitudes, values, and behaviors.

The goal of a personality assessment is to provide a comprehensive and integrated understanding of an individual's unique personality style, including their strengths, weaknesses, and potential vulnerabilities. This information can be useful in a variety of contexts, including clinical treatment planning, vocational counseling, and forensic evaluation.

It is important to note that personality assessments should always be conducted by qualified professionals with appropriate training and expertise in the use of these measures. Additionally, while personality assessments can provide valuable insights into an individual's personality style, they are not infallible and should always be considered alongside other sources of information when making important decisions about treatment or management.

Somatoform disorders are a group of psychological disorders characterized by the presence of physical symptoms that cannot be fully explained by a medical condition or substance abuse. These symptoms cause significant distress and impairment in social, occupational, or other important areas of functioning. The individual's belief about the symptoms is not consistent with the medical evaluation and often leads to excessive or repeated medical evaluations.

Examples of somatoform disorders include:

1. Somatization disorder: characterized by multiple physical symptoms that cannot be explained medically, affecting several parts of the body.
2. Conversion disorder: characterized by the presence of one or more neurological symptoms (such as blindness, paralysis, or difficulty swallowing) that cannot be explained medically and appear to have a psychological origin.
3. Pain disorder: characterized by chronic pain that is not fully explained by a medical condition.
4. Hypochondriasis: characterized by an excessive preoccupation with having a serious illness, despite reassurance from medical professionals.
5. Body dysmorphic disorder: characterized by the obsessive idea that some aspect of one's own body part or appearance is severely flawed and warrants exceptional measures to hide or fix it.

It's important to note that these disorders are not caused by intentional deceit or malingering, but rather reflect a genuine belief in the presence of physical symptoms and distress related to them.

Anxiety: A feeling of worry, nervousness, or unease, typically about an imminent event or something with an uncertain outcome. In a medical context, anxiety refers to a mental health disorder characterized by feelings of excessive and persistent worry, fear, or panic that interfere with daily activities. It can also be a symptom of other medical conditions, such as heart disease, diabetes, or substance abuse disorders. Anxiety disorders include generalized anxiety disorder, panic disorder, social anxiety disorder, and phobias.

Medical Definition:

"Risk factors" are any attribute, characteristic or exposure of an individual that increases the likelihood of developing a disease or injury. They can be divided into modifiable and non-modifiable risk factors. Modifiable risk factors are those that can be changed through lifestyle choices or medical treatment, while non-modifiable risk factors are inherent traits such as age, gender, or genetic predisposition. Examples of modifiable risk factors include smoking, alcohol consumption, physical inactivity, and unhealthy diet, while non-modifiable risk factors include age, sex, and family history. It is important to note that having a risk factor does not guarantee that a person will develop the disease, but rather indicates an increased susceptibility.

Psychometrics is a branch of psychology that deals with the theory and technique of psychological measurement, such as the development and standardization of tests used to measure intelligence, aptitude, personality, attitudes, and other mental abilities or traits. It involves the construction and validation of measurement instruments, including the determination of their reliability and validity, and the application of statistical methods to analyze test data and interpret results. The ultimate goal of psychometrics is to provide accurate, objective, and meaningful measurements that can be used to understand individual differences and make informed decisions in educational, clinical, and organizational settings.

Borderline Personality Disorder (BPD) is a mental health disorder characterized by a pervasive pattern of instability in interpersonal relationships, self-image, affect, and mood, as well as marked impulsivity that begins by early adulthood and is present in various contexts.

Individuals with BPD often experience intense and fluctuating emotions, ranging from profound sadness, anxiety, and anger to feelings of happiness or calm. They may have difficulty managing these emotions, leading to impulsive behavior, self-harm, or suicidal ideation.

People with BPD also tend to have an unstable sense of self, which can lead to rapid changes in their goals, values, and career choices. They often struggle with feelings of emptiness and boredom, and may engage in risky behaviors such as substance abuse, reckless driving, or binge eating to alleviate these feelings.

Interpersonal relationships are often strained due to the individual's fear of abandonment, intense emotional reactions, and difficulty regulating their emotions. They may experience idealization and devaluation of others, leading to rapid shifts in how they view and treat people close to them.

Diagnosis of BPD is typically made by a mental health professional using criteria outlined in the Diagnostic and Statistical Manual of Mental Disorders (DSM-5), which is published by the American Psychiatric Association. Treatment for BPD may include psychotherapy, medication, and support groups to help individuals manage their symptoms and improve their quality of life.

There is no formal medical definition for "child of impaired parents." However, it generally refers to a child who has at least one parent with physical, mental, or psychological challenges that impact their ability to care for themselves and/or their children. These impairments may include substance abuse disorders, mental illnesses, chronic medical conditions, or developmental disabilities.

Children of impaired parents often face unique challenges and stressors in their lives, which can affect their emotional, social, and cognitive development. They may have to take on additional responsibilities at home, experience neglect or abuse, or witness disturbing behaviors related to their parent's impairment. As a result, these children are at higher risk for developing mental health issues, behavioral problems, and academic difficulties.

Support services and interventions, such as family therapy, counseling, and community resources, can help mitigate the negative effects of growing up with impaired parents and improve outcomes for these children.

The brain is the central organ of the nervous system, responsible for receiving and processing sensory information, regulating vital functions, and controlling behavior, movement, and cognition. It is divided into several distinct regions, each with specific functions:

1. Cerebrum: The largest part of the brain, responsible for higher cognitive functions such as thinking, learning, memory, language, and perception. It is divided into two hemispheres, each controlling the opposite side of the body.
2. Cerebellum: Located at the back of the brain, it is responsible for coordinating muscle movements, maintaining balance, and fine-tuning motor skills.
3. Brainstem: Connects the cerebrum and cerebellum to the spinal cord, controlling vital functions such as breathing, heart rate, and blood pressure. It also serves as a relay center for sensory information and motor commands between the brain and the rest of the body.
4. Diencephalon: A region that includes the thalamus (a major sensory relay station) and hypothalamus (regulates hormones, temperature, hunger, thirst, and sleep).
5. Limbic system: A group of structures involved in emotional processing, memory formation, and motivation, including the hippocampus, amygdala, and cingulate gyrus.

The brain is composed of billions of interconnected neurons that communicate through electrical and chemical signals. It is protected by the skull and surrounded by three layers of membranes called meninges, as well as cerebrospinal fluid that provides cushioning and nutrients.

A case-control study is an observational research design used to identify risk factors or causes of a disease or health outcome. In this type of study, individuals with the disease or condition (cases) are compared with similar individuals who do not have the disease or condition (controls). The exposure history or other characteristics of interest are then compared between the two groups to determine if there is an association between the exposure and the disease.

Case-control studies are often used when it is not feasible or ethical to conduct a randomized controlled trial, as they can provide valuable insights into potential causes of diseases or health outcomes in a relatively short period of time and at a lower cost than other study designs. However, because case-control studies rely on retrospective data collection, they are subject to biases such as recall bias and selection bias, which can affect the validity of the results. Therefore, it is important to carefully design and conduct case-control studies to minimize these potential sources of bias.

Psychotic disorders are a group of severe mental health conditions characterized by distorted perceptions, thoughts, and emotions that lead to an inability to recognize reality. The two most common symptoms of psychotic disorders are hallucinations and delusions. Hallucinations are when a person sees, hears, or feels things that aren't there, while delusions are fixed, false beliefs that are not based on reality.

Other symptoms may include disorganized speech, disorganized behavior, catatonic behavior, and negative symptoms such as apathy and lack of emotional expression. Schizophrenia is the most well-known psychotic disorder, but other types include schizoaffective disorder, delusional disorder, brief psychotic disorder, shared psychotic disorder, and substance-induced psychotic disorder.

Psychotic disorders can be caused by a variety of factors, including genetics, brain chemistry imbalances, trauma, and substance abuse. Treatment typically involves a combination of medication, therapy, and support services to help manage symptoms and improve quality of life.

Suicide is defined in the medical field as the intentional taking of one's own life. It is a complex phenomenon with various contributing factors, including psychological, biological, environmental, and sociocultural elements. Suicide is a significant global public health concern that requires comprehensive understanding, prevention, and intervention strategies. If you or someone you know is struggling with thoughts of self-harm or suicide, it's essential to seek help from a mental health professional immediately.

Affective disorders, psychotic are a category of mental health conditions characterized by significant disturbances in mood, thinking, and behavior. These disorders combine the symptoms of both mood disorders (such as depression or bipolar disorder) and psychotic disorders (such as schizophrenia).

In psychotic affective disorders, individuals experience severe changes in their mood, such as prolonged periods of depression or mania, along with psychotic features like hallucinations, delusions, or disorganized thinking and speech. These symptoms can significantly impair a person's ability to function in daily life and may require intensive treatment, including medication and therapy.

Examples of psychotic affective disorders include:

1. Psychotic Depression: A severe form of major depressive disorder that includes psychotic symptoms like delusions or hallucinations, often with a theme of guilt or worthlessness.
2. Bipolar Disorder with Psychotic Features: During manic or depressive episodes, some individuals with bipolar disorder may experience psychotic symptoms such as delusions or hallucinations. These symptoms can vary in intensity and may require hospitalization and intensive treatment.
3. Schizoaffective Disorder: A mental health condition that includes features of both schizophrenia and a mood disorder, such as depression or bipolar disorder. Individuals with this disorder experience psychotic symptoms like hallucinations and delusions, along with significant changes in mood.

It is essential to seek professional help if you suspect you or someone you know may have a psychotic affective disorder. Early intervention and treatment can significantly improve outcomes and quality of life.

In medical and psychological terms, "affect" refers to a person's emotional or expressive state, mood, or dispositions that are outwardly manifested in their behavior, facial expressions, demeanor, or speech. Affect can be described as being congruent or incongruent with an individual's thoughts and experiences.

There are different types of affect, including:

1. Neutral affect: When a person shows no apparent emotion or displays minimal emotional expressiveness.
2. Positive affect: When a person exhibits positive emotions such as happiness, excitement, or enthusiasm.
3. Negative affect: When a person experiences and displays negative emotions like sadness, anger, or fear.
4. Blunted affect: When a person's emotional response is noticeably reduced or diminished, often observed in individuals with certain mental health conditions, such as schizophrenia.
5. Flat affect: When a person has an almost complete absence of emotional expressiveness, which can be indicative of severe depression or other mental health disorders.
6. Labile affect: When a person's emotional state fluctuates rapidly and frequently between positive and negative emotions, often observed in individuals with certain neurological conditions or mood disorders.

Clinicians may assess a patient's affect during an interview or examination to help diagnose mental health conditions, evaluate treatment progress, or monitor overall well-being.

A questionnaire in the medical context is a standardized, systematic, and structured tool used to gather information from individuals regarding their symptoms, medical history, lifestyle, or other health-related factors. It typically consists of a series of written questions that can be either self-administered or administered by an interviewer. Questionnaires are widely used in various areas of healthcare, including clinical research, epidemiological studies, patient care, and health services evaluation to collect data that can inform diagnosis, treatment planning, and population health management. They provide a consistent and organized method for obtaining information from large groups or individual patients, helping to ensure accurate and comprehensive data collection while minimizing bias and variability in the information gathered.

Panic Disorder is a type of anxiety disorder characterized by recurrent, unexpected panic attacks and significant worry about the implications of these attacks or fear of their occurrence. A panic attack is a sudden surge of intense fear or discomfort that reaches a peak within minutes, and includes physical symptoms such as accelerated heart rate, sweating, trembling, shortness of breath, and feelings of impending doom or danger. In Panic Disorder, these attacks are not triggered by specific situations or stimuli, but can occur spontaneously and without warning. The individual may also develop avoidance behaviors to prevent future panic attacks, which can interfere with daily functioning and quality of life.

The gyrus cinguli, also known as the cingulate gyrus, is a structure located in the brain. It forms part of the limbic system and plays a role in various functions such as emotion, memory, and perception of pain. The gyrus cinguli is situated in the medial aspect of the cerebral hemisphere, adjacent to the corpus callosum, and curves around the frontal portion of the corpus callosum, forming a C-shaped structure. It has been implicated in several neurological and psychiatric conditions, including depression, anxiety disorders, and chronic pain syndromes.

Anhedonia is a medical term that describes the inability to feel pleasure. It is a common symptom of depression and other mental health disorders, such as schizophrenia. Anhedonia can manifest as a lack of interest in activities that were once enjoyed, a reduced ability to experience pleasure from social interactions or sexual activity, or an inability to feel positive emotions like happiness or joy.

Anhedonia is different from simply feeling sad or down. It is a more profound and persistent loss of the ability to experience pleasure, which can significantly impact a person's quality of life and overall well-being. The exact cause of anhedonia is not fully understood, but it is believed to be related to changes in brain chemistry and function, particularly in areas involved in reward processing and motivation. Treatment for anhedonia typically involves addressing the underlying mental health condition, such as depression or schizophrenia, through a combination of medication and therapy.

Emotions are complex psychological states that involve three distinct components: a subjective experience, a physiological response, and a behavioral or expressive response. Emotions can be short-lived, such as a flash of anger, or more long-lasting, such as enduring sadness. They can also vary in intensity, from mild irritation to intense joy or fear.

Emotions are often distinguished from other psychological states, such as moods and temperament, which may be less specific and more enduring. Emotions are typically thought to have a clear cause or object, such as feeling happy when you receive good news or feeling anxious before a job interview.

There are many different emotions that people can experience, including happiness, sadness, anger, fear, surprise, disgust, and shame. These emotions are often thought to serve important adaptive functions, helping individuals respond to challenges and opportunities in their environment.

In medical contexts, emotions may be relevant to the diagnosis and treatment of various mental health conditions, such as depression, anxiety disorders, and bipolar disorder. Abnormalities in emotional processing and regulation have been implicated in many psychiatric illnesses, and therapies that target these processes may be effective in treating these conditions.

According to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), neurotic disorders are not a recognized category. However, the term "neurosis" has been used historically in psychiatry and psychology to refer to a group of mental disorders characterized by anxiety, obsessions, depressive moods, phobias, or hypochondriacal fears. These symptoms are often considered to be the result of internal conflicts, typically related to stress, frustration, or interpersonal difficulties.

The DSM-5 has replaced the category of neurotic disorders with several specific mental disorders that were previously classified under this heading. These include:

1. Anxiety Disorders (e.g., panic disorder, social anxiety disorder, generalized anxiety disorder)
2. Obsessive-Compulsive and Related Disorders (e.g., obsessive-compulsive disorder, body dysmorphic disorder, hoarding disorder)
3. Trauma- and Stressor-Related Disorders (e.g., post-traumatic stress disorder, acute stress disorder, adjustment disorders)
4. Mood Disorders (e.g., major depressive disorder, persistent depressive disorder)
5. Somatic Symptom and Related Disorders (e.g., illness anxiety disorder, conversion disorder)

These specific disorders are defined by their own unique diagnostic criteria and should be evaluated based on those guidelines.

Medical Definition:

Magnetic Resonance Imaging (MRI) is a non-invasive diagnostic imaging technique that uses a strong magnetic field and radio waves to create detailed cross-sectional or three-dimensional images of the internal structures of the body. The patient lies within a large, cylindrical magnet, and the scanner detects changes in the direction of the magnetic field caused by protons in the body. These changes are then converted into detailed images that help medical professionals to diagnose and monitor various medical conditions, such as tumors, injuries, or diseases affecting the brain, spinal cord, heart, blood vessels, joints, and other internal organs. MRI does not use radiation like computed tomography (CT) scans.

Psychological stress is the response of an individual's mind and body to challenging or demanding situations. It can be defined as a state of emotional and physical tension resulting from adversity, demand, or change. This response can involve a variety of symptoms, including emotional, cognitive, behavioral, and physiological components.

Emotional responses may include feelings of anxiety, fear, anger, sadness, or frustration. Cognitive responses might involve difficulty concentrating, racing thoughts, or negative thinking patterns. Behaviorally, psychological stress can lead to changes in appetite, sleep patterns, social interactions, and substance use. Physiologically, the body's "fight-or-flight" response is activated, leading to increased heart rate, blood pressure, muscle tension, and other symptoms.

Psychological stress can be caused by a wide range of factors, including work or school demands, financial problems, relationship issues, traumatic events, chronic illness, and major life changes. It's important to note that what causes stress in one person may not cause stress in another, as individual perceptions and coping mechanisms play a significant role.

Chronic psychological stress can have negative effects on both mental and physical health, increasing the risk of conditions such as anxiety disorders, depression, heart disease, diabetes, and autoimmune diseases. Therefore, it's essential to identify sources of stress and develop effective coping strategies to manage and reduce its impact.

Serotonin plasma membrane transport proteins, also known as serotonin transporters (SERTs), are membrane-spanning proteins that play a crucial role in the regulation of serotonergic neurotransmission. They are responsible for the reuptake of serotonin (5-hydroxytryptamine or 5-HT) from the synaptic cleft back into the presynaptic neuron, thereby terminating the signal transmission and allowing for its recycling or degradation.

Structurally, SERTs belong to the family of sodium- and chloride-dependent neurotransmitter transporters and contain 12 transmembrane domains with intracellular N- and C-termini. The binding site for serotonin is located within the transmembrane domain, while the substrate-binding site is formed by residues from both the transmembrane and extracellular loops.

Serotonin transporters are important targets for various psychotropic medications, including selective serotonin reuptake inhibitors (SSRIs), tricyclic antidepressants (TCAs), and monoamine oxidase inhibitors (MAOIs). These drugs act by blocking the SERT, increasing synaptic concentrations of serotonin, and enhancing serotonergic neurotransmission. Dysregulation of serotonin transporters has been implicated in several neurological and psychiatric disorders, such as major depressive disorder, anxiety disorders, obsessive-compulsive disorder, and substance abuse.

Recurrence, in a medical context, refers to the return of symptoms or signs of a disease after a period of improvement or remission. It indicates that the condition has not been fully eradicated and may require further treatment. Recurrence is often used to describe situations where a disease such as cancer comes back after initial treatment, but it can also apply to other medical conditions. The likelihood of recurrence varies depending on the type of disease and individual patient factors.

Tricyclic antidepressants (TCAs) are a class of medications that were commonly used to treat depression. The name "tricyclic" comes from the chemical structure of these drugs, which contain three rings in their molecular makeup. TCAs were first developed in the 1950s and remained a popular choice for treating depression until the introduction of selective serotonin reuptake inhibitors (SSRIs) in the late 1980s.

TCAs work by increasing the levels of neurotransmitters, such as serotonin and norepinephrine, in the brain. Neurotransmitters are chemical messengers that transmit signals between nerve cells. By increasing the levels of these neurotransmitters, TCAs can help to improve mood and alleviate symptoms of depression.

Some common examples of tricyclic antidepressants include amitriptyline, imipramine, and nortriptyline. While TCAs are effective in treating depression, they can have significant side effects, including dry mouth, blurred vision, constipation, and drowsiness. In addition, TCAs can be dangerous in overdose and may increase the risk of suicide in some individuals. As a result, they are typically used as a last resort when other treatments have failed.

Overall, tricyclic antidepressants are a class of medications that were commonly used to treat depression but have largely been replaced by newer drugs due to their side effects and potential risks.

Conduct Disorder is a mental health disorder that typically begins in childhood or adolescence and is characterized by a repetitive pattern of behavior that violates the rights of others or major age-appropriate societal norms and rules. The behaviors fall into four main categories: aggression to people and animals, destruction of property, deceitfulness or theft, and serious violation of rules.

The specific symptoms of Conduct Disorder can vary widely among individuals, but they generally include:

1. Aggression to people and animals: This may include physical fights, bullying, threatening others, cruelty to animals, and use of weapons.
2. Destruction of property: This may include deliberate destruction of others' property, arson, and vandalism.
3. Deceitfulness or theft: This may include lying, shoplifting, stealing, and breaking into homes, buildings, or cars.
4. Serious violation of rules: This may include running away from home, truancy, staying out late without permission, and frequent violations of school rules.

Conduct Disorder can have serious consequences for individuals who suffer from it, including academic failure, substance abuse, depression, anxiety, and difficulties in interpersonal relationships. It is important to note that Conduct Disorder should be diagnosed by a qualified mental health professional based on a comprehensive evaluation.

Life change events refer to significant changes or transitions in an individual's personal circumstances that may have an impact on their health and well-being. These events can include things like:

* Marriage or divorce
* Birth of a child or loss of a loved one
* Job loss or retirement
* Moving to a new home or city
* Changes in financial status
* Health diagnoses or serious illnesses
* Starting or ending of a significant relationship

Research has shown that life change events can have a profound effect on an individual's stress levels, mental health, and physical health. Some life change events may be positive and exciting, while others may be challenging and difficult to cope with. In either case, it is important for individuals to take care of themselves during times of transition and seek support as needed.

Irritable mood is not a formal medical diagnosis, but it is often described as a symptom in various mental health conditions. The Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) does not have a specific definition for irritable mood. However, the term "irritable" is used to describe a mood state in several psychiatric disorders such as:

1. Major Depressive Disorder (MDD): In MDD, an individual may experience an irritable mood along with other symptoms like depressed mood, loss of interest or pleasure, changes in appetite and sleep, fatigue, feelings of worthlessness or excessive guilt, difficulty thinking, concentrating, or making decisions, and recurrent thoughts of death or suicide.
2. Bipolar Disorder: In bipolar disorder, an individual may experience irritable mood during a manic or hypomanic episode. During these episodes, the person may also have increased energy, decreased need for sleep, racing thoughts, rapid speech, distractibility, and excessive involvement in pleasurable activities that have a high potential for painful consequences.
3. Disruptive Mood Dysregulation Disorder (DMDD): This disorder is characterized by severe and recurrent temper outbursts that are grossly out of proportion to the situation and occur at least three times per week, along with an irritable or angry mood most of the time between temper outbursts.
4. Premenstrual Dysphoric Disorder (PMDD): In PMDD, an individual may experience irritability, anger, and increased interpersonal conflicts in addition to other symptoms like depressed mood, anxiety, and physical symptoms during the late luteal phase of their menstrual cycle.

It is essential to consult a mental health professional if you or someone else experiences persistent irritable mood or any other symptoms that may indicate an underlying mental health condition.

"Sex factors" is a term used in medicine and epidemiology to refer to the differences in disease incidence, prevalence, or response to treatment that are observed between males and females. These differences can be attributed to biological differences such as genetics, hormones, and anatomy, as well as social and cultural factors related to gender.

For example, some conditions such as autoimmune diseases, depression, and osteoporosis are more common in women, while others such as cardiovascular disease and certain types of cancer are more prevalent in men. Additionally, sex differences have been observed in the effectiveness and side effects of various medications and treatments.

It is important to consider sex factors in medical research and clinical practice to ensure that patients receive appropriate and effective care.

The "age of onset" is a medical term that refers to the age at which an individual first develops or displays symptoms of a particular disease, disorder, or condition. It can be used to describe various medical conditions, including both physical and mental health disorders. The age of onset can have implications for prognosis, treatment approaches, and potential causes of the condition. In some cases, early onset may indicate a more severe or progressive course of the disease, while late-onset symptoms might be associated with different underlying factors or etiologies. It is essential to provide accurate and precise information regarding the age of onset when discussing a patient's medical history and treatment plan.

Longitudinal studies are a type of research design where data is collected from the same subjects repeatedly over a period of time, often years or even decades. These studies are used to establish patterns of changes and events over time, and can help researchers identify causal relationships between variables. They are particularly useful in fields such as epidemiology, psychology, and sociology, where the focus is on understanding developmental trends and the long-term effects of various factors on health and behavior.

In medical research, longitudinal studies can be used to track the progression of diseases over time, identify risk factors for certain conditions, and evaluate the effectiveness of treatments or interventions. For example, a longitudinal study might follow a group of individuals over several decades to assess their exposure to certain environmental factors and their subsequent development of chronic diseases such as cancer or heart disease. By comparing data collected at multiple time points, researchers can identify trends and correlations that may not be apparent in shorter-term studies.

Longitudinal studies have several advantages over other research designs, including their ability to establish temporal relationships between variables, track changes over time, and reduce the impact of confounding factors. However, they also have some limitations, such as the potential for attrition (loss of participants over time), which can introduce bias and affect the validity of the results. Additionally, longitudinal studies can be expensive and time-consuming to conduct, requiring significant resources and a long-term commitment from both researchers and study participants.

Suicidal ideation is a medical term used to describe thoughts about, or an unusual preoccupation with, suicide. The range of suicidal ideation varies greatly from fleeting thoughts, to extensive thoughts, to detailed planning, role playing, and incomplete attempts, which may be deliberately constructed to not complete or to be discovered, or may be fully intended to result in death.

It's important to take any mention of suicide seriously and seek immediate help from a healthcare professional if someone is experiencing suicidal ideation. Mental health conditions such as depression, bipolar disorder, schizophrenia, borderline personality disorder, and substance abuse are commonly associated with an increased risk of suicidal thoughts.

If you or someone you know is struggling with suicidal thoughts, please reach out to a mental health professional or trusted person immediately. In the US, contact the National Suicide Prevention Lifeline at 1-800-273-TALK (1-800-273-8255) or use the Crisis Text Line by texting HOME to 741741.

Cognitive disorders are a category of mental health disorders that primarily affect cognitive abilities including learning, memory, perception, and problem-solving. These disorders can be caused by various factors such as brain injury, degenerative diseases, infection, substance abuse, or developmental disabilities. Examples of cognitive disorders include dementia, amnesia, delirium, and intellectual disability. It's important to note that the specific definition and diagnostic criteria for cognitive disorders may vary depending on the medical source or classification system being used.

Sleep disorders are a group of conditions that affect the ability to sleep well on a regular basis. They can include problems with falling asleep, staying asleep, or waking up too early in the morning. These disorders can be caused by various factors such as stress, anxiety, depression, medical conditions, or substance abuse.

The American Academy of Sleep Medicine (AASM) recognizes over 80 distinct sleep disorders, which are categorized into the following major groups:

1. Insomnia - difficulty falling asleep or staying asleep.
2. Sleep-related breathing disorders - abnormal breathing during sleep such as obstructive sleep apnea.
3. Central disorders of hypersomnolence - excessive daytime sleepiness, including narcolepsy.
4. Circadian rhythm sleep-wake disorders - disruption of the internal body clock that regulates the sleep-wake cycle.
5. Parasomnias - abnormal behaviors during sleep such as sleepwalking or night terrors.
6. Sleep-related movement disorders - repetitive movements during sleep such as restless legs syndrome.
7. Isolated symptoms and normal variants - brief and occasional symptoms that do not warrant a specific diagnosis.

Sleep disorders can have significant impacts on an individual's quality of life, productivity, and overall health. If you suspect that you may have a sleep disorder, it is recommended to consult with a healthcare professional or a sleep specialist for proper evaluation and treatment.

The prefrontal cortex is the anterior (frontal) part of the frontal lobe in the brain, involved in higher-order cognitive processes such as planning complex cognitive behavior, personality expression, decision making, and moderating social behavior. It also plays a significant role in working memory and executive functions. The prefrontal cortex is divided into several subregions, each associated with specific cognitive and emotional functions. Damage to the prefrontal cortex can result in various impairments, including difficulties with planning, decision making, and social behavior regulation.

Psychodrama is not typically defined in the context of medical terminology, but it is a recognized form of psychotherapy that uses role-playing and dramatic techniques to examine and gain insight into a person's emotions, thoughts, and behaviors. According to the American Society of Group Psychotherapy and Psychodrama (ASGPP), psychodrama is defined as "an action method, often conducted in group settings, which allows participants to enact real-life situations, past experiences, or future plans in order to gain insight, increase self-awareness, and practice new behaviors."

In a psychodrama session, the therapist (known as the psychodramatist) guides the protagonist (the individual who presents an issue or situation for exploration) through a series of scenes that recreate or represent their real-life experiences. The protagonist may assume different roles in these scenes and interact with other group members who take on auxiliary roles to help bring the scene to life.

The goal of psychodrama is to enable participants to explore their emotions, thoughts, and behaviors in a safe and supportive environment, allowing them to gain new perspectives, develop empathy for others, and practice healthier ways of interacting with their world. Psychodrama can be helpful for individuals dealing with various psychological issues, including anxiety, depression, trauma, grief, and relational difficulties.

A cross-sectional study is a type of observational research design that examines the relationship between variables at one point in time. It provides a snapshot or a "cross-section" of the population at a particular moment, allowing researchers to estimate the prevalence of a disease or condition and identify potential risk factors or associations.

In a cross-sectional study, data is collected from a sample of participants at a single time point, and the variables of interest are measured simultaneously. This design can be used to investigate the association between exposure and outcome, but it cannot establish causality because it does not follow changes over time.

Cross-sectional studies can be conducted using various data collection methods, such as surveys, interviews, or medical examinations. They are often used in epidemiology to estimate the prevalence of a disease or condition in a population and to identify potential risk factors that may contribute to its development. However, because cross-sectional studies only provide a snapshot of the population at one point in time, they cannot account for changes over time or determine whether exposure preceded the outcome.

Therefore, while cross-sectional studies can be useful for generating hypotheses and identifying potential associations between variables, further research using other study designs, such as cohort or case-control studies, is necessary to establish causality and confirm any findings.

Autistic Disorder, also known as Autism or Classic Autism, is a neurodevelopmental disorder that affects communication and behavior. It is characterized by:

1. Persistent deficits in social communication and social interaction across multiple contexts, including:
* Deficits in social-emotional reciprocity;
* Deficits in nonverbal communicative behaviors used for social interaction;
* Deficits in developing, maintaining, and understanding relationships.
2. Restricted, repetitive patterns of behavior, interests, or activities, as manifested by at least two of the following:
* Stereotyped or repetitive motor movements, use of objects, or speech;
* Insistence on sameness, inflexible adherence to routines, or ritualized patterns of verbal or nonverbal behavior;
* Highly restricted, fixated interests that are abnormal in intensity or focus;
* Hyper- or hyporeactivity to sensory input or unusual interest in sensory aspects of the environment.
3. Symptoms must be present in the early developmental period (but may not become fully manifest until social demands exceed limited capacities) and limit or impair everyday functioning.
4. Symptoms do not occur exclusively during the course of a schizophrenia spectrum disorder or other psychotic disorders.

Autistic Disorder is part of the autism spectrum disorders (ASDs), which also include Asperger's Syndrome and Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS). The current diagnostic term for this category of conditions, according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), is Autism Spectrum Disorder.

In the field of medicine, "time factors" refer to the duration of symptoms or time elapsed since the onset of a medical condition, which can have significant implications for diagnosis and treatment. Understanding time factors is crucial in determining the progression of a disease, evaluating the effectiveness of treatments, and making critical decisions regarding patient care.

For example, in stroke management, "time is brain," meaning that rapid intervention within a specific time frame (usually within 4.5 hours) is essential to administering tissue plasminogen activator (tPA), a clot-busting drug that can minimize brain damage and improve patient outcomes. Similarly, in trauma care, the "golden hour" concept emphasizes the importance of providing definitive care within the first 60 minutes after injury to increase survival rates and reduce morbidity.

Time factors also play a role in monitoring the progression of chronic conditions like diabetes or heart disease, where regular follow-ups and assessments help determine appropriate treatment adjustments and prevent complications. In infectious diseases, time factors are crucial for initiating antibiotic therapy and identifying potential outbreaks to control their spread.

Overall, "time factors" encompass the significance of recognizing and acting promptly in various medical scenarios to optimize patient outcomes and provide effective care.

Analysis of Variance (ANOVA) is a statistical technique used to compare the means of two or more groups and determine whether there are any significant differences between them. It is a way to analyze the variance in a dataset to determine whether the variability between groups is greater than the variability within groups, which can indicate that the groups are significantly different from one another.

ANOVA is based on the concept of partitioning the total variance in a dataset into two components: variance due to differences between group means (also known as "between-group variance") and variance due to differences within each group (also known as "within-group variance"). By comparing these two sources of variance, ANOVA can help researchers determine whether any observed differences between groups are statistically significant, or whether they could have occurred by chance.

ANOVA is a widely used technique in many areas of research, including biology, psychology, engineering, and business. It is often used to compare the means of two or more experimental groups, such as a treatment group and a control group, to determine whether the treatment had a significant effect. ANOVA can also be used to compare the means of different populations or subgroups within a population, to identify any differences that may exist between them.

Postpartum depression is a type of depressive disorder that occurs in a woman after giving birth (the postpartum period). The symptoms are similar to those of other forms of depression, such as low mood, loss of interest or pleasure in activities, changes in appetite and sleep patterns, feelings of guilt or worthlessness, difficulty thinking, concentrating or making decisions, and thoughts of death or suicide. However, in postpartum depression, these symptoms are more severe and last longer than those typically experienced after childbirth. Postpartum depression can make it difficult for a woman to care for herself or her baby and can affect the bonding between mother and child. It is important to seek medical help if you think you may be experiencing postpartum depression. Treatment may include counseling, medication, or a combination of both.

Health surveys are research studies that collect data from a sample population to describe the current health status, health behaviors, and healthcare utilization of a particular group or community. These surveys may include questions about various aspects of health such as physical health, mental health, chronic conditions, lifestyle habits, access to healthcare services, and demographic information. The data collected from health surveys can be used to monitor trends in health over time, identify disparities in health outcomes, develop and evaluate public health programs and policies, and inform resource allocation decisions. Examples of national health surveys include the National Health Interview Survey (NHIS) and the Behavioral Risk Factor Surveillance System (BRFSS).

Neuropsychological tests are a type of psychological assessment that measures cognitive functions, such as attention, memory, language, problem-solving, and perception. These tests are used to help diagnose and understand the cognitive impact of neurological conditions, including dementia, traumatic brain injury, stroke, Parkinson's disease, and other disorders that affect the brain.

The tests are typically administered by a trained neuropsychologist and can take several hours to complete. They may involve paper-and-pencil tasks, computerized tasks, or interactive activities. The results of the tests are compared to normative data to help identify any areas of cognitive weakness or strength.

Neuropsychological testing can provide valuable information for treatment planning, rehabilitation, and assessing response to treatment. It can also be used in research to better understand the neural basis of cognition and the impact of neurological conditions on cognitive function.

Alcoholism is a chronic and often relapsing brain disorder characterized by the excessive and compulsive consumption of alcohol despite negative consequences to one's health, relationships, and daily life. It is also commonly referred to as alcohol use disorder (AUD) or alcohol dependence.

The diagnostic criteria for AUD include a pattern of alcohol use that includes problems controlling intake, continued use despite problems resulting from drinking, development of a tolerance, drinking that leads to risky behaviors or situations, and withdrawal symptoms when not drinking.

Alcoholism can cause a wide range of physical and psychological health problems, including liver disease, heart disease, neurological damage, mental health disorders, and increased risk of accidents and injuries. Treatment for alcoholism typically involves a combination of behavioral therapies, medications, and support groups to help individuals achieve and maintain sobriety.

Psychotropic drugs, also known as psychoactive drugs, are a class of medications that affect the function of the central nervous system, leading to changes in consciousness, perception, mood, cognition, or behavior. These drugs work by altering the chemical neurotransmitters in the brain, such as dopamine, serotonin, and norepinephrine, which are involved in regulating mood, thought, and behavior.

Psychotropic drugs can be classified into several categories based on their primary therapeutic effects, including:

1. Antipsychotic drugs: These medications are used to treat psychosis, schizophrenia, and other related disorders. They work by blocking dopamine receptors in the brain, which helps reduce hallucinations, delusions, and disordered thinking.
2. Antidepressant drugs: These medications are used to treat depression, anxiety disorders, and some chronic pain conditions. They work by increasing the availability of neurotransmitters such as serotonin, norepinephrine, or dopamine in the brain, which helps improve mood and reduce anxiety.
3. Mood stabilizers: These medications are used to treat bipolar disorder and other mood disorders. They help regulate the ups and downs of mood swings and can also be used as adjunctive treatment for depression and anxiety.
4. Anxiolytic drugs: Also known as anti-anxiety medications, these drugs are used to treat anxiety disorders, panic attacks, and insomnia. They work by reducing the activity of neurotransmitters such as GABA, which can help reduce anxiety and promote relaxation.
5. Stimulant drugs: These medications are used to treat attention deficit hyperactivity disorder (ADHD) and narcolepsy. They work by increasing the availability of dopamine and norepinephrine in the brain, which helps improve focus, concentration, and alertness.

It is important to note that psychotropic drugs can have significant side effects and should only be used under the close supervision of a qualified healthcare provider.

Schizophrenia is a severe mental disorder characterized by disturbances in thought, perception, emotion, and behavior. It often includes hallucinations (usually hearing voices), delusions, paranoia, and disorganized speech and behavior. The onset of symptoms typically occurs in late adolescence or early adulthood. Schizophrenia is a complex, chronic condition that requires ongoing treatment and management. It significantly impairs social and occupational functioning, and it's often associated with reduced life expectancy due to comorbid medical conditions. The exact causes of schizophrenia are not fully understood, but research suggests that genetic, environmental, and neurodevelopmental factors play a role in its development.

Thiophenes are organic compounds that contain a heterocyclic ring made up of four carbon atoms and one sulfur atom. The structure of thiophene is similar to benzene, with the benzene ring being replaced by a thiophene ring. Thiophenes are aromatic compounds, which means they have a stable, planar ring structure and delocalized electrons.

Thiophenes can be found in various natural sources such as coal tar, crude oil, and some foods like onions and garlic. They also occur in certain medications, dyes, and pesticides. Some thiophene derivatives have been synthesized and studied for their potential therapeutic uses, including anti-inflammatory, antiviral, and antitumor activities.

In the medical field, thiophenes are used in some pharmaceuticals as building blocks to create drugs with various therapeutic effects. For example, tipepidine, a cough suppressant, contains a thiophene ring. Additionally, some anesthetics and antipsychotic medications also contain thiophene moieties.

It is important to note that while thiophenes themselves are not typically considered medical terms, they play a role in the chemistry of various pharmaceuticals and other medical-related compounds.

Personality disorders are a class of mental health conditions characterized by deeply ingrained, inflexible patterns of thinking, feeling, and behaving that deviate significantly from the norms of their culture. These patterns often lead to distress for the individual and/or impairments in personal relationships, work, or social functioning.

The Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), identifies ten specific personality disorders, which are grouped into three clusters based on descriptive similarities:

1. Cluster A (Odd or Eccentric) - characterized by odd, eccentric, or unusual behaviors:
* Paranoid Personality Disorder
* Schizoid Personality Disorder
* Schizotypal Personality Disorder
2. Cluster B (Dramatic, Emotional, or Erratic) - marked by dramatic, emotional, or erratic behaviors:
* Antisocial Personality Disorder
* Borderline Personality Disorder
* Histrionic Personality Disorder
* Narcissistic Personality Disorder
3. Cluster C (Anxious or Fearful) - featuring anxious, fearful behaviors:
* Avoidant Personality Disorder
* Dependent Personality Disorder
* Obsessive-Compulsive Personality Disorder

It is important to note that personality disorders can be challenging to diagnose and treat. They often require comprehensive assessments by mental health professionals, such as psychologists or psychiatrists, who specialize in personality disorders. Effective treatments typically involve long-term, specialized psychotherapies, with some cases potentially benefiting from medication management for co-occurring symptoms like anxiety or depression.

Genetic predisposition to disease refers to an increased susceptibility or vulnerability to develop a particular illness or condition due to inheriting specific genetic variations or mutations from one's parents. These genetic factors can make it more likely for an individual to develop a certain disease, but it does not guarantee that the person will definitely get the disease. Environmental factors, lifestyle choices, and interactions between genes also play crucial roles in determining if a genetically predisposed person will actually develop the disease. It is essential to understand that having a genetic predisposition only implies a higher risk, not an inevitable outcome.

Follow-up studies are a type of longitudinal research that involve repeated observations or measurements of the same variables over a period of time, in order to understand their long-term effects or outcomes. In medical context, follow-up studies are often used to evaluate the safety and efficacy of medical treatments, interventions, or procedures.

In a typical follow-up study, a group of individuals (called a cohort) who have received a particular treatment or intervention are identified and then followed over time through periodic assessments or data collection. The data collected may include information on clinical outcomes, adverse events, changes in symptoms or functional status, and other relevant measures.

The results of follow-up studies can provide important insights into the long-term benefits and risks of medical interventions, as well as help to identify factors that may influence treatment effectiveness or patient outcomes. However, it is important to note that follow-up studies can be subject to various biases and limitations, such as loss to follow-up, recall bias, and changes in clinical practice over time, which must be carefully considered when interpreting the results.

Pervasive developmental disorders (PDD) are a group of conditions that affect the development and functioning of the brain, leading to delays in many areas of development. The American Psychiatric Association's Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) has replaced the term "pervasive developmental disorders" with "autism spectrum disorder" and "other neurodevelopmental disorders."

Autism spectrum disorder (ASD) is a neurodevelopmental disorder characterized by persistent deficits in social communication and interaction across multiple contexts, as well as restricted, repetitive patterns of behavior, interests, or activities. The symptoms of ASD can range from mild to severe, and the condition affects approximately 1 in 54 children in the United States.

Other neurodevelopmental disorders that were previously classified as PDDs include:

1. Intellectual disability (ID): a condition characterized by significant limitations in intellectual functioning and adaptive behavior, which covers many everyday social and practical skills. This disorder used to be referred to as "mental retardation."
2. Communication disorders: these are disorders that affect an individual's ability to communicate, including language disorders, speech sound disorders, and stuttering.
3. Attention-deficit/hyperactivity disorder (ADHD): a neurodevelopmental disorder characterized by symptoms of inattention, hyperactivity, and impulsivity.
4. Specific learning disorder: a neurodevelopmental disorder that affects an individual's ability to learn and use specific academic skills, such as reading, writing, or mathematics.
5. Motor disorders: these are disorders that affect an individual's movement and coordination, including developmental coordination disorder, stereotypic movement disorder, and tic disorders.

The medical definition of 'Child Development Disorders, Pervasive' has been replaced with more specific diagnoses in the DSM-5 to better reflect the diverse nature of these conditions and improve diagnostic accuracy and treatment planning.

According to the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5), an Adjustment Disorder is a mental health condition that occurs as a reaction to a stressful life event or significant change. It is characterized by emotional or behavioral symptoms that cause distress and interfere with daily functioning, but do not meet the criteria for other more specific mental disorders.

The symptoms of an Adjustment Disorder typically develop within three months of the identified stressor and may include:

* Depressed mood
* Anxiety
* Irritability or anger
* Worrying
* Difficulty sleeping
* Loss of appetite
* Difficulty concentrating
* Physical symptoms, such as headaches or stomachaches

The symptoms must be out of proportion to the severity or intensity of the stressor and may lead to significant impairment in social, occupational, or academic functioning. The diagnosis is not given if the symptoms persist for more than six months after the stressor has ended.

There are several subtypes of Adjustment Disorders, including:

* Adjustment Disorder with Depressed Mood
* Adjustment Disorder with Anxiety
* Adjustment Disorder with Mixed Anxiety and Depressed Mood
* Adjustment Disorder with Disturbance of Conduct
* Adjustment Disorder with Emotional or Behavioral Symptoms Not Otherwise Specified

Treatment for Adjustment Disorders typically involves psychotherapy, such as cognitive-behavioral therapy (CBT) or solution-focused brief therapy, to help individuals develop coping skills and manage their symptoms. In some cases, medication may also be recommended to alleviate symptoms of anxiety or depression.

In medical terms, "outpatients" refers to individuals who receive medical care or treatment at a hospital or clinic without being admitted as inpatients. This means that they do not stay overnight or for an extended period; instead, they visit the healthcare facility for specific services such as consultations, diagnostic tests, treatments, or follow-up appointments and then return home afterward. Outpatient care can include various services like primary care, specialty clinics, dental care, physical therapy, and more. It is often more convenient and cost-effective than inpatient care, as it allows patients to maintain their daily routines while receiving necessary medical attention.

Genotype, in genetics, refers to the complete heritable genetic makeup of an individual organism, including all of its genes. It is the set of instructions contained in an organism's DNA for the development and function of that organism. The genotype is the basis for an individual's inherited traits, and it can be contrasted with an individual's phenotype, which refers to the observable physical or biochemical characteristics of an organism that result from the expression of its genes in combination with environmental influences.

It is important to note that an individual's genotype is not necessarily identical to their genetic sequence. Some genes have multiple forms called alleles, and an individual may inherit different alleles for a given gene from each parent. The combination of alleles that an individual inherits for a particular gene is known as their genotype for that gene.

Understanding an individual's genotype can provide important information about their susceptibility to certain diseases, their response to drugs and other treatments, and their risk of passing on inherited genetic disorders to their offspring.

Logistic models, specifically logistic regression models, are a type of statistical analysis used in medical and epidemiological research to identify the relationship between the risk of a certain health outcome or disease (dependent variable) and one or more independent variables, such as demographic factors, exposure variables, or other clinical measurements.

In contrast to linear regression models, logistic regression models are used when the dependent variable is binary or dichotomous in nature, meaning it can only take on two values, such as "disease present" or "disease absent." The model uses a logistic function to estimate the probability of the outcome based on the independent variables.

Logistic regression models are useful for identifying risk factors and estimating the strength of associations between exposures and health outcomes, adjusting for potential confounders, and predicting the probability of an outcome given certain values of the independent variables. They can also be used to develop clinical prediction rules or scores that can aid in decision-making and patient care.

Combat disorders are a category of mental health conditions that can occur in military personnel as a result of their experiences during combat. These disorders can include post-traumatic stress disorder (PTSD), acute stress disorder, and adjustment disorders, among others. Combat disorders may be caused by exposure to traumatic events, such as experiencing or witnessing combat, the threat of death or serious injury, or the loss of fellow soldiers. Symptoms can include flashbacks, nightmares, avoidance of reminders of the trauma, difficulty sleeping, irritability, and feelings of detachment or numbness. Treatment for combat disorders typically involves a combination of medication and therapy.

Prospective studies, also known as longitudinal studies, are a type of cohort study in which data is collected forward in time, following a group of individuals who share a common characteristic or exposure over a period of time. The researchers clearly define the study population and exposure of interest at the beginning of the study and follow up with the participants to determine the outcomes that develop over time. This type of study design allows for the investigation of causal relationships between exposures and outcomes, as well as the identification of risk factors and the estimation of disease incidence rates. Prospective studies are particularly useful in epidemiology and medical research when studying diseases with long latency periods or rare outcomes.

"Age factors" refer to the effects, changes, or differences that age can have on various aspects of health, disease, and medical care. These factors can encompass a wide range of issues, including:

1. Physiological changes: As people age, their bodies undergo numerous physical changes that can affect how they respond to medications, illnesses, and medical procedures. For example, older adults may be more sensitive to certain drugs or have weaker immune systems, making them more susceptible to infections.
2. Chronic conditions: Age is a significant risk factor for many chronic diseases, such as heart disease, diabetes, cancer, and arthritis. As a result, age-related medical issues are common and can impact treatment decisions and outcomes.
3. Cognitive decline: Aging can also lead to cognitive changes, including memory loss and decreased decision-making abilities. These changes can affect a person's ability to understand and comply with medical instructions, leading to potential complications in their care.
4. Functional limitations: Older adults may experience physical limitations that impact their mobility, strength, and balance, increasing the risk of falls and other injuries. These limitations can also make it more challenging for them to perform daily activities, such as bathing, dressing, or cooking.
5. Social determinants: Age-related factors, such as social isolation, poverty, and lack of access to transportation, can impact a person's ability to obtain necessary medical care and affect their overall health outcomes.

Understanding age factors is critical for healthcare providers to deliver high-quality, patient-centered care that addresses the unique needs and challenges of older adults. By taking these factors into account, healthcare providers can develop personalized treatment plans that consider a person's age, physical condition, cognitive abilities, and social circumstances.

I'm sorry for any confusion, but "United States" is a geopolitical entity, specifically the name of the country consisting of 50 states, and it is not a medical term or concept. Therefore, I can't provide a medical definition for it. If you have any questions related to health, medicine, or biology, I would be happy to try to help answer those!

Community psychiatry is a branch of psychiatry that focuses on providing mental health services within the context of a person's community, rather than in a traditional clinical setting such as a hospital or clinic. The goal of community psychiatry is to provide comprehensive, accessible, and personalized mental health care that is integrated into the individual's natural support systems, including their family, friends, and social networks.

Community psychiatrists work closely with other mental health professionals, social workers, and community organizations to develop and implement treatment plans that address the unique needs of each individual. They may provide services in a variety of settings, such as community mental health centers, group homes, schools, and primary care clinics.

The approach of community psychiatry recognizes that mental illness affects not only the individual but also their family, friends, and larger community. Therefore, interventions often focus on improving social determinants of health, such as housing, employment, and education, in addition to providing traditional mental health treatments like medication and therapy.

Overall, community psychiatry aims to reduce stigma around mental illness, improve access to care, and promote recovery and resilience in individuals with mental health conditions.

I'm sorry for any confusion, but "Netherlands" is not a medical term. It is a country located in Western Europe, known for its artistic heritage, elaborate canal system, and legalized marijuana and prostitution. If you have any questions about medical terms or concepts, I would be happy to help with those!

Psychopathology is a branch of psychology and medicine that involves the study and classification of mental disorders, including their causes, symptoms, and treatment. It is an interdisciplinary field that draws on various methods and perspectives from psychology, neuroscience, genetics, sociology, and other related disciplines to understand and explain abnormal behavior and mental processes.

The term "psychopathology" can also refer specifically to the presence of a mental disorder or to the symptoms and features of a particular mental disorder. For example, one might say that someone has a psychopathology or that they exhibit certain psychopathological symptoms.

Psychopathology is often contrasted with normal psychology, which focuses on understanding and explaining typical behavior and mental processes. However, it is important to note that the boundary between normal and abnormal behavior is not always clear-cut, and many psychological phenomena exist on a continuum rather than falling neatly into one category or the other.

A serotonin receptor, specifically the 5-HT1A subtype, is a type of G protein-coupled receptor found in the central and peripheral nervous systems. These receptors are activated by the neurotransmitter serotonin (5-hydroxytryptamine or 5-HT) and play important roles in regulating various physiological processes, including neurotransmission, neuronal excitability, and neuroendocrine function.

The 5-HT1A receptor is widely distributed throughout the brain and spinal cord, where it is involved in modulating mood, anxiety, cognition, memory, and pain perception. Activation of this receptor can have both inhibitory and excitatory effects on neuronal activity, depending on the location and type of neuron involved.

In addition to its role in normal physiology, the 5-HT1A receptor has been implicated in various pathological conditions, including depression, anxiety disorders, schizophrenia, and drug addiction. As a result, drugs that target this receptor have been developed for the treatment of these conditions. These drugs include selective serotonin reuptake inhibitors (SSRIs), which increase the availability of serotonin in the synaptic cleft and enhance 5-HT1A receptor activation, as well as direct agonists of the 5-HT1A receptor, such as buspirone, which is used to treat anxiety disorders.

Microbial drug resistance is a significant medical issue that refers to the ability of microorganisms (such as bacteria, viruses, fungi, or parasites) to withstand or survive exposure to drugs or medications designed to kill them or limit their growth. This phenomenon has become a major global health concern, particularly in the context of bacterial infections, where it is also known as antibiotic resistance.

Drug resistance arises due to genetic changes in microorganisms that enable them to modify or bypass the effects of antimicrobial agents. These genetic alterations can be caused by mutations or the acquisition of resistance genes through horizontal gene transfer. The resistant microbes then replicate and multiply, forming populations that are increasingly difficult to eradicate with conventional treatments.

The consequences of drug-resistant infections include increased morbidity, mortality, healthcare costs, and the potential for widespread outbreaks. Factors contributing to the emergence and spread of microbial drug resistance include the overuse or misuse of antimicrobials, poor infection control practices, and inadequate surveillance systems.

To address this challenge, it is crucial to promote prudent antibiotic use, strengthen infection prevention and control measures, develop new antimicrobial agents, and invest in research to better understand the mechanisms underlying drug resistance.

A phenotype is the physical or biochemical expression of an organism's genes, or the observable traits and characteristics resulting from the interaction of its genetic constitution (genotype) with environmental factors. These characteristics can include appearance, development, behavior, and resistance to disease, among others. Phenotypes can vary widely, even among individuals with identical genotypes, due to differences in environmental influences, gene expression, and genetic interactions.

'Hypericum' is a genus of flowering plants, also known as St. John's Wort. While it is primarily used in herbal medicine and not considered a standard medical term, it is important to note that some species of Hypericum have been found to have medicinal properties. The most commonly studied and used species is Hypericum perforatum, which has been found to have potential benefits in treating depression, anxiety, and sleep disorders. However, its use as a medical treatment is still a subject of ongoing research and debate, and it can interact with several medications. Always consult with a healthcare provider before starting any new supplement or medication.

Primary health care is defined by the World Health Organization (WHO) as:

"Essential health care that is based on practical, scientifically sound and socially acceptable methods and technology made universally accessible to individuals and families in the community through their full participation and at a cost that the community and country can afford. It forms an integral part both of the country's health system, of which it is the central function and main focus, and of the overall social and economic development of the community. It is the first level of contact of individuals, the family and community with the national health system bringing health care as close as possible to where people live and work, and constitutes the first element of a continuing health care process."

Primary health care includes a range of services such as preventive care, health promotion, curative care, rehabilitation, and palliative care. It is typically provided by a team of health professionals including doctors, nurses, midwives, pharmacists, and other community health workers. The goal of primary health care is to provide comprehensive, continuous, and coordinated care to individuals and families in a way that is accessible, affordable, and culturally sensitive.

A cohort study is a type of observational study in which a group of individuals who share a common characteristic or exposure are followed up over time to determine the incidence of a specific outcome or outcomes. The cohort, or group, is defined based on the exposure status (e.g., exposed vs. unexposed) and then monitored prospectively to assess for the development of new health events or conditions.

Cohort studies can be either prospective or retrospective in design. In a prospective cohort study, participants are enrolled and followed forward in time from the beginning of the study. In contrast, in a retrospective cohort study, researchers identify a cohort that has already been assembled through medical records, insurance claims, or other sources and then look back in time to assess exposure status and health outcomes.

Cohort studies are useful for establishing causality between an exposure and an outcome because they allow researchers to observe the temporal relationship between the two. They can also provide information on the incidence of a disease or condition in different populations, which can be used to inform public health policy and interventions. However, cohort studies can be expensive and time-consuming to conduct, and they may be subject to bias if participants are not representative of the population or if there is loss to follow-up.

Brain mapping is a broad term that refers to the techniques used to understand the structure and function of the brain. It involves creating maps of the various cognitive, emotional, and behavioral processes in the brain by correlating these processes with physical locations or activities within the nervous system. Brain mapping can be accomplished through a variety of methods, including functional magnetic resonance imaging (fMRI), positron emission tomography (PET) scans, electroencephalography (EEG), and others. These techniques allow researchers to observe which areas of the brain are active during different tasks or thoughts, helping to shed light on how the brain processes information and contributes to our experiences and behaviors. Brain mapping is an important area of research in neuroscience, with potential applications in the diagnosis and treatment of neurological and psychiatric disorders.

The amygdala is an almond-shaped group of nuclei located deep within the temporal lobe of the brain, specifically in the anterior portion of the temporal lobes and near the hippocampus. It forms a key component of the limbic system and plays a crucial role in processing emotions, particularly fear and anxiety. The amygdala is involved in the integration of sensory information with emotional responses, memory formation, and decision-making processes.

In response to emotionally charged stimuli, the amygdala can modulate various physiological functions, such as heart rate, blood pressure, and stress hormone release, via its connections to the hypothalamus and brainstem. Additionally, it contributes to social behaviors, including recognizing emotional facial expressions and responding appropriately to social cues. Dysfunctions in amygdala function have been implicated in several psychiatric and neurological conditions, such as anxiety disorders, depression, post-traumatic stress disorder (PTSD), and autism spectrum disorder (ASD).

According to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), alcohol-related disorders are a category of mental disorders defined by a problematic pattern of alcohol use that leads to clinically significant impairment or distress. The disorders include:

1. Alcohol Use Disorder (AUD): A chronic relapsing brain disorder characterized by an impaired ability to stop or control alcohol use despite adverse social, occupational, or health consequences. AUD can be mild, moderate, or severe, and recovery is possible regardless of severity. The symptoms include problems controlling intake of alcohol, continued use despite problems resulting from drinking, development of a tolerance, drinking that leads to risky situations, or withdrawal symptoms when not drinking.
2. Alcohol Intoxication: A state of acute impairment in mental and motor function caused by the recent consumption of alcohol. The symptoms include slurred speech, unsteady gait, nystagmus, impaired attention or memory, stupor, or coma. In severe cases, it can lead to respiratory depression, hypothermia, or even death.
3. Alcohol Withdrawal: A syndrome that occurs when alcohol use is heavily reduced or stopped after prolonged and heavy use. The symptoms include autonomic hyperactivity, increased hand tremor, insomnia, nausea or vomiting, transient visual, tactile, or auditory hallucinations or illusions, psychomotor agitation, anxiety, and grand mal seizures.
4. Other Alcohol-Induced Disorders: These include alcohol-induced sleep disorder, alcohol-induced sexual dysfunction, and alcohol-induced major neurocognitive disorder.

It is important to note that alcohol use disorders are complex conditions that can be influenced by a variety of factors, including genetics, environment, and personal behavior. If you or someone you know is struggling with alcohol use, it is recommended to seek professional help.

Agoraphobia is an anxiety disorder characterized by fear and avoidance of places, situations, or events that may trigger feelings of panic, fear, or embarrassment. People with agoraphobia may feel anxious about being in crowded places, standing in line, using public transportation, or being outside their home alone. They may also have a fear of leaving their "safe" place or experience severe anxiety when they are in a situation where escape might be difficult or help unavailable. In severe cases, agoraphobia can lead to avoidance of many activities and significant impairment in social, occupational, and other areas of functioning.

Attention Deficit and Disruptive Behavior Disorders (ADDBDs) are a group of childhood-onset disorders characterized by persistent patterns of behavior that are difficult for the individual to control. These disorders include Attention Deficit Hyperactivity Disorder (ADHD), Oppositional Defiant Disorder (ODD), and Conduct Disorder (CD).

Attention Deficit Hyperactivity Disorder (ADHD) is characterized by symptoms of inattention, hyperactivity, and impulsivity that interfere with daily functioning. These symptoms must be present for at least six months and occur in multiple settings, such as school, home, and social situations.

Oppositional Defiant Disorder (ODD) is characterized by a pattern of negative, hostile, and defiant behavior towards authority figures, which includes arguing with adults, losing temper, actively defying rules, and deliberately annoying others. These symptoms must be present for at least six months and occur more frequently than in other children of the same age and developmental level.

Conduct Disorder (CD) is characterized by a repetitive and persistent pattern of behavior that violates the rights of others or major age-appropriate societal norms and rules. These behaviors include aggression towards people and animals, destruction of property, deceitfulness or theft, and serious violation of rules.

It's important to note that these disorders can co-occur with other mental health conditions, such as mood disorders, anxiety disorders, and learning disabilities. Proper diagnosis and treatment are essential for managing the symptoms and improving the individual's quality of life.

Microbial sensitivity tests, also known as antibiotic susceptibility tests (ASTs) or bacterial susceptibility tests, are laboratory procedures used to determine the effectiveness of various antimicrobial agents against specific microorganisms isolated from a patient's infection. These tests help healthcare providers identify which antibiotics will be most effective in treating an infection and which ones should be avoided due to resistance. The results of these tests can guide appropriate antibiotic therapy, minimize the potential for antibiotic resistance, improve clinical outcomes, and reduce unnecessary side effects or toxicity from ineffective antimicrobials.

There are several methods for performing microbial sensitivity tests, including:

1. Disk diffusion method (Kirby-Bauer test): A standardized paper disk containing a predetermined amount of an antibiotic is placed on an agar plate that has been inoculated with the isolated microorganism. After incubation, the zone of inhibition around the disk is measured to determine the susceptibility or resistance of the organism to that particular antibiotic.
2. Broth dilution method: A series of tubes or wells containing decreasing concentrations of an antimicrobial agent are inoculated with a standardized microbial suspension. After incubation, the minimum inhibitory concentration (MIC) is determined by observing the lowest concentration of the antibiotic that prevents visible growth of the organism.
3. Automated systems: These use sophisticated technology to perform both disk diffusion and broth dilution methods automatically, providing rapid and accurate results for a wide range of microorganisms and antimicrobial agents.

The interpretation of microbial sensitivity test results should be done cautiously, considering factors such as the site of infection, pharmacokinetics and pharmacodynamics of the antibiotic, potential toxicity, and local resistance patterns. Regular monitoring of susceptibility patterns and ongoing antimicrobial stewardship programs are essential to ensure optimal use of these tests and to minimize the development of antibiotic resistance.

The double-blind method is a study design commonly used in research, including clinical trials, to minimize bias and ensure the objectivity of results. In this approach, both the participants and the researchers are unaware of which group the participants are assigned to, whether it be the experimental group or the control group. This means that neither the participants nor the researchers know who is receiving a particular treatment or placebo, thus reducing the potential for bias in the evaluation of outcomes. The assignment of participants to groups is typically done by a third party not involved in the study, and the codes are only revealed after all data have been collected and analyzed.

Anti-bacterial agents, also known as antibiotics, are a type of medication used to treat infections caused by bacteria. These agents work by either killing the bacteria or inhibiting their growth and reproduction. There are several different classes of anti-bacterial agents, including penicillins, cephalosporins, fluoroquinolones, macrolides, and tetracyclines, among others. Each class of antibiotic has a specific mechanism of action and is used to treat certain types of bacterial infections. It's important to note that anti-bacterial agents are not effective against viral infections, such as the common cold or flu. Misuse and overuse of antibiotics can lead to antibiotic resistance, which is a significant global health concern.

A mutation is a permanent change in the DNA sequence of an organism's genome. Mutations can occur spontaneously or be caused by environmental factors such as exposure to radiation, chemicals, or viruses. They may have various effects on the organism, ranging from benign to harmful, depending on where they occur and whether they alter the function of essential proteins. In some cases, mutations can increase an individual's susceptibility to certain diseases or disorders, while in others, they may confer a survival advantage. Mutations are the driving force behind evolution, as they introduce new genetic variability into populations, which can then be acted upon by natural selection.

A chronic disease is a long-term medical condition that often progresses slowly over a period of years and requires ongoing management and care. These diseases are typically not fully curable, but symptoms can be managed to improve quality of life. Common chronic diseases include heart disease, stroke, cancer, diabetes, arthritis, and COPD (chronic obstructive pulmonary disease). They are often associated with advanced age, although they can also affect children and younger adults. Chronic diseases can have significant impacts on individuals' physical, emotional, and social well-being, as well as on healthcare systems and society at large.

Mental health services refer to the various professional health services designed to treat and support individuals with mental health conditions. These services are typically provided by trained and licensed mental health professionals, such as psychiatrists, psychologists, social workers, mental health counselors, and marriage and family therapists. The services may include:

1. Assessment and diagnosis of mental health disorders
2. Psychotherapy or "talk therapy" to help individuals understand and manage their symptoms
3. Medication management for mental health conditions
4. Case management and care coordination to connect individuals with community resources and support
5. Psychoeducation to help individuals and families better understand mental health conditions and how to manage them
6. Crisis intervention and stabilization services
7. Inpatient and residential treatment for severe or chronic mental illness
8. Prevention and early intervention services to identify and address mental health concerns before they become more serious
9. Rehabilitation and recovery services to help individuals with mental illness achieve their full potential and live fulfilling lives in the community.

"Postmortem changes," also known as "autolysis" or "decomposition," refer to the natural biological processes that occur in a deceased body after death. These changes include various chemical, physical, and biological alterations such as livor mortis (pooling of blood), algor mortis (drop in body temperature), rigor mortis (stiffening of muscles), putrefaction (breakdown by microorganisms), and decomposition by insects and other animals. These changes help forensic experts estimate the time since death, known as the postmortem interval.

The Hypothalamo-Hypophyseal system, also known as the hypothalamic-pituitary system, is a crucial part of the endocrine system that regulates many bodily functions. It consists of two main components: the hypothalamus and the pituitary gland.

The hypothalamus is a region in the brain that receives information from various parts of the body and integrates them to regulate vital functions such as body temperature, hunger, thirst, sleep, and emotional behavior. It also produces and releases neurohormones that control the secretion of hormones from the pituitary gland.

The pituitary gland is a small gland located at the base of the brain, just below the hypothalamus. It consists of two parts: the anterior pituitary (also called adenohypophysis) and the posterior pituitary (also called neurohypophysis). The anterior pituitary produces and releases several hormones that regulate various bodily functions such as growth, metabolism, reproduction, and stress response. The posterior pituitary stores and releases hormones produced by the hypothalamus, including antidiuretic hormone (ADH) and oxytocin.

The hypothalamo-hypophyseal system works together to maintain homeostasis in the body by regulating various physiological processes through hormonal signaling. Dysfunction of this system can lead to several endocrine disorders, such as diabetes insipidus, pituitary tumors, and hypothalamic-pituitary axis disorders.

The frontal lobe is the largest lobes of the human brain, located at the front part of each cerebral hemisphere and situated in front of the parietal and temporal lobes. It plays a crucial role in higher cognitive functions such as decision making, problem solving, planning, parts of social behavior, emotional expressions, physical reactions, and motor function. The frontal lobe is also responsible for what's known as "executive functions," which include the ability to focus attention, understand rules, switch focus, plan actions, and inhibit inappropriate behaviors. It is divided into five areas, each with its own specific functions: the primary motor cortex, premotor cortex, Broca's area, prefrontal cortex, and orbitofrontal cortex. Damage to the frontal lobe can result in a wide range of impairments, depending on the location and extent of the injury.

Brain-Derived Neurotrophic Factor (BDNF) is a type of protein called a neurotrophin, which is involved in the growth and maintenance of neurons (nerve cells) in the brain. BDNFA is encoded by the BDNF gene and is widely expressed throughout the central nervous system. It plays an essential role in supporting the survival of existing neurons, encouraging the growth and differentiation of new neurons and synapses, and contributing to neuroplasticity - the ability of the brain to change and adapt as a result of experience. Low levels of BDNF have been associated with several neurological disorders, including depression, Alzheimer's disease, and Huntington's disease.

Social adjustment, in the context of mental health and psychology, refers to an individual's ability to adapt and function effectively within their social environment. It involves developing and maintaining positive relationships with others, fulfilling various social roles (such as being a family member, friend, or employee), and meeting the expectations and demands of one's social group.

Social adjustment can be affected by various factors, including an individual's personality traits, coping skills, mental and physical health status, and life experiences. Poor social adjustment can lead to feelings of isolation, loneliness, and dissatisfaction with life, as well as increased risk for mental health problems such as depression and anxiety.

Assessing social adjustment is an important aspect of mental health care, as it can provide valuable insights into an individual's overall functioning and quality of life. Treatments such as psychotherapy and social skills training may be used to help improve social adjustment in individuals who are struggling in this area.

Tic disorders are a group of conditions characterized by the presence of repetitive, involuntary movements or sounds, known as tics. These movements or sounds can vary in complexity and severity, and they may be worsened by stress or strong emotions.

There are several different types of tic disorders, including:

1. Tourette's disorder: This is a neurological condition characterized by the presence of both motor (movement-related) and vocal tics that have been present for at least one year. The tics may wax and wane in severity over time, but they do not disappear for more than three consecutive months.
2. Persistent (chronic) motor or vocal tic disorder: This type of tic disorder is characterized by the presence of either motor or vocal tics (but not both), which have been present for at least one year. The tics may wax and wane in severity over time, but they do not disappear for more than three consecutive months.
3. Provisional tic disorder: This type of tic disorder is characterized by the presence of motor or vocal tics (or both) that have been present for less than one year. The tics may wax and wane in severity over time, but they do not disappear for more than three consecutive months.
4. Tic disorder not otherwise specified: This category is used to describe tic disorders that do not meet the criteria for any of the other types of tic disorders.

Tic disorders are thought to be caused by a combination of genetic and environmental factors, and they often co-occur with other conditions such as attention deficit hyperactivity disorder (ADHD) and obsessive-compulsive disorder (OCD). Treatment for tic disorders may include behavioral therapy, medication, or a combination of both.

Affective symptoms refer to emotional or mood-related disturbances that can occur in various medical and psychological conditions. These symptoms may include:

1. Depression: feelings of sadness, hopelessness, loss of interest or pleasure in activities, changes in appetite and sleep patterns, fatigue, difficulty concentrating, and thoughts of death or suicide.
2. Anxiety: excessive worry, fear, or nervousness, often accompanied by physical symptoms such as a rapid heartbeat, sweating, and trembling.
3. Irritability: easily annoyed or agitated, often leading to outbursts of anger or frustration.
4. Mania or hypomania: abnormally elevated mood, increased energy, decreased need for sleep, racing thoughts, and impulsive or risky behavior.
5. Apathy: lack of interest, motivation, or emotion, often leading to social withdrawal and decreased activity levels.
6. Mood lability: rapid and unpredictable shifts in mood, ranging from extreme happiness to sadness, anger, or anxiety.

Affective symptoms can significantly impact a person's quality of life and ability to function in daily activities. They may be caused by a variety of factors, including genetics, brain chemistry imbalances, stress, trauma, and medical conditions. Proper diagnosis and treatment are essential for managing affective symptoms and improving overall well-being.

Psychiatry is the branch of medicine focused on the diagnosis, treatment, and prevention of mental, emotional, and behavioral disorders. A psychiatrist is a medically trained doctor who specializes in psychiatry, and they are qualified to assess both the mental and physical aspects of psychological problems. They can use a variety of treatments, including psychotherapy, medications, psychoeducation, and psychosocial interventions, to help patients manage their symptoms and improve their quality of life.

Psychiatrists often work in multidisciplinary teams that include other mental health professionals such as psychologists, social workers, and mental health nurses. They may provide services in a range of settings, including hospitals, clinics, community mental health centers, and private practices.

It's important to note that while I strive to provide accurate and helpful information, my responses should not be used as a substitute for professional medical advice, diagnosis, or treatment. If you or someone else has concerns about mental health, it is always best to consult with a qualified healthcare provider.

The pituitary-adrenal system, also known as the hypothalamic-pituitary-adrenal (HPA) axis, is a complex set of interactions between the hypothalamus, the pituitary gland, and the adrenal glands. This system plays a crucial role in the body's response to stress through the release of hormones that regulate various physiological processes.

The hypothalamus, located within the brain, receives information from the nervous system about the internal and external environment and responds by releasing corticotropin-releasing hormone (CRH) and vasopressin. These hormones then travel to the anterior pituitary gland, where they stimulate the release of adrenocorticotropic hormone (ACTH).

ACTH is transported through the bloodstream to the adrenal glands, which are located on top of the kidneys. The adrenal glands consist of two parts: the outer cortex and the inner medulla. ACTH specifically targets the adrenal cortex, causing it to release cortisol and other glucocorticoids, as well as androgens such as dehydroepiandrosterone (DHEA).

Cortisol has numerous effects on metabolism, immune function, and cardiovascular regulation. It helps regulate blood sugar levels, suppresses the immune system, and aids in the breakdown of fats, proteins, and carbohydrates to provide energy during stressful situations. DHEA can be converted into male and female sex hormones (androgens and estrogens) in various tissues throughout the body.

The pituitary-adrenal system is tightly regulated through negative feedback mechanisms. High levels of cortisol, for example, inhibit the release of CRH and ACTH from the hypothalamus and pituitary gland, respectively, thereby limiting further cortisol production. Dysregulation of this system has been implicated in several medical conditions, including Cushing's syndrome (overproduction of cortisol) and Addison's disease (underproduction of cortisol).

"Competitive bidding" is not a medical term, but rather a business or procurement concept that can be applied in various industries, including healthcare. In the context of healthcare, competitive bidding typically refers to a process where healthcare providers or suppliers submit bids to provide goods or services to a payer, such as a government agency or insurance company, at the lowest possible price.

The goal of competitive bidding is to promote cost savings and efficiency in the delivery of healthcare services. For example, Medicare uses a competitive bidding program for certain medical equipment and supplies, such as wheelchairs and oxygen equipment, where suppliers submit bids and are awarded contracts based on their ability to provide high-quality items at the lowest price.

However, it's important to note that while competitive bidding can lead to cost savings, it may also have unintended consequences, such as reducing provider participation or limiting access to certain services in some areas. Therefore, it is essential to balance cost savings with quality and access considerations when implementing competitive bidding programs in healthcare.

The limbic system is a complex set of structures in the brain that includes the hippocampus, amygdala, fornix, cingulate gyrus, and other nearby areas. It's associated with emotional responses, instinctual behaviors, motivation, long-term memory formation, and olfaction (smell). The limbic system is also involved in the modulation of visceral functions and drives, such as hunger, thirst, and sexual drive.

The structures within the limbic system communicate with each other and with other parts of the brain, particularly the hypothalamus and the cortex, to regulate various physiological and psychological processes. Dysfunctions in the limbic system can lead to a range of neurological and psychiatric conditions, including depression, anxiety disorders, post-traumatic stress disorder (PTSD), and certain types of memory impairment.

Reproducibility of results in a medical context refers to the ability to obtain consistent and comparable findings when a particular experiment or study is repeated, either by the same researcher or by different researchers, following the same experimental protocol. It is an essential principle in scientific research that helps to ensure the validity and reliability of research findings.

In medical research, reproducibility of results is crucial for establishing the effectiveness and safety of new treatments, interventions, or diagnostic tools. It involves conducting well-designed studies with adequate sample sizes, appropriate statistical analyses, and transparent reporting of methods and findings to allow other researchers to replicate the study and confirm or refute the results.

The lack of reproducibility in medical research has become a significant concern in recent years, as several high-profile studies have failed to produce consistent findings when replicated by other researchers. This has led to increased scrutiny of research practices and a call for greater transparency, rigor, and standardization in the conduct and reporting of medical research.

Psychological adaptation refers to the process by which individuals adjust and cope with stressors, challenges, or changes in their environment or circumstances. It involves modifying thoughts, feelings, behaviors, and copabilities to reduce the negative impact of these stressors and promote well-being. Psychological adaptation can occur at different levels, including intrapersonal (within the individual), interpersonal (between individuals), and cultural (within a group or society).

Examples of psychological adaptation include:

* Cognitive restructuring: changing negative thoughts and beliefs to more positive or adaptive ones
* Emotion regulation: managing and reducing intense or distressing emotions
* Problem-solving: finding solutions to practical challenges or obstacles
* Seeking social support: reaching out to others for help, advice, or comfort
* Developing coping strategies: using effective ways to deal with stressors or difficulties
* Cultivating resilience: bouncing back from adversity and learning from negative experiences.

Psychological adaptation is an important aspect of mental health and well-being, as it helps individuals adapt to new situations, overcome challenges, and maintain a sense of control and optimism in the face of stressors or changes.

Dependent Personality Disorder (DPD) is a mental health condition in which an individual has an extreme fear of being abandoned or rejected, leading them to rely excessively on others for support and decision-making. According to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), to be diagnosed with DPD, an individual must exhibit at least five of the following symptoms:

1. Difficulty making everyday decisions without excessive advice and reassurance from others.
2. Need for others to assume responsibility for most major areas of their life.
3. Has difficulty expressing disagreement with others due to fear of loss of support or approval.
4. Has difficulty initiating projects or doing things on their own due to a lack of self-confidence in judgment or abilities.
5. Goes to excessive lengths to obtain nurturance and support from others, including volunteering to do things that are not enjoyable.
6. Feels uncomfortable or helpless when alone because of exaggerated fears of being unable to care for themselves.
7. Urgently seeks another relationship as a source of care and support when a close relationship ends.
8. Is unrealistically preoccupied with fears of being left to take care of themselves.

These symptoms must be present for an extended period, typically lasting for at least two years or more, and cause significant distress or impairment in social, occupational, or other areas of functioning. Additionally, the symptoms cannot be better explained by another mental health condition, such as bipolar disorder or major depressive disorder.

It is important to note that seeking help from a mental health professional is essential for an accurate diagnosis and treatment plan if you suspect you may have DPD.

I'm sorry for any confusion, but "Oregon" is not a medical term or concept. It is a geographical location, being the name of a state in the United States, located in the Pacific Northwest region. If you have any questions related to medical topics, I would be happy to try and help answer those for you!

Child guidance clinics are mental health clinics specifically designed to assess, diagnose, and treat children and adolescents with behavioral, emotional, and social difficulties. These clinics are typically staffed by a multidisciplinary team of healthcare professionals, including psychologists, psychiatrists, social workers, and other specialists who work together to provide comprehensive care for children and their families.

The services offered at child guidance clinics may include individual and group therapy, family therapy, psychological testing and assessment, medication management, and case management. The goal of these clinics is to help children and adolescents develop healthy social and emotional skills, improve their behavior and academic performance, and promote overall well-being.

Child guidance clinics often work closely with schools, community organizations, and other healthcare providers to ensure that children receive coordinated and continuous care. They may also provide training and education to parents, teachers, and other professionals who work with children to help them better understand and respond to the unique needs of children with mental health challenges.

Functional neuroimaging is a branch of medical imaging that involves the use of various techniques to measure and visualize the metabolic activity or blood flow in different regions of the brain. These measurements can be used to infer the level of neural activation in specific brain areas, allowing researchers and clinicians to study the functioning of the brain in various states, such as during rest, cognitive tasks, or disease processes.

Some common functional neuroimaging techniques include:

1. Functional Magnetic Resonance Imaging (fMRI): This technique uses magnetic fields and radio waves to measure changes in blood flow and oxygenation levels in the brain, which are associated with neural activity.
2. Positron Emission Tomography (PET): This technique involves the injection of a small amount of radioactive tracer into the body, which is taken up by active brain cells. The resulting gamma rays are then detected and used to create images of brain activity.
3. Single-Photon Emission Computed Tomography (SPECT): Similar to PET, SPECT uses a radioactive tracer to measure blood flow in the brain, but with lower resolution and sensitivity.
4. Functional Near-Infrared Spectroscopy (fNIRS): This technique uses near-infrared light to measure changes in oxygenation levels in the brain, providing a non-invasive and relatively inexpensive method for studying brain function.

Functional neuroimaging has numerous applications in both research and clinical settings, including the study of cognitive processes, the diagnosis and monitoring of neurological and psychiatric disorders, and the development of new treatments and interventions.

Hydrocortisone is a synthetic glucocorticoid, which is a class of steroid hormones. It is identical to the naturally occurring cortisol, a hormone produced by the adrenal gland that helps regulate metabolism and helps your body respond to stress. Hydrocortisone has anti-inflammatory effects and is used to treat various inflammatory conditions such as allergies, skin disorders, and autoimmune diseases. It works by suppressing the immune system's response to reduce swelling, redness, itching, and other symptoms caused by inflammation.

Hydrocortisone is available in different forms, including oral tablets, topical creams, lotions, gels, and ointments, as well as injectable solutions. The specific use and dosage depend on the condition being treated and the individual patient's medical history and current health status.

As with any medication, hydrocortisone can have side effects, especially when used in high doses or for extended periods. Common side effects include increased appetite, weight gain, mood changes, insomnia, and skin thinning. Long-term use of hydrocortisone may also increase the risk of developing osteoporosis, diabetes, cataracts, and other health problems. Therefore, it is essential to follow your healthcare provider's instructions carefully when using this medication.

Paroxetine is a selective serotonin reuptake inhibitor (SSRI) medication that is primarily used to treat major depressive disorders, obsessive-compulsive disorder, panic disorder, social anxiety disorder, generalized anxiety disorder, and post-traumatic stress disorder. It works by increasing the levels of serotonin, a neurotransmitter in the brain that helps maintain mental balance, leading to an improvement in mood and other symptoms associated with these conditions.

Paroxetine is available under various brand names, such as Paxil and Seroxat, and it comes in different forms, including tablets, capsules, and liquid solutions. The medication is typically taken once daily, although the dosage may vary depending on the individual's needs and the specific condition being treated.

As with any medication, paroxetine can have side effects, such as nausea, dizziness, dry mouth, and sleep disturbances. In some cases, it may also cause more serious side effects, including increased risk of suicidal thoughts or behaviors in children, adolescents, and young adults, as well as an increased risk of bleeding and hyponatremia (low sodium levels).

It is important to consult with a healthcare provider before starting paroxetine or any other medication, and to follow their instructions carefully regarding dosage, timing, and potential interactions with other drugs or medical conditions.

A facial expression is a result of the contraction or relaxation of muscles in the face that change the physical appearance of an individual's face to convey various emotions, intentions, or physical sensations. Facial expressions can be voluntary or involuntary and are a form of non-verbal communication that plays a crucial role in social interaction and conveying a person's state of mind.

The seven basic facial expressions of emotion, as proposed by Paul Ekman, include happiness, sadness, fear, disgust, surprise, anger, and contempt. These facial expressions are universally recognized across cultures and can be detected through the interpretation of specific muscle movements in the face, known as action units, which are measured and analyzed in fields such as psychology, neurology, and computer vision.

Moclobemide is a type of antidepressant known as a reversible inhibitor of monoamine oxidase A (RIMA). It works by increasing the levels of neurotransmitters (chemical messengers) in the brain, such as serotonin and noradrenaline, which helps to improve mood and alleviate symptoms of depression.

Moclobemide is specifically designed to inhibit only monoamine oxidase A, which metabolizes neurotransmitters in the brain, and not monoamine oxidase B, which is found in other parts of the body. This selectivity reduces the risk of serious side effects associated with non-selective monoamine oxidase inhibitors (MAOIs), such as hypertensive crisis caused by interactions with tyramine-rich foods or certain medications.

Moclobemide is used to treat major depressive disorders and may also be used off-label for other conditions, such as social anxiety disorder or panic disorder. It is available in various forms, including tablets and oral solution, and is typically taken two to three times a day. As with any medication, moclobemide should be taken under the supervision of a healthcare provider, who will determine the appropriate dosage and monitor for potential side effects.

Quality of Life (QOL) is a broad, multidimensional concept that usually includes an individual's physical health, psychological state, level of independence, social relationships, personal beliefs, and their relationship to salient features of their environment. It reflects the impact of disease and treatment on a patient's overall well-being and ability to function in daily life.

The World Health Organization (WHO) defines QOL as "an individual's perception of their position in life in the context of the culture and value systems in which they live and in relation to their goals, expectations, standards and concerns." It is a subjective concept, meaning it can vary greatly from person to person.

In healthcare, QOL is often used as an outcome measure in clinical trials and other research studies to assess the impact of interventions or treatments on overall patient well-being.

General Adaptation Syndrome (GAS) is not a term that is typically used in modern medical or clinical settings. However, it does have a historical significance in the field of stress research. It was first introduced by Hans Selye, an Austrian-Canadian endocrinologist, in 1936 as a model to describe the body's response to stress.

GAS is a three-stage response:

1. Alarm Stage: The initial stage where the body recognizes the stressor and responds with a "fight or flight" reaction, which includes the activation of the sympathetic nervous system and the release of stress hormones like adrenaline and cortisol.

2. Resistance Stage: If the stressor continues, the body tries to adapt by increasing its resistance. This stage is characterized by the continued release of stress hormones, which can have both beneficial (like increased alertness and energy) and detrimental effects (like impaired immune function and digestion).

3. Exhaustion Stage: If the stressor remains unresolved, the body's resources become depleted, leading to the exhaustion stage. At this point, the body's ability to resist the stressor is significantly reduced, making it more susceptible to disease and illness.

While GAS is not a term used in current medical practice, the concept of the body's response to stress is still very relevant. Modern research often uses the term "allostatic load" to describe the wear and tear on the body due to chronic stress.

Child abuse is a broad term that refers to any form of physical, emotional, or sexual mistreatment or neglect that causes harm to a child's health, development, or dignity. According to the World Health Organization (WHO), child abuse includes:

1. Physical abuse: Non-accidental injuries caused by hitting, kicking, shaking, burning, or otherwise harming a child's body.
2. Sexual abuse: Any sexual activity involving a child, such as touching or non-touching behaviors, exploitation, or exposure to pornographic material.
3. Emotional abuse: Behaviors that harm a child's emotional well-being and self-esteem, such as constant criticism, humiliation, threats, or rejection.
4. Neglect: Failure to provide for a child's basic needs, including food, clothing, shelter, medical care, education, and emotional support.

Child abuse can have serious short-term and long-term consequences for the physical, emotional, and psychological well-being of children. It is a violation of their fundamental human rights and a public health concern that requires prevention, early detection, and intervention.

Socioeconomic factors are a range of interconnected conditions and influences that affect the opportunities and resources a person or group has to maintain and improve their health and well-being. These factors include:

1. Economic stability: This includes employment status, job security, income level, and poverty status. Lower income and lack of employment are associated with poorer health outcomes.
2. Education: Higher levels of education are generally associated with better health outcomes. Education can affect a person's ability to access and understand health information, as well as their ability to navigate the healthcare system.
3. Social and community context: This includes factors such as social support networks, discrimination, and community safety. Strong social supports and positive community connections are associated with better health outcomes, while discrimination and lack of safety can negatively impact health.
4. Healthcare access and quality: Access to affordable, high-quality healthcare is an important socioeconomic factor that can significantly impact a person's health. Factors such as insurance status, availability of providers, and cultural competency of healthcare systems can all affect healthcare access and quality.
5. Neighborhood and built environment: The physical conditions in which people live, work, and play can also impact their health. Factors such as housing quality, transportation options, availability of healthy foods, and exposure to environmental hazards can all influence health outcomes.

Socioeconomic factors are often interrelated and can have a cumulative effect on health outcomes. For example, someone who lives in a low-income neighborhood with limited access to healthy foods and safe parks may also face challenges related to employment, education, and healthcare access that further impact their health. Addressing socioeconomic factors is an important part of promoting health equity and reducing health disparities.

Antisocial Personality Disorder (ASPD) is a mental health condition characterized by a pervasive pattern of disregard for the rights of others, lack of empathy, and manipulative behaviors. It is defined in the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), as follows:

A. A consistent pattern of behavior that violates the basic rights of others and major age-appropriate societal norms and rules, as indicated by the presence of at least three of the following:

1. Failure to conform to social norms and laws, indicated by repeatedly performing acts that are grounds for arrest.
2. Deceitfulness, as indicated by repeated lying, use of aliases, or conning others for personal profit or pleasure.
3. Impulsivity or failure to plan ahead; indication of this symptom may include promiscuity.
4. Irritability and aggressiveness, as indicated by repeated physical fights or assaults.
5. Reckless disregard for safety of self or others.
6. Consistent irresponsibility, as indicated by repeated failure to sustain consistent work behavior or honor financial obligations.
7. Lack of remorse, as indicated by being indifferent to or rationalizing having hurt, mistreated, or stolen from another.

B. The individual is at least 18 years of age.

C. There is evidence of conduct disorder with onset before the age of 15 years.

D. The occurrence of antisocial behavior is not exclusively during the course of schizophrenia or bipolar disorder.

E. The individual's criminal behavior has not been better explained by a conduct disorder diagnosis or antisocial behavior that began before the age of 15 years.

It's important to note that ASPD can be challenging to diagnose, and it often requires a comprehensive evaluation from a mental health professional with experience in personality disorders.

Antimanic agents are a class of medications primarily used to treat mania, a symptom of bipolar disorder. These agents help to control and reduce the severity of manic episodes, which can include symptoms such as elevated or irritable mood, increased energy, decreased need for sleep, racing thoughts, and impulsive or risky behavior.

The most commonly used antimanic agents are mood stabilizers, such as lithium and valproate (Depakote), and atypical antipsychotics, such as olanzapine (Zyprexa), risperidone (Risperdal), quetiapine (Seroquel), and aripiprazole (Abilify). These medications work by altering the levels or activity of certain neurotransmitters in the brain, such as dopamine, serotonin, and norepinephrine.

Electroconvulsive therapy (ECT) is also considered an effective antimanic treatment for severe mania that has not responded to medication. ECT involves applying electrical currents to the brain while the patient is under anesthesia, which induces a seizure and can help to reduce symptoms of mania.

It's important to note that antimanic agents should only be used under the supervision of a qualified healthcare provider, as they can have significant side effects and interactions with other medications. Additionally, a comprehensive treatment plan for bipolar disorder typically includes psychotherapy, education, and support to help manage the condition and prevent future episodes.

Single Nucleotide Polymorphism (SNP) is a type of genetic variation that occurs when a single nucleotide (A, T, C, or G) in the DNA sequence is altered. This alteration must occur in at least 1% of the population to be considered a SNP. These variations can help explain why some people are more susceptible to certain diseases than others and can also influence how an individual responds to certain medications. SNPs can serve as biological markers, helping scientists locate genes that are associated with disease. They can also provide information about an individual's ancestry and ethnic background.

An endophenotype is a measurable biological or neurophysiological characteristic that is associated with a particular disease or disorder. It is thought to be a heritable component that contributes to the development and expression of the disease, and can be used to help understand the underlying genetic and neural mechanisms of the disorder. Endophenotypes are often quantifiable and can be observed in individuals both with and without the disorder, making them useful for research purposes. They may include biochemical measures, neurophysiological measures, neuroanatomical measures, or cognitive/neural performance measures.

'Diseases in Twins' is a field of study that focuses on the similarities and differences in the occurrence, development, and outcomes of diseases among twins. This research can provide valuable insights into the genetic and environmental factors that contribute to various medical conditions.

Twins can be classified into two types: monozygotic (identical) and dizygotic (fraternal). Monozygotic twins share 100% of their genes, while dizygotic twins share about 50%, similar to non-twin siblings. By comparing the concordance rates (the likelihood of both twins having the same disease) between monozygotic and dizygotic twins, researchers can estimate the heritability of a particular disease.

Studying diseases in twins also helps understand the role of environmental factors. When both twins develop the same disease, but they are discordant for certain risk factors (e.g., one twin smokes and the other does not), it suggests that the disease may have a stronger genetic component. On the other hand, when both twins share similar risk factors and develop the disease, it implies that environmental factors play a significant role.

Diseases in Twins research has contributed to our understanding of various medical conditions, including infectious diseases, cancer, mental health disorders, and developmental disorders. This knowledge can lead to better prevention strategies, early detection methods, and more targeted treatments for these diseases.

... is a term used in psychiatry to describe people with major depressive disorder (MDD) who do not ... Anxiety disorders are one of the most common disorder types associated with treatment-resistant depression. The two disorders ... Other psychiatric disorders that may predict treatment-resistant depression include attention deficit hyperactivity disorder, ... Cases of treatment-resistant depression may also be referred to by which medications people with treatment-resistant depression ...
... in major depressive disorder (MDD); most found alleviation of depressive symptoms. There have been only two RCTs in treatment- ... resistant MDD; both were small, and one found an effect and the other did not. One meta-analysis of the data focused on ... tDCS is a CE approved treatment for major depressive disorder (MDD) in the UK, EU, Australia, and Mexico. As of 2015, tDCS has ... A systematic review of placebo-controlled trials investigating tDCS treatment for major depressive disorder was published 2020 ...
VNS devices are used to treat drug-resistant epilepsy and treatment-resistant major depressive disorder (TR-MDD). In the United ... such devices had been tested in clinical trials for treatment resistant major depressive disorder as of 2017. James L. Corning ... It is used as an add-on treatment for certain types of intractable epilepsy and treatment-resistant depression. ... Carreno FR, Frazer A (July 2017). "Vagal Nerve Stimulation for Treatment-Resistant Depression". Neurotherapeutics. 14 (3): 716- ...
The first randomized controlled trial in patients with non-treatment-resistant major depressive disorder, by Corrigan et al., ... February 2016). "Clinical Experience With High-Dosage Pramipexole in Patients With Treatment-Resistant Depressive Episodes in ... October 2002). "Pramipexole in treatment-resistant depression: a 16-week naturalistic study". Bipolar Disorders. 4 (5): 307-314 ... Pramipexole has also been used as a treatment for REM sleep behaviour disorder, but it is not licensed for use in this disorder ...
ECT is used, where possible, with informed consent in treatment-resistant major depressive disorder, treatment-resistant ... Compared with repetitive transcranial magnetic stimulation (rTMS) for people with treatment-resistant major depressive disorder ... depressive disorders, and bipolar disorder and in the Chinese literature, ECT is an effective treatment for schizophrenia and ... For major depressive disorder, despite a Canadian guideline and some experts arguing for using ECT as a first line treatment, ...
... prefrontal theta QEEG cordance value predicts response to venlafaxine treatment in patients with resistant depressive disorder ... A major area of study has been major depressive disorder, in efforts to develop biomarkers that could help guide treatment. ... biomarkers in major depressive disorder". Journal of Psychiatric Research. 44 (2): 90-98. doi:10.1016/j.jpsychires.2009.06.006 ... Theta Cordance Predicts 6-Month Antidepressant Response to Subcallosal Cingulate Deep Brain Stimulation for Treatment-Resistant ...
... may also be prescribed for off-label use in treatment-resistant cases of bipolar disorder and major depressive ... "Treatment". nhs.uk. Attention deficit hyperactivity disorder (ADHD). 1 June 2018. Retrieved 24 October 2022. Robison LS, Ananth ... Fone KC, Nutt DJ (February 2005). "Stimulants: use and abuse in the treatment of attention deficit hyperactivity disorder". ... Wingo AP, Ghaemi SN (2008). "Frequency of stimulant treatment and of stimulant-associated mania / hypomania in bipolar disorder ...
... of people with treatment-resistant major depressive disorder, whether it is unipolar or bipolar. Follow-up treatment is still ... TMS was approved by the FDA for treatment-resistant major depressive disorder in 2008 and as of 2014 clinical evidence supports ... de Sousa RT, Zanetti MV, Brunoni AR, Machado-Vieira R (2015-10-13). "Challenging Treatment-Resistant Major Depressive Disorder ... Bschor T (June 2014). "Lithium in the treatment of major depressive disorder". Drugs. Springer Science and Business Media LLC. ...
... for treatment-resistant major depressive disorder. This marked the first approval of a new type of antidepressant in decades. ... CIII Nasal Spray for Adults with Treatment-Resistant Depression (TRD) Who Have Cycled Through Multiple Treatments Without ... which promises a shorter and simpler treatment for multi-drug-resistant tuberculosis (MDR-TB). In 1984, Centocor developed ... neurological disorders, anesthesia and analgesia, gastrointestinal disorders, fungal infection, HIV/AIDS, allergies and cancer ...
All drugs listed are specifically under development for major depressive disorder (MDD) and/or treatment-resistant depression ( ... Nagele P, Zorumski CF, Conway C (April 2018). "Exploring Nitrous Oxide as Treatment of Mood Disorders: Basic Concepts". Journal ... Zorumski CF, Nagele P, Mennerick S, Conway CR (2015). "Treatment-Resistant Major Depression: Rationale for NMDA Receptors as ... Dhir A (January 2017). "Investigational drugs for treating major depressive disorder". Expert Opinion on Investigational Drugs ...
One study found that BA25 is metabolically overactive in treatment-resistant depression. A different study found that metabolic ... "Predictors of nonresponse to cognitive behavioural therapy or venlafaxine using glucose metabolism in major depressive disorder ... Deep Brain Stimulation for Treatment-Resistant Depression neuron.org, March 3, 2005. Retrieved November 18, 2018. Konarski JZ, ... "A multicenter pilot study of subcallosal cingulate area deep brain stimulation for treatment-resistant depression". Journal of ...
It is currently being investigated for the treatment of major depressive disorder, treatment-resistant depression (TRD), ... including major depressive disorder, treatment-resistant depression (TRD), bipolar depression, schizophrenia and obsessive- ... for Treatment Resistant Depression, Schizophrenia, and Obsessive Compulsive Disorder" at ClinicalTrials.gov Tang VM, Blumberger ... Currently it is thought that MST works in patients with major depressive disorder by activating the connection between the ...
... pilot trial of the oral selective NR2B antagonist MK-0657 in patients with treatment-resistant major depressive disorder". ... "Cerecor Receives Fast Track Designation for CERC-301 for the Treatment of Major Depressive Disorder". Yahoo! Finance. 2013. ... in patients with treatment-refractory major depressive disorder". Journal of Clinical Psychopharmacology. 28 (6): 631-637. doi: ... The trial consisted of 135 patients diagnosed with MDD who were resistant to SSRI/SNRI treatment. The study lasted 28 days and ...
The TCAs are used primarily in the clinical treatment of mood disorders such as major depressive disorder (MDD), dysthymia, and ... treatment-resistant variants. They are also used in the treatment of a number of other medical disorders, including cyclic ... and panic disorder (PD), post-traumatic stress disorder (PTSD), body dysmorphic disorder (BDD), eating disorders like anorexia ... and anxiety disorders such as generalized anxiety disorder (GAD), social phobia (SP) also known as social anxiety disorder (SAD ...
... granted breakthrough therapy designation for psilocybin-assisted therapy for treatment-resistant major depressive disorder. In ... Patra, Suravi (2016-12-01). "Return of the psychedelics: Psilocybin for treatment resistant depression". Asian Journal of ... "FDA grants Breakthrough Therapy Designation to Usona Institute's psilocybin program for major depressive disorder". www. ... Methadone Maintenance Treatment. Lindesmith Center 1997. Rpt. in Methadone Is an Effective Treatment for Heroin Addiction. ...
It is specifically used as a therapy for treatment-resistant depression (TRD) and for major depressive disorder (MDD) with co- ... for the treatment of treatment-resistant depression. "Anti-depressant spray not recommended on NHS". BBC News. 28 January 2020 ... "Esketamine Nasal Spray for the Rapid Reduction of Depressive Symptoms in Major Depressive Disorder With Acute Suicidal Ideation ... Gastaldon C, Papola D, Ostuzzi G, Barbui C (December 2019). "Esketamine for treatment resistant depression: a trick of smoke ...
... "treatment-resistant". In addition to being a recognized treatment for major depressive disorder, phenelzine is effective in ... Phenelzine is primarily used in the treatment of major depressive disorder (MDD). Patients with depressive symptomology ... social anxiety disorder, bulimia, post-traumatic stress disorder (PTSD), and obsessive-compulsive disorder (OCD). Phenelzine is ... 2003). "Pharmacological treatment of social anxiety disorder: a meta-analysis". Depression and Anxiety. 18 (1): 29-40. doi: ...
... includes patients with treatment-resistant, non-psychotic, major depressive disorder, characterized by ... Endogenous depression (melancholia) is an atypical sub-class of major depressive disorder (clinical depression). It could be ... Indeed, this view of endogenous depression is at the root of the popular view that mood disorders are a reflection of a ' ... The forefront indication that a depressive episode is manifesting is the sudden loss of energy or motivation in daily routines ...
Track designation to the development of rapastinel as an adjunctive therapy in treatment-resistant major depressive disorder. ... "Allergan Announces Phase 3 Results for Rapastinel as an Adjunctive Treatment of Major Depressive Disorder (MDD)". Archived from ... "Allergan's Rapastinel Receives FDA Breakthrough Therapy Designation for Adjunctive Treatment of Major Depressive Disorder (MDD ... FDA for adjunctive treatment of major depressive disorder. On March 6, 2019, Allergan announced rapastinel failed to ...
... for treatment-resistant depression and major depressive disorder) and MDMA (for post-traumatic stress disorder). Humans have ... In 2019, the FDA approved the use of esketamine for intranasal use for major depressive disorder (MDD) and treatment-resistant ... status to psilocybin for treatment-resistant depression and major depressive disorder in order to hasten the process for ... Romeo B, Karila L, Martelli C, Benyamina A (October 2020). "Efficacy of psychedelic treatments on depressive symptoms: A meta- ...
Valdivia, Ivan; Rossy, Nadine (2004). "Brief Treatment Strategies for Major Depressive Disorder: Advice for the Primary Care ... Insomnia or hypersomnia and aches, pains, or digestive problems that are resistant to treatment may also be present. Although ... Depression (differential diagnoses) Depressive personality disorder Major depressive disorder Mental breakdown Costandi, Moheb ... Common comorbid disorders include eating disorders, substance-related disorders, panic disorder, and obsessive-compulsive ...
Ketamine has been tested for treatment-resistant bipolar depression, major depressive disorder, and people in a suicidal crisis ... These were very treatment-resistant patients." Naughton, M; Clarke, G; O'Leary, OF; Cryan, JF; Dinan, TG (Mar 2014). "A review ... More than 90% of all suicides are related to a mood disorder, such as bipolar disorder, depression, addiction, PTSD, or other ... Ligature Resistant - Preventing suicides. (Webarchive template wayback links, Articles with short description, Short ...
"A Safety and Efficacy Study of JNJ26489112 in Patients With Treatment-Resistant Major Depressive Disorder" at ClinicalTrials. ... JNJ-26489112 was studied as a treatment for major depressive disorder. This clinical trial was terminated in 2013 due to a " ... JNJ-26489112 is an anticonvulsant drug being developed by Johnson & Johnson for the treatment of epilepsy. JNJ-26489112 was ...
... of people with treatment-resistant major depressive disorder, whether it is unipolar or bipolar. Follow-up treatment is still ... TMS was approved by the FDA for treatment-resistant major depressive disorder (trMDD) in 2008 and as of 2014 evidence supports ... Under mood disorders, ICD-11 classifies major depressive disorder as either single episode depressive disorder (where there is ... 6A70 Single episode depressive disorder and 6A71 Recurrent depressive disorder "Diagnostic Criteria for Major Depressive ...
... and major depressive disorder. In recognition of his significant contributions to new treatments for mood and anxiety disorders ... and is the first model of a rapid-acting antidepressant with efficacy for treatment-resistant symptoms of mood disorders. His ... in Mental Health 2019 Colvin Prize for Outstanding Achievement in Mood Disorders Research 2017 Ketamine for Treatment-Resistant ... Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial. Am J ...
2008). "An association between serotonin receptor 3B gene (HTR3B) and treatment-resistant schizophrenia (TRS) in a Japanese ... Kato M, Serretti A (2008). "Review and meta-analysis of antidepressant pharmacogenetic findings in major depressive disorder". ... 2009). "A common variant in DRD3 receptor is associated with autism spectrum disorder". Biol. Psychiatry. 65 (7): 625-630. doi: ... 2009). "Identification of new putative susceptibility genes for several psychiatric disorders by association analysis of ...
... a drug for the treatment of major depressive disorder This disambiguation page lists articles associated with the title CERC. ... Cercs, a municipality in Berguedà, Catalonia Rislenemdaz, developmental code name CERC-301, a drug for treatment-resistant ...
... proposed to more thoroughly treat standard major depressive disorder and treatment-resistant major depressive disorder, shows ... in different parts of the brain of persons who had killed themselves with major depressive disorder, bipolar disorder, and ... Patients with major depressive disorder treated with antidepressants have an increase in regulatory T cells and a decrease in ... Through all these studies there seems to be a slight difference in symptoms of major depressive disorder with and without ...
... are under development for the treatment of mood disorders, including major depressive disorder and treatment-resistant ... 3,5-Dibromo-L-phenylalanine has been proposed a novel therapeutic drug candidate for treatment of neuropsychiatric disorders ... Wijesinghe R (2014). "Emerging Therapies for Treatment Resistant Depression". Ment Health Clin. 4 (5): 56. doi:10.9740/mhc. ... potential applications for the treatment of neurological and neuropsychiatric disorders". Recent Patents on CNS Drug Discovery ...
... a safe and effective intervention for treatment-resistant depression in patients with either unipolar major depressive disorder ... The treatment halved the amount of extant scar tissue within a year. 15 February - Nevada becomes the first US state to allow ... It may be possible to one day create an "unlimited" supply of human eggs to aid fertility treatment, US doctors say. 27 ... 2012). "Lipid storage disorders block lysosomal trafficking by inhibiting a TRP channel and lysosomal calcium release". Nature ...
"Efficacy of bupropion and the selective serotonin reuptake inhibitors in the treatment of major depressive disorder with high ... Ruberto VL, Jha MK, Murrough JW (June 2020). "Pharmacological Treatments for Patients with Treatment-Resistant Depression". ... Dhillon S, Yang LP, Curran MP (2008). "Bupropion: a review of its use in the management of major depressive disorder". Drugs. ... 2020). "Pharmacologic treatment of attention deficit hyperactivity disorder in adults: A systematic review and network meta- ...
... treatment for depression in children, adolescents, teens at NIH/NIMH with Dr. Daniel Pine. ... TMS for Youth with Treatment-Resistant Major Depressive Disorder. @font-face{font-family:Roboto;font-style:normal;font-weight ... TMS for Youth with Treatment-Resistant Major Depressive Disorder. ... Ages 13 to 17 years who are currently depressed, and do not have psychosis, bipolar disorder, or autism spectrum disorder, and ...
Patients with treatment-resistant major depressive disorder are needed for a brain imaging research study ...
Future studies are required to identify effective and multimodal pharmacological treatments that efficiently treat depression ... Pharmacotherapy for the treatment of depression in patients with alzheimers disease: a treatment-resistant depressive disorder ... Pharmacotherapy for the treatment of depression in patients with alzheimers disease: a treatment-resistant depressive disorder ... Vortioxetine: a New Treatment for Major Depressive Disorder. Connolly KR, Thase ME. Connolly KR, et al. Expert Opin ...
The efficacy and safety of riluzole vs placebo as an adjunct to antidepressant medication in outpatients with major depressive ... disorder (MDD) was examined in a 3-site, 8-week, … ... Riluzole for Treatment-Resistant Major Depressive Disorder ... Sequential Parallel Comparison Design Trial of Adjunctive Riluzole for Treatment-Resistant Major Depressive Disorder Sanjay J ... in a randomized placebo-controlled trial of adjunctive riluzole in patients with treatment-resistant major depressive disorder. ...
Experts agreed that a dimensional definition for treatment resistance was a useful concept to describe the heterogeneity of ... Risk factors and comorbidities were identified as potential predictors for treatment resistance. Conclusions: TRD is a ... Treatment-resistant depression (TRD) is a debilitating chronic mental illness that confers increased morbidity and mortality, ... Treatment-resistant major depressive disorder: Canadian expert consensus on definition and assessment ...
... current best evidence for the use of second-generation antipsychotics in treatment of patients with major depressive disorder. ... Major depressive disorder; NTP: Nortriptyline; OLZ: Olanzapine; PBO: Placebo; SERT: Sertraline; TRD: Treatment-resistant ... Antidepressants have been the standard treatment option for major depressive disorder (MDD) based on the monoamine hypothesis. ... Second-generation Antipsychotics in the Treatment of Major Depressive Disorder. Current Evidence. ...
Use of nitrous oxide in the treatment of major depressive disorder and treatment-resistant major depressive disorder: A ... Antidepressive agents; Depressive disorder, major; Depressive disorder, treatment-resistant; Meta-analysis; Nitrous oxide ... Use of nitrous oxide in the treatment of major depressive disorder and treatment-resistant ... of patients do not respond effectively to conventional treatment, leading to treatment-resistant depressive mood disorder ( ...
In patients referred for electroconvulsive therapy (ECT) for treatment-resistant major depression without psychosis, ... noninferiority ELEKT-D trial included 403 patients referred to ECT clinics at 5 clinical sites for treatment-resistant major ... "The decline in memory performance appeared to be greater with ECT than with ketamine at the end-of-treatment visit, but the ... "Both ketamine and ECT appeared to be associated with improved quality of life immediately after the initial treatment phase." ...
With appropriate treatment, 70-80% of individuals with major depressive disorder can achi... ... Major depressive disorder has significant potential morbidity and mortality, contributing to suicide (see the image below), ... The treatment of SSRI-resistant depression in adolescents (TORDIA): in search of the best next step. Depress Anxiety. 2009. 26( ... Major Depressive Disorder with Psychotic Features. The presentation of severe major depressive disorder may include psychotic ...
Use of second generation antipsychotics for treatment-resistant major depressive disorder Rebecca Waite, PharmD, BCPP Rebecca ... The study included patients with and without treatment-resistant major depressive disorder. The study reported a significant ... Rebecca Waite; Use of second generation antipsychotics for treatment-resistant major depressive disorder. Mental Health ... Subject: Use of second generation antipsychotics for treatment-resistant major depressive disorder ...
Depressive Disorder / blood * Depressive Disorder / drug therapy * Depressive Disorder / immunology* * Drug Resistance ... treatment resistant depression (TRD) both before and after subchronic treatment with antidepressants. Serum IL-6 and IL-1Ra ... Increased serum IL-6 and IL-1 receptor antagonist concentrations in major depression and treatment resistant depression ... the above disorders may persist despite successful antidepressive treatment. ...
... premenstrual dysphoric disorder-specific dosing for Prozac (fluoxetine), frequency-based adverse effects, comprehensive ... Major Depressive Disorder. Indicated for acute and maintenance treatment of major depressive disorder (MDD) in children aged ≥8 ... Resistant Depression. Indicated in combination with olanzapine for treatment of resistant depression (MMD in patients who do ... Major Depressive Disorder. Indicated for acute and maintenance treatment of major depressive disorder (MDD) ...
... "treatment-resistant depression." The relevant MeSH Heading found for that concept is Depressive Disorder, Treatment-Resistant. ...
Depressive Disorder, Major. Depressive Disorder, Treatment-Resistant. Nervous System Physiological Phenomena. Suicide ... Treatment resistant depression & the neurobiology of suicide / NIMH, NIH. Author: NIMH Workshop: Treatment Resistant Depression ... Treatment Resistant Depression & the Neurobiology of Suicide. Download VideoCast. You can download this VideoCast and play it ... CIT): Join experts from the National Institute of Mental Health (NIMH) for a workshop on treatment resistant depression and the ...
Major Depressive Disorder;. Treatment-Resistant Depression;. Depression Investigational Drug(s). TP0473292. Investigational ... 4. Have major depressive disorder. 5. Have a current episode of depression lasting at least 4 weeks. 6. Ability to take oral ... Major depressive disorder (MDD) is a common, chronic mental illness. It can take weeks to months for antidepressants to work. ... An Investigation of the Antidepressant Effects of the mGlu2/3 receptor antagonist TS-161 in Treatment-Resistant Depression. ...
Acute treatment of depressive episodes associated with Bipolar I Disorder.. *Treatment resistant depression (Major Depressive ... Fluoxetine monotherapy is not indicated for the treatment of treatment resistant depression (Major Depressive Disorder in ... Major Depressive Disorder, OCD, Bulimia, and Panic Disorder Combined (N=1,533) Major Depressive Disorder (N=392) OCD (N=266) ... indicated for the treatment of depressive episodes associated with Bipolar I Disorder or the treatment of treatment resistant ...
Acute treatment of depressive episodes associated with Bipolar I Disorder.. *Treatment resistant depression (Major Depressive ... Major Depressive Disorder, OCD, Bulimia, and Panic Disorder Combined (N=1533) Major Depressive Disorder (N=392) OCD (N=266) ... Fluoxetine capsules monotherapy is not indicated for the treatment of treatment resistant depression (Major Depressive Disorder ... indicated for the treatment of depressive episodes associated with Bipolar I Disorder or the treatment of treatment resistant ...
Depressive Disorder, Treatment-Resistant [‎1]‎. Derivados de Benzeno [‎2]‎. DERMATITE [‎2]‎. DERMATITE ALERGICA [‎1]‎. ...
... to manage treatment-resistant depression ( ... depressive disorder (MDD) and suicidal thoughts or actions. Esketamine is in a ... Anxiety/Treatments and Therapies ... Anxiety ... Phobias/Treatments and Therapies ... Phobias ... Schizophrenia/Treatments and ... Treatment-Resistant Depression (Mayo Foundation for Medical Education and Research) Depression/Specifics ... Depression ... ... Substance Use Disorders (NAMI) Dual Diagnosis/Learn More ... Dual Diagnosis ... Substance use disorders - the repeated misuse ...
... trajectories and the possible implications of sex-specific treatment and prevention strategies for major depressive disorder. ... male major depressive disorder often receives less attention. However, research is warranted since there are significant sex ... that females are twice as likely to suffer from major depressive disorder than males. Twenty-four depressed and 10 healthy male ... study with a large sample addressing putative sex differences in major depressive disorder during adolescence, a period when ...
Acute treatment of depressive episodes associated with Bipolar I Disorder.. *Treatment resistant depression (Major Depressive ... Fluoxetine monotherapy is not indicated for the treatment of treatment resistant depression (Major Depressive Disorder in ... indicated for the treatment of depressive episodes associated with Bipolar I Disorder or the treatment of treatment resistant ... Major Depressive Disorder (MDD). • Obsessive Compulsive Disorder (OCD). • Bulimia Nervosa*. • Panic Disorder*. • Depressive ...
Acute treatment of depressive episodes associated with Bipolar I Disorder.. *Treatment resistant depression (Major Depressive ... Major Depressive Disorder, OCD, Bulimia, and Panic Disorder Combined (N=1533) Major Depressive Disorder (N=392) OCD (N=266) ... Fluoxetine capsules monotherapy is not indicated for the treatment of treatment resistant depression (Major Depressive Disorder ... indicated for the treatment of depressive episodes associated with Bipolar I Disorder or the treatment of treatment resistant ...
... discusses strategies to improve symptoms in patients with inadequate or partial response to initial antidepressant treatment. ... And so we use the term treatment resistance sometimes to say that person was resistant to that treatment that led to an ... Treatment Augmentation in Major Depressive Disorder: Expert Insights on Real-World Considerations. *Authors: Joseph F. Goldberg ... Treatment Augmentation in Major Depressive Disorder: Expert Insights on Real-World Considerations. Authors: Joseph F. Goldberg ...
Treatment-resistant depression is a term used in psychiatry to describe people with major depressive disorder (MDD) who do not ... Anxiety disorders are one of the most common disorder types associated with treatment-resistant depression. The two disorders ... Other psychiatric disorders that may predict treatment-resistant depression include attention deficit hyperactivity disorder, ... Cases of treatment-resistant depression may also be referred to by which medications people with treatment-resistant depression ...
Fast Five Quiz: Treatment-Resistant HIV. Fast Five Quiz February 24, 2023 ... Fast Five Quiz: Major Depressive Disorder Management. Fast Five Quiz February 28, 2023 ... USC doctors review guidelines for first-line treatment of ITP in patients of average risk and discuss when it is appropriate to ... The Curbsiders share an experts tips on managing acute pain in hospitalized patients with opioid use disorder -- whats right ...
Major Depressive Disorder. .related-link:not(:first-child):before { content: , ; } Psychiatry. .related-link:not(:first- ... The Treatments. ECT and subanesthetic intravenous ketamine are both promising options for patients with treatment-resistant ... Each participant was diagnosed with treatment-resistant major depression without psychosis and were assigned to receive either ... Ketamine was noninferior to ECT as therapy for treatment-resistant major depression without psychosis, the authors wrote. ...
J. (2011). Moderate exercise improves depression parameters in treatment-resistant patients with major depressive disorder. ... You can get help and treatment for mental health conditions.. Learning ways to manage stress and reaching out for help when you ... OWH and the OWH helpline do not see patients and are unable to: diagnose your medical condition; provide treatment; prescribe ... OWH and the OWH helpline do not see patients and are unable to: diagnose your medical condition; provide treatment; prescribe ...
... but some treatment options can help. Learn more. ... Treatment-resistant depression can be difficult to manage, ... Zhdanava, M., et al. (2021). The prevalence and national burden of treatment-resistant depression and major depressive disorder ... www.psychiatrist.com/jcp/depression/prevalence-national-burden-treatment-resistant-depression-major-depressive-disorder-in-us. ... If a person with major depressive disorder (MDD) has not responded to at least two types of medication, they have treatment- ...
BackgroundsStudies to date detailing trajectories of depressive symptom dimensions in patients undergoing index ... it has been one of the most effective treatments for severe mental disorders such as major depressive disorder and ... Depressive Symptom Dimensions in Treatment-Resistant Major Depression and Their Modulation With Electroconvulsive Therapy. J ... Patients with a history of bipolar disorder, schizophrenia spectrum disorder, other psychotic disorders, or major neurological ...
This study evaluated the effectiveness and tolerability of vortioxetine at supratherapeutic dosages in patients with treatment- ... Vortioxetine: a new alternative for the treatment of major depressive disorder. Rev Psiquiatr Salud Ment (Engl Ed). 2018;11(1): ... Only a few treatments are approved for treatment-resistant depression.. *When the approved treatments for treatment-resistant ... A meta-analysis of randomized, placebo-controlled trials of vortioxetine for the treatment of major depressive disorder in ...
  • After 3 months, collaborative care was more effective on the primary outcome measure of treatment response (i.e. reduction in symptoms of ≥50%) on the Patient Health Questionnaire-9 (PHQ-9). (cambridge.org)
  • depressive symptoms could also be related to schizoaffective disorder or other psychotic illnesses. (news-medical.net)
  • they alleviate depressive symptoms by augmenting serotonin levels in the brain. (news-medical.net)
  • A combination of psychotherapy and medication is a typical course of treatment for someone with severe symptoms. (news-medical.net)
  • Inadequate response has most commonly been defined as less than 50% reduction in depressive symptoms following treatment with at least one antidepressant medication, although definitions vary widely. (wikipedia.org)
  • If left untreated, the symptoms of these disorders can interfere with both evaluation and treatment. (wikipedia.org)
  • The two disorders commonly co-exist, and have some similar symptoms. (wikipedia.org)
  • Another factor is that medications used to treat comorbid medical disorders may lessen the effectiveness of antidepressants or cause depression symptoms. (wikipedia.org)
  • People with depression who also display psychotic symptoms such as delusions or hallucinations are more likely to be treatment resistant. (wikipedia.org)
  • Both groups experienced an improvement in depressive symptoms. (medicalnewstoday.com)
  • Subjects took an average of nearly 6 weeks to respond, and about 7 weeks to achieve remission from depressive symptoms. (uspharmacist.com)
  • In 2000, Berman et al published the first double-blind, placebo-controlled, crossover trial evaluating the use a single dose of 0.5 mg/kg ketamine over 40 minutes in eight patients with recurrent unipolar major depression and one with bipolar disorder, which showed progressive decreases in depressive symptoms within 3 days of treatment. (uspharmacist.com)
  • Interest in ketamine's antidepressant effects has grown since 2000, when a small study suggested the drug rapidly improved depressive symptoms. (medscape.com)
  • Research now suggests ketamine reduces symptoms in patients with treatment-resistant depression (TRD). (medscape.com)
  • Studies linking ketamine to relief of depressive symptoms are small and mostly retrospective, and none has offered longitudinal information on long-term outcomes, including side effects and the risk of addiction. (medscape.com)
  • According to CDC data released in August, almost 11% of American adults seriously contemplated suicide in June, and nearly a third reported symptoms of anxiety or a depressive disorder. (medpagetoday.com)
  • To put this into context, comparative data from the 2019 National Health Interview Survey reported that only 18.5% of American adults had major depressive symptoms prior to the pandemic. (medpagetoday.com)
  • Compared with 2017-2018 National Health and Nutrition Examination Survey data, adults reported a significant uptick in mild, moderate, and severe major depressive symptoms this year. (medpagetoday.com)
  • In a phase III trial presented at this September's virtual Psych Congress meeting , 30 mg of daily zuranolone -- an investigational oral GABA-active agent -- significantly reduced symptoms of postpartum depression after 2 weeks of treatment. (medpagetoday.com)
  • Pharmacological agents weren't the only advancements seen this year, as an accelerated, high-dose transcranial magnetic stimulation therapy helped significantly reduce symptoms of treatment-resistant depression in a small study reported in the American Journal of Psychiatry . (medpagetoday.com)
  • Looking at 21 adults who underwent this therapy, depressive symptoms significantly improved by a mean of 5 points on the Montgomery-Ã…sberg Depression Rating Scale (MADRS) after only 5 days of treatment. (medpagetoday.com)
  • However, on the other hand, pimavanserin did succeed as a treatment for improving symptoms of dementia-related psychosis in the phase III HARMONY study. (medpagetoday.com)
  • Globally, in 2016, depressive symptoms are in the 16th place for Disability-Adjusted Life Year(s) (DALYs), and are in the top 20 DALYs for all regions and continents other than Africa ( WHO, 2018a ). (frontiersin.org)
  • Vortioxetine demonstrated good tolerability and a beneficial effect on cognition that appears largely independent from the effect on depressive symptoms. (psychiatrictimes.com)
  • The combination treatment seemed to have benefits beyond depressive symptoms. (dr-bob.org)
  • Research suggests that pregabalin may be effective at reducing the symptoms of generalized anxiety disorder (GAD) . (psychcentral.com)
  • A 2015 review of several studies found evidence that gabapentin may treat symptoms of social anxiety disorder and post-traumatic stress disorder (PTSD) . (psychcentral.com)
  • Gabapentin also reduced participants' anxiety before surgery, and reduced symptoms in some people with panic disorder. (psychcentral.com)
  • In addition, there's some evidence that gabapentin may work with fluoxetine (Prozac) to reduce symptoms of obsessive-compulsive disorder (OCD) . (psychcentral.com)
  • Spravato is also used to treat depressive symptoms in adults with major depressive disorder (MDD) with suicidal thoughts or actions. (drugs.com)
  • In our study we included patients with major depressive disorder, who still had residual symptoms and functional impairment despite receiving antidepressant treatment. (news-medical.net)
  • This is a very interesting study targeting remaining depressive symptoms in patients who insufficiently responded to previous treatment trials of antidepressants. (news-medical.net)
  • PMID 17363961 ] Clinical involvement of catechol-O-methyltransferase polymorphisms in schizophrenia spectrum disorders: influence on the severity of psychotic symptoms and on the response to neuroleptic treatment. (snpedia.com)
  • Research has found ketamine to be especially helpful in cases of treatment-resistant depression that have not responded to other medications, and for patients suffering from severe symptoms, including suicidality, who need rapid relief. (webmd.com)
  • Studies show that 60% or more of patients find relief from depressive symptoms with these infusions, and relief can be relatively short-acting, within 1 to 3 weeks. (webmd.com)
  • Ketamine can actually induce neurogeneration, or creation of nerve cells in the brain, particularly in the hippocampus, which is a part of your brain responsible for memory," Olivardia explains in the ADDitude webinar " The ADHD-Depression Link in Adults: Symptoms & Treatments . (webmd.com)
  • Clinical Effectiveness of Intravenous Racemic Ketamine Infusions in a Large Community Sample of Patients with Treatment-Resistant Depression, Suicidal Ideation, and Generalized Anxiety Symptoms: A Retrospective Chart Review," "The prevalence and national burden of treatment-resistant depression and major depressive disorder in the United States," "Ketamine for Depression, 4: In What Dose, at What Rate, by What Route, for How Long, and at What Frequency? (webmd.com)
  • Neuroscientists recently discovered a small molecule that can effectively alleviate stress-induced depressive symptoms in mice by preventing aversive memory formation with a lower dosage, offering a new direction for developing anti-depressants in the future. (sciencedaily.com)
  • In a prior clinical trial with 120 patients with MDD, we demonstrated that the combination of tDCS with sertraline 50mg/day had increased, faster effects on depressive symptoms (Brunoni et al. (fapesp.br)
  • The study shall make use of the unique dataset collected prospectively at the WTC Health Program, beginning in 2002, to study longitudinal trajectories of WTC-related PTSD and depressive symptoms in 10,800 cohort members who completed three monitoring visits at the WTC Health Program, each approximately two years apart. (cdc.gov)
  • In police responders, the focus of this presentation, longitudinal PTSD symptoms were best characterized by 4 classes, with the majority (77.8%) in a resistant/resilient trajectory and the remainder exhibiting chronic (5.3%), recovering (8.4%) or delayed-onset (8.5%) symptom trajectories. (cdc.gov)
  • These results also highlight the importance of early assessment and treatment of hyperarousal symptoms in disaster responders. (cdc.gov)
  • Results of our WTC Trajectories study suggest that WTC-related posttraumatic stress disorder (PTSD) symptoms in WTC responders are heterogeneous in nature and associated uniquely with pre-, peri- and post-trauma risk and protective factors. (cdc.gov)
  • In the last decades, several studies have indicated that exercise can be effective in preventing or reducing depressive symptoms, both in healthy and psychiatric populations. (bvsalud.org)
  • The first report of DBS for a psychiatric indication, published in The Lancet in 1999, described implantation of electrodes into the bilateral anterior limbs of the internal capsule for treatment of refractory Obsessive-Compulsive Disorder (OCD) in a series of four patients. (medscape.com)
  • Other psychiatric disorders that may predict treatment-resistant depression include attention deficit hyperactivity disorder, personality disorders, obsessive compulsive disorder, and eating disorders. (wikipedia.org)
  • Mental health conditions include depression, anxiety, obsessive-compulsive disorder and schizophrenia. (frontiersin.org)
  • The economic burden of depression in the United States-including major depressive disorder (MDD), bipolar disorder, and dysthymia-was estimated at $83.1 billion in 2000. (psychiatrist.com)
  • 2,3 The economic burden of depression, including MDD, bipolar disorder, and dysthymia, has also increased from an estimated $83.1 billion in 2000 to $210.5 billion in 2010. (uspharmacist.com)
  • 8 Ketamine has generated significant interest in the treatment of MDD, bipolar depression, and in depression with suicidal ideation after the publication of a number of studies demonstrating its rapid-acting antidepressant effect following low IV doses. (uspharmacist.com)
  • Critically important to the clinician is the section on management of mood disorders, which provides treatment guidelines for major depressive disorder and bipolar disorder, as well as information on understanding, and preventing, suicide in children, adolescents, and adults. (appi.org)
  • Bipolar I disorder and major depressive disorder show similar brain activation during depression. (uc.edu)
  • PMID 17547583 ] is associated with bipolar disorder and influences prefrontal aspects of verbal memory in bipolar patients and healthy controls. (snpedia.com)
  • Bipolar I disorder and schizophrenia: a 440-single-nucleotide polymorphism screen of 64 candidate genes among Ashkenazi Jewish case-parent trios. (snpedia.com)
  • Read the latest research as well as in-depth information on clinical depression, schizophrenia, bipolar disorder, ADHD and other mental health disorders in adults, teens, and children. (sciencedaily.com)
  • Depression is one part of bipolar disorder . (medlineplus.gov)
  • Alert Lurasidone (Latuda) Gets FDA Nod for Bipolar Depression in Kids Lurasidone is now indicated for the treatment of major depressive episodes associated with bipolar I disorder in children and adolescents aged 10 to 17 years. (medscape.com)
  • Treatment-resistant depression (TRD) was defined as unresponsiveness to at least 2 antidepressants, and treatment-resistant tendency (TRT) was defined as unresponsiveness to the first antidepressant. (psychiatrist.com)
  • In total, 88% of patients started treatment with antidepressants or ECT. (bvsalud.org)
  • Switching people with treatment-resistant depression to a different class of antidepressants may also be effective. (wikipedia.org)
  • citation needed] Some off label antidepressants are low dose ketamine and highly serotonergic catecholamines (including very controlled use of MDMA in the treatment of PTSD and crippling depression/anxiety). (wikipedia.org)
  • While there appears to be no definitive, standardized definition for treatment resistant-depression (TRD), it is generally accepted as failure to respond to at least two adequate trials of different classes of antidepressants, an adequate trial being defined as an adequate dose given for an adequate duration (i.e., 6 or 8 weeks). (uspharmacist.com)
  • There are treatments for depression, but up to a third of people don't respond to treatment, even after trying different antidepressants. (news-medical.net)
  • Now a new pilot study from Korea indicates that neurofeedback may be offer a viable treatment to patients suffering from TRD, if used with antidepressants. (news-medical.net)
  • 1 Among patients who receive treatment, approximately 30% have treatment-resistant depression (ie, an inadequate response to ≥2 different antidepressants at adequate dosing and duration during a depressive episode). (ahdbonline.com)
  • Pharmacologic treatments for MDD include 1 or more antidepressants, including serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), atypical antidepressants, tricyclics, tetracyclics, and monoamine oxidase inhibitors (MAOIs), among others. (ahdbonline.com)
  • The esketamine Phase 2 clinical trial data presented by Janssen in May 2016 at the Society of Biological Psychiatry 71st Annual Scientific Meeting in Atlanta, Georgia, provided preliminary clinical evidence to support the Breakthrough Therapy Designation for major depressive disorder with imminent risk for suicide. (jnj.com)
  • Treatment-resistant depression is a term used in psychiatry to describe people with major depressive disorder (MDD) who do not respond adequately to a course of appropriate antidepressant medication within a certain time. (wikipedia.org)
  • Although not yet FDA approved, new JAMA Psychiatry research suggested synthetic psilocybin -- the compound naturally occurring in magic mushrooms -- may be a promising treatment for major depressive disorder. (medpagetoday.com)
  • Deep Brain Stimulation of the Ventral Capsule/Ventral Striatum for Treatment Resistant Depression: A Decade of Clinical Follow-up The Journal of Clinical Psychiatry October 2021. (upenn.edu)
  • The impact of depression is greatest for those who do not benefit from standard treatments," said -Michael E. Thase, MD, Professor of Psychiatry and Director of the Mood and Anxiety Disorders Treatment and Research Program, Perelman School of Medicine, University of Pennsylvania, and a principal investigator of esketamine. (ahdbonline.com)
  • Among the study's outcomes, the investigators identified psychiatric and nonpsychiatric comorbid conditions, antidepressant treatments, healthcare resource utilization, lost workdays, all-cause mortality, and intentional self-harm. (medpagetoday.com)
  • The Burlingame Center for Psychiatric Research and Education is currently recruiting patients 18-64 years of age for a 12-month double-blind and open-label study for the treatment major depressive disorder using an add-on medication with an anti-depressant treatment. (hartfordhealthcare.org)
  • The association of treatment resistance with physical and psychiatric comorbidities remains unclear in elderly patients with late-onset major depressive disorder (MDD). (psychiatrist.com)
  • Psychiatric disorders in older primary care patients. (psychiatrist.com)
  • We update these findings using recent data, focusing on MDD alone and accounting for comorbid physical and psychiatric disorders. (psychiatrist.com)
  • While neuromodulation techniques are currently used primarily for the management of chronic pain and movement disorders, there has been considerable interest in their use for medically refractory psychiatric disease. (medscape.com)
  • There is also substantial public trepidation about the use of surgical therapies in the treatment of psychiatric disease as a direct consequence of the abuse of psychosurgery in the mid-twentieth century, specifically the heavy human toll exacted by the careless and widespreaduse of the frontal lobotomy. (medscape.com)
  • The two surgical neuromodulatory therapies currently in use for the treatment of psychiatric conditions are deep brain stimulation (DBS) and vagal nerve stimulation (VNS). (medscape.com)
  • Larger trials followed, followed by trials using DBS to treat other psychiatric diseases, particularly Major Depressive Disorder (MDD). (medscape.com)
  • Some factors that contribute to inadequate treatment are: a history of repeated or severe adverse childhood experiences, early discontinuation of treatment, insufficient dosage of medication, patient noncompliance, misdiagnosis, cognitive impairment, low income and other socio-economic variables, and concurrent medical conditions, including comorbid psychiatric disorders. (wikipedia.org)
  • Comorbid psychiatric disorders commonly go undetected in the treatment of depression. (wikipedia.org)
  • Serotonin Syndrome and MAOIs: Do not use MAOIs intended to treat psychiatric disorders with fluoxetine or within 5 weeks of stopping treatment with fluoxetine. (nih.gov)
  • Do not use fluoxetine within 14 days of stopping an MAOI intended to treat psychiatric disorders. (nih.gov)
  • Off-label use of ketamine, the anesthetic-turned-potential treatment for resistant depression, is soaring in the United States and has many experts in the psychiatric community concerned. (medscape.com)
  • This new edition of The American Psychiatric Association Publishing Textbook of Mood Disorders is a systematic and painstaking reconceptualization of its predecessor. (appi.org)
  • The American Psychiatric Association Publishing Textbook of Mood Disorders equips clinicians and trainees with the knowledge they need to alleviate suffering in their patients with mood disorders. (appi.org)
  • DCS is still used in the treatment of multidrug-resistant tuberculosis and has been researched in other psychiatric applications such as trauma, and anxiety-related disorders. (ucalgary.ca)
  • Major depressive disorder (MDD) is a common psychiatric condition, mostly treated with antidepressant drugs, which are limited for issues such as refractoriness and adverse effects. (fapesp.br)
  • Study results underscore the importance of prevention, screening and treatment efforts targeting high-risk disaster responders, in particular those with prior psychiatric history, higher disaster-related trauma exposure and work-related medical conditions. (cdc.gov)
  • In addition, 46.2% (n=5907) of patients received psychotherapy at some point before initiation of their third treatment. (medpagetoday.com)
  • In treatment-resistant depression adding further treatments such as psychotherapy, lithium, or aripiprazole is weakly supported as of 2019. (wikipedia.org)
  • Some researchers have begun investigating the efficacy of psychotherapy in conjunction with pharmacology for treatment-resistant depression cases. (psychologytoday.com)
  • They found that the former was more efficacious, and opined that psychotherapy should be included in treatment-resistant depression guidelines. (psychologytoday.com)
  • Treatment-resistant depression-its definition and approaches to its treatment-is addressed in a dedicated chapter that covers diagnostic accuracy, pseudoresistance, comorbidity, pharmacological management, adjunctive strategies, psychotherapy, neuromodulation, and novel and experimental therapies. (appi.org)
  • Further work is needed to both replicate these results and compare this strategy with alternative treatment options (e.g. psychotherapy or additional pharmacotherapeutic steps). (news-medical.net)
  • Major depressive disorder is one of the leading causes of disability worldwide, and up to a third of patients will fail to respond to conventional pharmaco- or psychotherapy. (ru.nl)
  • Treatment usually consists of medications, psychotherapy, or both and sometimes electroconvulsive therapy (ECT) or rapid transcranial magnetic stimulation (rTMS). (msdmanuals.com)
  • ECT is highly effective, achieving a response rate of 70-80% and a remission rate of 50-60% even in treatment-resistant patients. (researchgate.net)
  • While the agents in current use help many patients, more than half of those treated fail to achieve remission and are resistant to treatment with a first-line antidepressant. (uspharmacist.com)
  • The researchers found that in the neurofeedback group, 8 of the 12 patients responded to treatment, and 5 of those responded well enough to be classified as being in remission. (news-medical.net)
  • Neurofeedback has been trialed with psychological conditions in the past, but as far as we know this is the first time that anyone has succeeded in achieving remission and overall recovery (functional recovery)with treatment-resistant depression. (news-medical.net)
  • Electroconvulsive therapy (ECT) is the single most potent treatment available for major depressive disorder, inducing remission even in those treatment-resistant patients. (ru.nl)
  • 5,6 Achieving and sustaining complete remission early in the treatment sequence is a crucial goal for patients with MDD. (ahdbonline.com)
  • For those not achieving remission, additional treatment steps are often required. (medscape.com)
  • The median time from the start of a major depressive episode to TRD was 552 days, and selective serotonin reuptake inhibitors were the most common class of antidepressant treatment in all treatment steps. (medpagetoday.com)
  • The median time from the start of the first antidepressant treatment to the start of the second was 165 days (IQR 72 to 375 days). (medpagetoday.com)
  • Approximately one-fourth of elderly patients responded poorly to the first antidepressant treatment during the first year of late-onset MDD. (psychiatrist.com)
  • Finally, people with more severe depression and those who are suicidal are more likely to be nonresponsive to antidepressant treatment. (wikipedia.org)
  • Electroconvulsive therapy (ECT) remains the most potent antidepressant treatment available for patients with major depressive disorder (MDD). (researchgate.net)
  • Clinical experience and preliminary scientific evidence support the option of augmenting when partial symptomatic improvement is observed during the current antidepressant treatment. (psychiatrictimes.com)
  • Repetitive transcranial magnetic stimulation (rTMS) provided promising results in the treatment of TRD after 2 or more antidepressant treatment trials failed. (psychiatrictimes.com)
  • 40 participants with MDD provided actigraphy data using wearable devices for one week after initiating antidepressant treatment in a randomized, double-blind, placebo-controlled trial. (cdc.gov)
  • High occurrence of mood and anxiety disorders among older adults: The National Comorbidity Survey Replication. (psychiatrist.com)
  • This particular survey found women were more likely than men to receive mental health treatment, while young adults ages 18 to 29 had the highest rates of major depressive disorder out of any age group. (medpagetoday.com)
  • Spravato is a nasal spray that is used together with medication taken by mouth to treat adults with depression that is resistant to to other treatments. (drugs.com)
  • Major depressive disorder (MDD) is a serious, life-threatening mental disorder that affects approximately 17.3 million adults, or nearly 7.1% of the US adult population. (ahdbonline.com)
  • Janssen Pharmaceuticals) was approved by the US Food and Drug Administration (FDA), in conjunction with an oral antidepressant, for the treatment of adults with treatment-resistant depression. (ahdbonline.com)
  • This article focuses on major depressive disorder in adults. (athealth.com)
  • Mood disorders can occur in adults, adolescents, or children. (msdmanuals.com)
  • Alert FDA Approves Ibalizumab for Multidrug-Resistant HIV-1 The FDA has approved ibalizumab-uiyk (Trogarzo, Theratechnologies Inc) for the treatment of adults with multidrug-resistant HIV-1. (medscape.com)
  • The drug's indication was expanded in 2020 to include major depressive disorder and acute suicidal ideation or behavior. (medscape.com)
  • This year, its label was expanded to include an indication for major depressive disorder with suicidal ideation or behavior based on the phase III ASPIRE studies . (medpagetoday.com)
  • Background: Major Depressive disorder (MDD) and Attention Deficit Hyperactivity Disorder (ADHD) are prevalent mental disorders that often co-occur. (researchgate.net)
  • PMID 15635644 ] A family based study of catechol-O-methyltransferase (COMT) and attention deficit hyperactivity disorder (ADHD). (snpedia.com)
  • Using artificial intelligence (AI) to analyze specialized brain MRI scans of adolescents with and without attention-deficit/hyperactivity disorder (ADHD), researchers found significant differences in nine brain white matter tracts in individuals with ADHD. (sciencedaily.com)
  • 2019), it's surprising that the idea of treatment resistance primarily considers a pharmacological standpoint. (psychologytoday.com)
  • Chief among these was the 2019 FDA approval of esketamine, a nasal formulation of ketamine, for the treatment of resistant depression. (medscape.com)
  • First approved in March 2019, the nasal spray used as an adjunct with an oral antidepressant was originally indicated for treatment-resistant depression. (medpagetoday.com)
  • In November 2019, the FDA granted Breakthrough Therapy Designation for psilocybin in the treatment of major depressive disorder. (medpagetoday.com)
  • METHODS: Data from US patients treated with BPaL between 14 October 2019 and 30 April 2022 were compiled and analyzed by the BPaL Implementation Group (BIG), including baseline examination and laboratory, electrocardiographic, and clinical monitoring throughout treatment and follow-up. (cdc.gov)
  • In this cohort, effective treatment required less than half the duration recommended in 2019 US guidelines for drug-resistant tuberculosis. (cdc.gov)
  • 27,189 patients with late-onset MDD were included, among whom 16.6% had the diagnosis of anxiety disorders, 1.5% had alcohol use disorders, and 1.6% had substance use disorder. (psychiatrist.com)
  • Anxiety disorders are one of the most common disorder types associated with treatment-resistant depression. (wikipedia.org)
  • Moreover, anxiety disorders are included in the top 20 DALYs list for the American continent ( WHO, 2018a ). (frontiersin.org)
  • Healthcare professionals often prescribe off-label medications for anxiety disorders . (psychcentral.com)
  • In fact, research suggests that up to 40% of people with anxiety disorders don't respond to current treatments for these conditions. (psychcentral.com)
  • That's a lot of people, since anxiety disorders are the most common class of mental health conditions, affecting about 264 million people around the world. (psychcentral.com)
  • It's frequently used off-label to treat anxiety disorders and post-traumatic stress, as it enhances transmission of GABA. (psychcentral.com)
  • Researchers in Sweden found that 1 in 9 patients with unipolar major depressive disorder experienced an episode that fulfilled the criteria for treatment-resistant depression, a condition associated with greater rates of anxiety, stress, sleep disorders, and substance use disorder versus patients without TRD. (medpagetoday.com)
  • It may not come as a surprise that treatment-resistant depression (TRD) is costly to patients. (medpagetoday.com)
  • During the first year of treatment, 22.1% of patients met TRT criteria, and 1.6% developed TRD. (psychiatrist.com)
  • Placebo-controlled study of relapse prevention with risperidone augmentation in older patients with resistant depression. (psychiatrist.com)
  • Treatment patterns in patients with treatment-resistant depression in Danish patients with major depressive disorder. (bvsalud.org)
  • To describe treatment patterns in patients with treatment -resistant depression (TRD) and major depressive disorder (MDD) stratified by depression severity and year of diagnosis . (bvsalud.org)
  • Selective serotonin reuptake inhibitors ( SSRIs ) were the most frequently used treatment during the study period and more than half (50.7%) of patients changed treatment at least once. (bvsalud.org)
  • Among patients with TRD, serotonin and noradrenaline reuptake inhibitors ( SNRIs ) were the most frequently used treatment (55.9%), and 37.0% initiated a new treatment the following year. (bvsalud.org)
  • Irrespective of patient characteristics and year of diagnosis , SSRIs and SNRIs are the most used treatments for depression , even after patients met the criteria for TRD. (bvsalud.org)
  • We confirm that guidelines for first treatment were followed for most patients diagnosed with MDD in Denmark , but for patients with TRD, choice of treatment was arbitrary. (bvsalud.org)
  • Ketamine produces rapid antidepressant effects in treatment-resistant depression (TRD), but the magnitude of response varies considerably between individual patients. (nih.gov)
  • If approved by the FDA, esketamine would be one of the first new approaches to treat major depressive disorder available to patients in the last 50 years. (jnj.com)
  • This designation reinforces the potential of esketamine as a novel treatment for patients with major depressive disorder who are at imminent risk for suicide, a condition for which there currently is no approved treatment and which represents a major public health challenge. (jnj.com)
  • Some studies have shown that patients with both MDD and panic disorder are the most likely to be nonresponsive to treatment. (wikipedia.org)
  • It may cause depressed patients to be noncompliant in their treatment, and the effects of certain substances can worsen the effects of depression. (wikipedia.org)
  • Unfortunately, as noted by Voineskos, treatment-resistant depression is generally defined as patients having failed two antidepressant trials. (psychologytoday.com)
  • 2021) did a meta-analysis and noted that "…patients meeting diagnostic criteria for a [personality disorder] tended to improve less than patients without a [personality disorder] after CBT for depression. (psychologytoday.com)
  • Ketamine is good alternative for patients who have been recommended for ECT for treatment of their resistant depression. (medicalnewstoday.com)
  • The finding that six sessions of ketamine was no less effective than nine sessions of ECT and produced milder side effects than ECT, has enormous implications for guiding which treatment should be recommended when patients fail to improve with first-line treatments. (medicalnewstoday.com)
  • Background: Electroconvulsive therapy (ECT) is the most effective intervention for patients with treatment resistant depression. (researchgate.net)
  • While we're waiting for these new treatments to come about, let's talk a bit about, how can we improve adherence to our treatments, and awareness and communication and education of our patients and our colleagues? (consultantlive.com)
  • Powerful magnetic pulses applied to the scalp to stimulate the brain can bring fast relief to many severely depressed patients for whom standard treatments have failed. (sciencedaily.com)
  • The researchers recruited 33 patients who had been diagnosed with treatment-resistant major depressive disorder. (sciencedaily.com)
  • In a scenario where enthusiasm for the drug is larger than the body of evidence supporting its clinical use, support is growing for the creation of a ketamine registry to collect data on dosage, treatment frequency, adverse events, and long-term outcomes in patients receiving the therapy for depression and other mental health conditions. (medscape.com)
  • Still, clinicians desperate to help the one-third of patients with major depression who fail to respond to first-line treatments often prescribe the drug anyway. (medscape.com)
  • In 2017, Sanacora, who also is director of the Yale Depression Research Program at the Yale School of Medicine, was the lead author of a consensus statement that sought to help physicians administer ketamine safely and appropriately in patients with severe depression and other mood disorders. (medscape.com)
  • Treatment challenges arise from the different biological dysfunctions implicated in different patients and the lack of biomarkers available to guide the choice of anti-depressants. (europa.eu)
  • The role of rare variants has not been well studied and few studies have investigated the genetics of TRD (patients with two or more failed treatments). (europa.eu)
  • This project will combine exome sequencing and genome-wide genotyping in the unique GSRD sample of 1346 MDD patients characterized for stages of treatment resistance (number of failed treatments). (europa.eu)
  • The study will assess the impact of clinical variables on genetic finding, and develop a genomic profile for TRD which can be used to guide treatment in patients. (europa.eu)
  • A small pilot study has indicated that neurofeedback - where patients concentrate on modifying their own brainwave patterns - has potential to treat many of the 100m people worldwide who suffer from Treatment-Resistant Depression (TRD). (news-medical.net)
  • Our results suggested that neurofeedback might be an effective complementary treatment to make patients feel well again and successfully engage with life. (news-medical.net)
  • furthermore, the risk for the relapse of MDD increases in patients who cycle through 3 or more treatment stages. (ahdbonline.com)
  • In phase 3 clinical trials, we saw this therapy provide sustained improvement to patients with treatment-resistant depression. (ahdbonline.com)
  • If confirmed, this could change practice and have a very significant impact on patients' treatment outcomes. (ucalgary.ca)
  • Analyzing real-world data, Heerlein and colleagues revealed that nearly 74% of the 411 patients with prescribing data included in their analysis had not responded to the newly prescribed treatment for depression by 6 months of treatment. (medscape.com)
  • Indeed, there is a general agreement that the incidence of neurobehavioral disorders is higher in patients with epilepsy than in the general population, although some authors argue that this apparent overrepresentation is due to sampling errors or inadequate control groups. (medscape.com)
  • Multiple interacting biologic and psychosocial factors determine the risk for the development of either schizophreniform psychoses or major depression in patients with epilepsy, and behavioral disorders in epilepsy have multiple risk factors and multifactorial etiologies. (medscape.com)
  • Although undoubtedly important in the care of the patient with epilepsy, advances in neurologic diagnosis and treatment tended to obscure the behavioral manifestations of epilepsy until Gibbs drew attention to the high incidence of behavioral disorders in patients with temporal lobe epilepsy. (medscape.com)
  • 58% of these patients have a history of depressive episodes, 32% have agoraphobia without panic or other anxiety disorder, and 13% have psychoses. (medscape.com)
  • 114 out of 160 adult patients were assessed by telephone using validated scales (Stress Reactions and Adjustment Disorder Checklist, 9-item Patient Health Questionnaire, 7-item Generalized Anxiety Disorder Scale and Insomnia Severity Index) and a few open-ended questions about expectations and anticipated areas of need during hospitalization, including experiences with isolation. (who.int)
  • Psychological distress may reduce treatment adherence to immediate psychological sequelae like excessive fear among confirmed and suspected COVID-19 patients. (who.int)
  • Using an initial 600-mg linezolid dose daily adjusted by therapeutic drug monitoring and careful clinical and laboratory monitoring for adverse effects, supportive care, and expert consultation throughout BPaL treatment, 3 patients (4.4%) with hematologic toxicity and 4 (5.9%) with neurotoxicity required a change in linezolid dose or frequency. (cdc.gov)
  • Experts still seek to understand how to help people with treatment-resistant major depression. (medicalnewstoday.com)
  • A​ recent study published in The New England Journal of Medicine compared the use of ketamine infusions with electroconvulsive therapy (ECT) - two interventions for treatment-resistant major depression. (medicalnewstoday.com)
  • Researchers recruited participants who had treatment-resistant major depression. (medicalnewstoday.com)
  • If someone has been unresponsive to two or more medications to treat depression, doctors may diagnose them with treatment-resistant major depression . (medicalnewstoday.com)
  • Neurostimulation is a mainstream treatment option for major depression. (researchgate.net)
  • The FDA-cleared treatment, known as Stanford Neuromodulation Therapy, incorporatesadvanced imaging technologies to guide stimulation with high-dose patterns of magnetic pulses that can modify brain activity related to major depression. (sciencedaily.com)
  • L-methylfolate as adjunctive therapy for SSRI-resistant major depression: results of two randomized, double-blind, parallel-sequential trials. (uc.edu)
  • Major depression is the leading cause of disability in the world, according to the World Health Organization, and roughly 6 to 7% of Americans will have a depressive episode in any given year. (webmd.com)
  • Electroconvulsive therapy (ECT) is a type of brain stimulation that is an option for treatment in cases of severe depression. (medicalnewstoday.com)
  • Background Repetitive transcranial magnetic stimulation (rTMS) on the dorsolateral prefrontal cortex (DLPFC) is an effective treatment for depression that has been proposed to work via the enhancement of cognitive control. (researchgate.net)
  • Yet it's been a mystery exactly how transcranial magnetic stimulation, as the treatment is known, changes the brain to dissipate depression. (sciencedaily.com)
  • Twenty-three received SNT treatment, and 10 received a sham treatment that mimicked SNT but without magnetic stimulation. (sciencedaily.com)
  • The antibiotic D-Cycloserine (DCS) helps magnetic stimulation (TMS) for people with major depressive disorder (MDD). (dr-bob.org)
  • University of Calgary researchers have shown that the antibiotic D-Cycloserine (DCS) increases the effectiveness of transcranial magnetic stimulation (TMS) for people with major depressive disorder (MDD). (ucalgary.ca)
  • Durability of symptomatic responses obtained with adjunctive vagus nerve stimulation in treatment-resistant depression. (sheppardpratt.org)
  • Transcranial magnetic stimulation (TMS) is gaining ground as a therapy for treatment-resistant depression. (athealth.com)
  • In this context, we investigate a non-pharmacological treatment known as transcranial direct current stimulation (tDCS). (fapesp.br)
  • Fast Five Quiz: Major Depressive Disorder Management - Medscape - Feb 28, 2023. (medscape.com)
  • Dysthymic Disorder/Chronic Depressive Disorder The Encyclopedia of Clinical Psychology. (upenn.edu)
  • Background: Electroconvulsive therapy (ECT) is one of the most effective treatments for severe depressive disorders. (researchgate.net)
  • Those with the most severe depression -- and the most misdirected brain signals -- were the most likely to benefit from the treatment. (sciencedaily.com)
  • Depressive disorders are characterized by sadness severe enough or persistent enough to interfere with function and often by decreased interest or pleasure in activities. (msdmanuals.com)
  • Depressive Disorders in Children and Adolescents Depressive disorders are characterized by sadness or irritability that is severe or persistent enough to interfere with functioning or cause considerable distress. (msdmanuals.com)
  • SSRIs and SNRIs were part of most combinations of treatment , regardless of depression severity, year of diagnosis , or presence of TRD. (bvsalud.org)
  • Meanwhile, the gold standard Montgomery Asberg Depression Rating Scale was used to measure depressive symptom severity. (dr-bob.org)
  • Their depression severity was calculated pretreatment, after one week and eight weeks of treatment. (cdc.gov)
  • Research suggests that propranolol may be just as effective as benzodiazepines (such as Xanax ) for panic in the short-term treatment of panic disorder . (psychcentral.com)
  • PMID 16525418 ] Association of the Val158Met catechol O-methyltransferase genetic polymorphism with panic disorder. (snpedia.com)
  • Geriatric depression treatment in nonresponders to selective serotonin reuptake inhibitors. (psychiatrist.com)
  • In this population-based, observational cohort study, Dr. Lundberg and his colleagues used data from the Stockholm Major Depressive Disorder (MDD) Cohort for episodes of MDD recorded between January 1, 2012, and December 31, 2017, that fulfilled the predefined criteria for TRD-at least three consecutive pharmacologic antidepressant treatments. (medpagetoday.com)
  • The BIG cohort demonstrates that early implementation of new tuberculosis treatments in the United States is feasible. (cdc.gov)
  • Earlier this year, the developer Sage Therapeutics announced that the FDA granted this agent Breakthrough Therapy Designation for the treatment of postpartum depression and major depressive disorder. (medpagetoday.com)
  • TITUSVILLE, N.J., Aug. 16, 2016 - Janssen Research & Development, LLC, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, announced today that the U.S. Food and Drug Administration (FDA) has granted a Breakthrough Therapy Designation for esketamine, an investigational antidepressant medication, for the indication of major depressive disorder with imminent risk for suicide. (jnj.com)
  • A​ new study found that ketamine infusion is comparable to electroconvulsive therapy in treating major depressive disorder. (medicalnewstoday.com)
  • The researchers found that using ketamine may be as effective as electroconvulsive therapy in helping people with treatment-resistant depression, with little to no side effects. (medicalnewstoday.com)
  • The investigators also found anxiety, stress, sleep disorders, and substance use disorder were more common comorbid conditions in TRD episodes. (medpagetoday.com)
  • Hence, to aid diagnostics of single and comorbid disorders, we aimed to examine the discrim. (researchgate.net)
  • It promotes synaptic connections within the brain for learning and memory, but it can also block other receptors, leading to rapid antidepressant action," explains Roberto Olivardia, PhD, in the ADDitude article " Treatment for Depression and ADHD: Treating Comorbid Mood Disorders Safely . (webmd.com)
  • At any time, 1 in 10 people worldwide are affected by a mental health disorder, bringing the absolute number to 792 million ( Ritchie and Roser, 2018 ). (frontiersin.org)
  • These include population growth, increase in MDD prevalence, increase in treatment cost per individual with MDD, changes in employment and treatment rates, as well as changes in the composition and quality of MDD treatment services. (psychiatrist.com)
  • Several studies, including those conducted in African countries with high prevalence of HIV, have shown a positive association between HIV and alcohol consumption, with a prevalence of HIV infection among people with alcohol-use disorders higher than in the general population. (who.int)
  • The term 'treatment-resistant depression' only takes into account failed pharmacological interventions. (psychologytoday.com)
  • Vortioxetine is an FDA-approved pharmacological option for the treatment of MDD. (psychiatrictimes.com)
  • This was followed by a progressive justment disorders, aggressive behaviour, acute psycho- increase in the number of cases and the government sis and suicide have also been reported in previous out- imposed a lockdown in the country on 24 March 2020, breaks of infectious diseases ( 2-4 ). (who.int)
  • Brain-machine inter-faces (BMIs) pro-vide a direct path-way to the brain to trans-late brain sig-nals into actions … Below, Shanechi (Note: Maryam Shanechi, PhD, assis-tant pro-fes-sor of elec-tri-cal and com-put-er engi-neer-ing) answers some ques-tions about her work and what the future might hold for our under-stand-ing and treat-ment of men-tal disorders. (sharpbrains.com)
  • Brain-derived neurotrophic factor (BDNF) has been investigated as a biomarker of treatment response in depression and has been implicated in the mechanism of action of ketamine. (nih.gov)
  • Now, research led by Stanford Medicine scientists has found that the treatment works by reversing the direction of abnormal brain signals. (sciencedaily.com)
  • The evidence has been steadily accumulating however - with the most recent study appearing in JAMA this summer pointing strongly to the role of antipsychotic treatment in leading to brain cell loss - article here and see article HERE . (rxisk.org)
  • The International League Against Epilepsy (ILAE) and the International Bureau for Epilepsy (IBE) define epilepsy as a disorder of the brain characterized by an enduring predisposition to generate epileptic seizures and by the biologic, cognitive, psychological, and social consequences of this condition. (medscape.com)
  • Depression is a disorder of the brain. (medlineplus.gov)
  • Randomised controlled trial to evaluate the effectiveness of collaborative care in a Dutch occupational healthcare setting: 126 workers on sick leave with major depressive disorder were randomised to usual care ( n = 61) or collaborative care ( n = 65). (cambridge.org)
  • Major depressive disorder is a prevalent condition in Dutch occupational healthcare settings. (cambridge.org)
  • This project will address the emerging healthcare problem of Treatment Resistant Depression (TRD). (europa.eu)
  • Your healthcare provider should check you for signs of abuse and dependence before and during treatment with this medicine. (drugs.com)
  • COMT genetic variation confers risk for psychotic and affective disorders: a case control study. (snpedia.com)
  • Investigational agents, most notably ketamine and its relatives, constitute an exciting frontier in the treatment of mood disorders, and the clinical application, routes of delivery, dosing, risks, and clinical trials are explored in a dedicated chapter that is both rigorous and thorough. (appi.org)
  • There is compelling evidence that childhood maltreatment (defined as exposure to emotional, physical, and sexual abuse and neglect before the age of 18 years) is a prominent risk factor for the development of mood disorders as well as for a pernicious course and poor treatment response in mood disorders. (appi.org)
  • These findings, as well as the underlying neurobiological and environmental interactions that may contribute to the development of mood disorders, are examined thoroughly and thoughtfully. (appi.org)
  • As our understanding of immune function in mood disorders has grown, psychoneuroimmunology has emerged as a focus of study likely to make major contributions to clinical practice in the coming decades. (appi.org)
  • Overview of Mood Disorders Mood disorders are emotional disturbances consisting of prolonged periods of excessive sadness, excessive elevated mood, or both. (msdmanuals.com)
  • Some people who are diagnosed with treatment-resistant depression may have an underlying undiagnosed health condition that is causing or contributing to their depression. (wikipedia.org)
  • citation needed] For lethargic syndromes, dysthymia, or caffeine-resistant amotivation, a dopaminergic stimulant such as methlyphenidate, or even dextroamphetamine or methamphetamine can be helpful. (wikipedia.org)
  • Cases of treatment-resistant depression may also be referred to by which medications people with treatment-resistant depression are resistant to (e.g. (wikipedia.org)
  • Duloxetine in the treatment of binge eating disorder with depressive disorders: a placebo-controlled trial. (uc.edu)
  • Lamotrigine in the treatment of binge-eating disorder with obesity: a randomized, placebo-controlled monotherapy trial. (uc.edu)
  • Olanzapine in the treatment of pathological gambling: a negative randomized placebo-controlled trial. (uc.edu)
  • Atomoxetine in the treatment of binge-eating disorder: a randomized placebo-controlled trial. (uc.edu)
  • People with personality disorders frequently have co-occurring depression. (psychologytoday.com)
  • In 1996, Thase wrote, "The role of personality disorders in the management of chronic, treatment-refractory depressive states is one of the least studied, yet more interesting topics in the treatment of mood disorder . (psychologytoday.com)
  • Depression is not uncommon as a symptom in Diagnostic and Statistical Manual (DSM) personality disorders, particularly borderline, histrionic, avoidant, and dependent personality disorders (DSM-5). (psychologytoday.com)
  • Substance abuse may also be a predictor of treatment-resistant depression. (wikipedia.org)
  • mental health problems, including substance-use disorders, are associated with increased risk of HIV infection and AIDS and interfere with their treatment, and conversely some mental disorders occur as a direct result of HIV infection. (who.int)
  • Single, repeated, and maintenance ketamine infusions for treatment-resistant depression: A randomized controlled trial. (webmd.com)
  • All participants were followed for 1 year to investigate the incidence of treatment resistance. (psychiatrist.com)
  • Researchers are still seeking to understand the best methods for treating depression that is resistant to medication interventions. (medicalnewstoday.com)
  • There is overlap in symptomatology between MDD and ADHD that complicates diagnostics and treatment selection. (researchgate.net)
  • Taking into account whether people believe they are receiving a real treatment or a fake one (placebo) could provide better insights that could help improve interventions for conditions such as depression and ADHD. (sciencedaily.com)
  • Another depressive feature that has been associated with poor response to treatment is longer duration of depressive episodes. (wikipedia.org)
  • Increasing the dosage of an antidepressant is a common strategy to treat depression that does not respond after adequate treatment duration. (wikipedia.org)
  • A new study, pub-lished in Psy-chi-a-try Research, has con-clud-ed that psy-chi-atric diag-noses are sci-en-tif-i-cal-ly worth-less as tools to iden-ti-fy dis-crete men-tal health disorders. (sharpbrains.com)
  • The goal of the study was to investigate whether subanesthetic intravenous ketamine was nearly as good as ECT for treatment-resistant depression. (medicalnewstoday.com)
  • The Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study was a large, multicenter, effectiveness trial sponsored by the National Institute of Mental Health (NIMH). (uspharmacist.com)
  • A total of 90% of the study subjects were able to achieve at least a 50% reduction in MADRS score and 70% were able to maintain this treatment response 1 month after treatment. (medpagetoday.com)
  • This personalised medicine study should facilitate the development of new evidence-based treatments and substantially reduce the time to identify the best treatment strategy in MDD. (europa.eu)
  • We need to emphasize that this is a small study - if you like, it's still at the level of clinical science rather than clinical treatment, so we are a long way from this finding its way into the clinic. (news-medical.net)
  • A recent WHO collaborative study on drug dependence treatment and HIV/AIDS found that substitution therapy of opioid dependence significantly reduced risks of HIV transmission in opioid-dependent individuals in low- and middle-income countries, consistent with the findings in high-income countries. (who.int)
  • Overall, the ketamine intervention group had fewer problems with memory recall after the three weeks of treatment. (medicalnewstoday.com)
  • Major depressive disorder affects approximately 16 million people in the U.S. 4 and 121 million people worldwide. (jnj.com)
  • Marfan syndrome is a genetic disorder that affects connective tissue throughout the body. (cdc.gov)
  • ECT is usually used as a treatment of last resort to treat MDD [major depressive disorder] because, it is considered the most effective treatment for this condition, but it is also associated with the highest rate of side effects, such as memory problems, which in some people can persist far beyond the end of the ECT treatments. (medicalnewstoday.com)
  • TMS is used to treat people who have treatment-resistant depression. (dr-bob.org)
  • Adding D-Cycloserine to the TMS treatment appears to enhance TMS's ability to drive synaptic plasticity and treat depression. (dr-bob.org)
  • Alert FDA OKs Durvalumab (Imfinzi) for Reducing Risk for NSCLC Progression The immunotherapy becomes the first treatment approved to reduce the risk for progression in hard-to-treat stage III non-small cell lung cancer. (medscape.com)
  • Treatment-resistant (refractory) depression has been a fertile topic for several decades (e.g. (psychologytoday.com)
  • 1. Depression and Other Common Mental Disorders. (psychiatrist.com)
  • Mental health is biopsychosocial, so treatment resistance should encourage other interventions, like therapy. (psychologytoday.com)
  • Major depressive disorder (MDD) is a mental illness affecting people's moods and everyday lives. (medicalnewstoday.com)
  • and Sagar V. Parikh, MD, FRCPC, comment on the need to improve awareness around depressive disorders and break the stigma of mental health treatment. (consultantlive.com)
  • While there is stigma across a lot of mental disorders, I think for the most part, most clinicians are understanding depression as a real thing, and as something worthy of treatment, and not a particularly shameful thing. (consultantlive.com)
  • With these new threats against mental health, development of new major depressive disorder treatments is needed now more than ever. (medpagetoday.com)
  • Besides these behavioural risks, mental disorders may also interfere with the ability to acquire and/or use information about HIV/AIDS and thus to practise safer behaviours or increase the likelihood of situations occurring in which risk behaviours are more common. (who.int)
  • in particular, sex workers, men who have sex with men, drug users and prisoners have higher levels of mental health disorders than the general population. (who.int)
  • And we say that behavioral disorders are caused by "mental" diseases to distinguish them from "real" diseases-infections, tumors, broken bones, burst blood vessels, polio. (cdc.gov)
  • Sometimes we even believe that people with mental diseases and behavioral disorders suffer more from weakness of spirit and flaws of character than from genuine disease. (cdc.gov)